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ABSTRACT 
 
Medical Laboratories Accreditation is covered by ISO 15189:2012 - Medical 
Laboratories — Requirements for Quality and Competence. In Portugal, 
accreditation processes are held under the auspices of the Portuguese 
Accreditation Institute (IPAC), which applies the Portuguese edition (NP EN ISO 
15189:2014). Accordingly, Medical Laboratories accreditation processes now 
require the estimate of measurement uncertainty (MU) associated to the results.  
The Guide to the Expression of Uncertainty in Measurement (GUM) describes 
the calculation of MU, not contemplating the specific aspects of medical 
laboratory testing. Several models have been advocated, yet without a final 
consensus.  
Given the lack of studies on MU in Portugal, especially on its application in the 
medical laboratory, it is the objective of this thesis to reach to a model that fulfils 
the IPAC’s accreditation regulations, in regards to this specific requirement. The 
study was based on the implementation of two formulae (MU-A and MU-B), 
using the Quality Management System (QMS) data of an ISO 15189 Accredited 
Laboratory. Including the laboratory’s two Cobas® 6000–c501 (Roche®) 
analysers (C1 and C2) the work focused three analytes: creatinine, glucose and 
total cholesterol. 
The MU-B model formula, combining the standard uncertainties of the method’s 
imprecision, of the calibrator’s assigned value and from the pre-analytical 
variation, was considered the one best fitting to the laboratory's objectives and 
to the study's purposes, representing well the dispersion of values reasonably 
attributable to the measurand final result. Expanded Uncertainties were: 
Creatinine - C1 = 9,60%; C2 = 5,80%; Glucose -  C1 = 8,32%; C2 = 8,34%;  
Cholesterol -  C1 = 4,00%; C2 =  3,54 %. 
 ii 
 
 
 
This evidence was confirmed by IPAC’s accreditation auditing (2015/2016), 
having the MU estimate presented contributed for the approval on the 
accreditation report and for the renewal of this recognition and certificate.  
Nonetheless, in global terms, it stands as necessary the investment from 
Manufacturers, Reference Laboratories and International Scientific 
Organisations providing reference methods and certified reference material, 
with high metrological traceability, focusing on the calibrators, as well as on the 
internal quality control materials. General laboratory investment is also needed 
to improve practice in the pre-analytical phase, assessing and estimating each 
own specific pre-analytical uncertainty. In addition, implementing MU estimate 
in the medical laboratory will require explicit and consensual guidelines, new 
tables with goals and allowable limits for MU and education, regarding this new 
tool, targeting the technical and medical laboratory’s staff, but also the 
laboratory users, physicians and patients. 
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1 INTRODUCTION 
 
The International Vocabulary of Metrology (VIM) [1] defines the concept of 
uncertainty as a non-negative parameter associated with the result of a 
measurement representative of the dispersion of values that can be attributed to 
the measurand. From the metrological point of view, a result is not complete 
unless it's accompanied by its uncertainty. 
In Metrology, the notion of uncertainty applied to the results reveals a 
fundamental importance when interpreting and evaluating those same results. 
Uncertainty, presenting itself as a quantitative indicator of the quality of the 
measurement, allows for interpretation and inferences regarding the reliability 
and confidence in those values. Thereby in areas such as the industry or 
calibration testing, measurement uncertainty (MU) is an accepted and 
disseminated concept and its application is done according to known and 
complex mathematical calculations and theoretical models, using probabilities 
and the law of propagation of uncertainty as the basis for this modelling.  
Published in 1995, and reedited in 2008, by a working group of the Joint 
Committee for Guides in Metrology (JCGM), the GUM: Guide to the expression 
of uncertainty in measurement [2], reveals the considerations and orientations 
from its member organizations on the matter (BIPM, IEC, IFCC, ILAC, ISO, 
IUPAC, IUPAP and OIML). The GUM describes in general terms the calculation 
of measurement uncertainties, being nowadays a reference strictly followed and 
widely implemented and cited with emphasis in the field of physical testing, but 
also in analytical chemistry. However, the specific aspects and conditions 
regarding the clinical testing in medical laboratories remain excluded, or simply 
not addressed - not in GUM, or in its derived documents from EA - European 
Co-operation for Accreditation (EA-4/16 – EA guidelines on the expression of 
uncertainty in quantitative testing) [3], or from the EURACHEM/CITAC (CG4 - 
Quantifying Uncertainty in Analytical Measurement) [4]. 
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Associate the medical laboratory clinical results with different sources of 
variation, such as biological variation, pre-analytical and analytical variation, has 
then been an objective of the clinical laboratories and both medical and 
technical communities. The aim has been to develop a concept of uncertainty 
suitable to clinical laboratory results, considering its own conjunctures and 
specifications, and including some intrinsic characteristics exclusive to them. 
Late studies have been seeking to answer questions regarding the applicability 
of the concept of uncertainty in Clinical Laboratories, with the final purpose of 
reaching a consensus model to estimate Measurement Uncertainty in the 
Medical Laboratory.  
 
 
1.1 Medical Laboratory Accreditation: 
 
The International Organization for Standardization (ISO) is a worldwide 
federation of national standards bodies (ISO member bodies), which develops 
and publishes International Standards. These standards are carried out through 
ISO technical committees, with representatives of each member body interested 
in the subject, for which a technical committee has been established. According 
to ISO, “a standard is a document that provides requirements, specifications, 
guidelines or characteristics that can be used consistently to ensure that 
materials, products, processes and services are fit for their purpose, safe, 
reliable and of good quality”. Having International Standards covering almost all 
aspects of technology, management and quality, worldwide certification and 
accreditation of laboratories has been guided by its standard’s requirements 
and specifications. 
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Laboratory Accreditation ensures the existence of the necessary technical skills 
and competences in the development of the laboratory processes, assuring the 
quality of the procedures and results. Medical Laboratories Accreditation is 
foreseen in ISO 15189:2012 - Medical Laboratories — Requirements for Quality 
and Competence [5]. The standard was prepared by Technical Committee 
ISO/TC 212 - Clinical laboratory testing and in vitro diagnostic test systems; and 
specifies the Quality Management System (QMS) requirements particular to 
medical laboratories. It was first released in 2003, with a second edition in 2007, 
which was later replaced, in 2012, by a technically revised third edition, the 
current version. 
It considers that “medical laboratory services are essential to patient care and 
therefore have to be available to meet the needs of all patients and the clinical 
personnel responsible for the care of those patients. Such services include 
arrangements for examination requests, patient preparation, patient 
identification, collection of samples, transportation, storage, processing and 
examination of clinical samples, together with subsequent interpretation, 
reporting and advice, in addition to the considerations of safety and ethics in 
medical laboratory work.”  
It is assumed that “a medical laboratory's fulfilment of the requirements of this 
International Standard means the laboratory meets both the technical 
competence requirements and the management system requirements that are 
necessary for it to consistently deliver technically valid results”. 
International Laboratory Accreditation Cooperation (ILAC) presents the ISO 
15189 Standard as “A tool to demonstrate the competence of medical 
laboratories and ensure the delivery of timely, accurate and reliable results”, 
which should be used by medical laboratories for development of their 
management systems and to maintain their own competence; and by 
accreditation bodies to confirm or recognise the competence of these 
laboratories through accreditation [6]. 
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It is considered that ISO 15189 covers the essential elements for medical 
laboratories to demonstrate the quality and competence of their services, which 
is validated through the periodic assessment of all factors in the laboratory that 
affect the production of test data, including the technical competence of staff; 
the validity and appropriateness of test methods, including pre- and post-
analytical; the traceability of measurements and calibrations to relevant 
standards; the suitability, calibration and maintenance of test equipment; the 
quality assurance of test results, demonstrated by Internal Quality Control (IQC) 
systems and by the regular participation in External Quality Assurance 
Schemes (EQAS); also having an acceptable turnaround time as well as the 
application of appropriate ethical values. 
ILAC points out benefits in accreditation process, regarding: the Healthcare 
Regulators, by providing a mechanism for measuring quality improvement and  
supporting consistency in the quality of care; the Patients, confirming that  the 
laboratory has up-to-date-technologies and its procedures and techniques 
reflect current best practice and that the staff providing the service are 
competent to undertake the tasks they perform; and for the Medical 
Laboratories, providing opportunity for external perspectives on the laboratory’s 
practice, encouraging the sharing of best practice; stimulating innovation and 
reducing risk; and providing international recognition. 
In 2007, the European Communities Confederation of Clinical Chemistry and 
Laboratory Medicine (EC4 - Working Group) presented the results of a 
questionnaire carried out in 2005 to explore the current status of accreditation in 
EU countries, which was sent to representatives of clinical biochemistry and 
laboratory medicine societies of EU countries [7].  From the answers of the 19 
societies that returned the survey, out of 25, was revealed that the accreditation 
of medical laboratories in the countries of the EU is mostly carried out, by 
National Accreditation Bodies (NAB), that work together in a regional 
cooperation, the European Cooperation for Accreditation (EA), and that some 
countries have established professional accreditation bodies specifically for 
medical laboratories, like the Clinical Pathology Accreditation (CPA - UK), which 
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have incorporated in their requirements all aspects of ISO 15189. The ISO 
15189 standard was found to be “widely accepted in the medical laboratory 
community”. 
The report also revealed that, although the majority of European Accreditation 
Bodies have a test-by-test accreditation policy, “many professionals would 
prefer accreditation of the entire service provided within the actual field of 
testing (i.e., hematology, immunology, etc.), with accreditation granted if the 
majority of tests offered within a service field fulfil the requirements of the ISO 
15189 standard”.  
So, having the discussion about the accreditation scope been an important 
issue in the last years, both EA and ILAC already acknowledged the possibility 
of implementing a flexible scope and issued guidelines and recommendations to 
the purpose [8, 9]. Also, in an additional position paper [10], EA recognized the 
benefits implementing a flexible scope. 
A flexible scope of accreditation, contrary to the fixed list of the methods/tests 
used under the test-by-test accreditation procedure, would not mention 
individual tests, but coherent groups of services within a medical field and with 
similar technical principles with provision of all applicable materials (and 
matrices such as serum, plasma, urine and blood cultures). 
These approaches were recently addressed as alternatives in an editorial piece 
by Mario Plebani, et al. [11] about the accreditation of medical laboratories 
under the ISO 15189 standard.  
A position paper by Marc Thelen, et al. [12], on behalf of the Working Group 
Accreditation ISO/CEN standards (WG-A/ISO) of the European Federation of 
Clinical Chemistry and Laboratory Medicine (EFLM), recommended the flexible 
scope for ISO 15189 accreditation, with a guidance based on an approach that 
has led to successful introduction of the flexible scope for ISO15189 
accreditation as intended in EA-4/17 in The Netherlands. 
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A recently published results (2016), of an EFLM survey initiated in 2014 on the 
accreditation process in European countries [13], concluded that the ISO 15189 
accreditation project has been widely accepted, revealing the efforts of the 
cooperative work done. The scientific societies and the NABs have provided 
support and incentives that enabled the laboratories and the laboratory 
professionals to move toward uniform implementation of the accreditation 
concept. However, numbers and percentages of accredited medical laboratories 
are disparate among the EU countries. Although not able to express the real 
total number of medical laboratories in each country, as there is no authority in 
each country responsible to give the total number of registered laboratories, the 
results showed that “some countries have already reached an almost complete 
implementation of accreditation” as “other countries are still at the beginning of 
this development”. 
29 responses were received, out of 39 countries to whom the delegates of the 
scientific societies have been sent the questionnaire. All the societies declared 
the existence of an accreditation process for medical laboratories by a NAB in 
their country. The accreditation process was declared mandatory by 5 countries 
(Belgium, France, Hungary, Ireland and Lithuania), with Belgium, Ireland and 
Lithuania only having a partial mandatory accreditation. Nevertheless, only 7 
countries declared to have 50% or more of medical laboratories already 
accredited (Finland, Ireland, the Netherlands, Sweden, Switzerland, the UK and 
Belgium), while around 60% of the countries (17 out of the 29 countries) have 
15% or below of medical laboratories accredited. 
Medical laboratories accreditation processes, in Portugal, are held under the 
auspices of the Portuguese Institute for Accreditation (Instituto Português de 
Acreditação - IPAC), which applies to the medical laboratories the Portuguese 
edition of the ISO standard, NP EN ISO 15189:2014 [14], being this process of 
voluntary participation. IPAC is a recognized member of the existing 
international organizations of accreditation, as the European co-operation for 
Accreditation (EA) or the International Laboratory Accreditation Cooperation 
(ILAC) and the International Accreditation Forum (IAF).  
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Portugal was not on the countries responding to the solicitation in the 
mentioned study. However, according to IPAC, since 2008 eighteen Medical 
Laboratories were accredited by its procedures, within the framework of NP EN 
ISO 15189. To date (2016), thirteen of which have a valid certificate.  
 
 
1.2 ISO 15189: Technical Requirements 
 
In Portugal, until 2015, the NP EN ISO 15189:2007 - Specific Requirements for 
Quality and Competence [15], specified the application of uncertainties in 
medical laboratories, recommending the estimate of measurement uncertainty, 
considering the need to have such data and to provide to the clients, on 
request, the results with this information.  
The revision and actualization on the ISO 15189:2007, to the version ISO 
15189:2012 [5] (NP EN ISO 15189:2014 in Portugal [14]), brought changes to 
several areas of its application scope, such as ethics, quality and risk 
management systems, purchase and withdraw of equipment, just to name a 
few. Moreover, it dealt with qualifications and competence assessment of the 
laboratory and its technical personnel and focused on the verification of the 
results, procedures of reporting the results, metrological procedures and 
traceability. Measurement uncertainty was also contemplated in this extent, 
having been included additional requirements regarding the MU estimate. On 
the new edition, in the Technical Requirements Section, when before was a 
recommendation “to determine the uncertainty of results, where relevant and 
possible” (5.6.2), it is now referred that the “laboratory shall determine 
Measurement Uncertainty for each measurement procedure in the examination 
phase used to report measured quantity values on patients’ samples” (5.5.1.4), 
making it a required requisite, or an obligation. 
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Subsequently, Medical Laboratories are now required to estimate the 
measurement uncertainty values associated their results, and to regularly 
review those estimates, in order to be eligible to apply for Accreditation under 
this same Standard, or to keep the existing accreditations. 
According to IPAC, in its Interpretative Guide of ISO 15189 [16], which is still 
awaiting the actualization following the transition to the NP EN ISO 15189:2014,  
several approaches or methodologies can be accepted for estimating the value 
of the uncertainty of results in the Laboratory of Clinical Pathology, as long as 
they prove to be technically valid and applicable to the methods in the study. It 
refers that “due to the generality of the ISO guideline, its application can be 
done using the sectorial guides adopted or recommended by IPAC, EA, ILAC, 
Eurachem or Eurolab”. 
Therefore, either concept can be applied the “modelling” approach, primarily 
introduced by the GUM, or other more “empirical” methodologies based in 
information from inter-laboratory assays, data from method validation or results 
of internal quality control for each specific analytical method, gathered from 
intra-laboratory runs, just having to prove to be technically valid and applicable 
to the methods in the study. Thus, in Portugal, until the application of the new 
version of ISO 15189, among other methodologies it has been accepted for a 
Laboratory to submit to IPAC an Accreditation Process for the ISO 15189 
Standard, indicating the determination of Total Error (TE), or Total Analytical 
Error (TAE), to fulfil the requirements of section 5: Technical Requirements, of 
the Standard; particularly on the Measurement uncertainty of measured quantity 
values, which contemplates standard deviation (SD) or coefficient of variation 
values (CV %) found in IQC and Bias (%) obtained from EQAS. The TE value 
obtained is evaluated, for each analyte, by comparing to maximum admissible 
values tables recognized and/or published by internationally scientific 
organizations [17, 18]. 
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In 1974 Westgard, Carey and Wold described “an approach for formulating 
criteria that could be used to judge whether an analytical method has 
acceptable precision and accuracy” [19], introducing the medical laboratory to 
the concept of Total Error.  More recently Westgard remembered that “at that 
time medical laboratories considered precision (imprecision) and accuracy 
(inaccuracy, bias) as separate sources of errors and evaluated their 
acceptability individually” [20]. TE was then recommended as an effort to 
provide a more quantitative approach for judging the acceptability of method 
performance. In practice, the authors recommended the determination of TE by 
combining the estimate of bias (systematic error), from a method comparison 
study or EQAS and the estimate of precision (random error) from a replication 
study or from the monthly QC data, using a multiple (z) of the standard 
deviation (SD) or coefficient of variation (CV); z=2; for a 95% confidence 
interval or limit of the possible analytic error [20, 21]. Another recent article 
defines the use of bias as an absolute value (|bias|), being added to the 
imprecision value adjusted by the coverage factor, which may be set as 1.96 for 
a two-sided 95% limit, or as 1.65 for a one-sided 95% limit [22]. 
Regarding the meaning and application of total error, it is explained that “the 
intended use of TE is to describe the maximum error that might occur in a test 
result obtained from a measurement procedure. In method validation studies, it 
provides a measure of quality that can be compared to the intended analytical 
quality of a test, which can be described in terms of an Allowable Total Error 
(TEa). TEa is an analytical quality requirement that sets a limit for both the 
imprecision (random error) and bias (systematic error) that are tolerable in a 
single measurement or single test result” [21]. 
This TEa values or specifications can be found, for example, in the “Desirable 
Biological Variation Database Specifications” (also known as the European 
Table or Ricos’ Table) [17], in the “Clinical Laboratory Improvement 
Amendments (CLIA) Regulations Table” [18] or in the” Guideline of the German 
Medical Association on Quality Assurance in Medical Laboratory Examinations 
(RiliBaek)” [23]. 
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The TE concept has nowadays more than 40 years of worldwide acceptance 
and implementation in the medical laboratory. Besides its applicability, the 
widespread determination of TE also relied in the use of simple mathematical 
models, applied to easily obtained data, directly from the day-to-day laboratorial 
work regarding the methods and results validation processes. Using a language 
that is prevalent in the medical lab, well-known to all pathologists and 
technicians, it benefiting from having International References determined and 
accepted for orientation and comparison, as the tables mentioned above. 
However, this does not meet the requirements of the GUM or the 
recommendations on other derived documents for the estimate of measurement 
uncertainty. Several aspects have been sorted out, advocating for 
incompatibilities between the two concepts. Being one of the premises in MU 
that any known bias should be corrected or eliminated, Kallner points out that “a 
common objection to the TE is that if a known bias is included, why keep it?”, 
and continues stating that “bias has a sign whereas the imprecision is a 
characteristic of a distribution” and “therefore the quantities included in the TE 
are not really comparable [24]. On this point, contrarily to the summation of the 
squares as applied in the MU estimate, TE considers a linear contribution of 
method bias, adding the bias value to a probability distribution, and also does 
not recognizing that “patient results could have other possible outcomes with 
less error than bias+z.SD” [25]. Moreover, seems to be a model “only valid 
when imprecision and bias are the only variables involved”, not considering “for 
biological variation and other evident additional causes of variation” [26].  
The question here is not just arguing about the validity of a concept with 
worldwide implementation over the last few decades in medical laboratories. 
The decisive point seems to be that it does not correspond to what is pretended 
with the measurement uncertainty estimate and to the requirements of the 
accreditation standard.  
 
 
23 
 
Arguments vary between affirming the necessity of implementing MU, 
disregarding the use of TE. It has been stated that laboratories “should cease to 
define a so-called allowable total error of result, with assessable biases” [27], or 
that “the concepts of TE and total analytical error represent a loss of information 
since two independent quantities are linearly added to create a single 
expression” and so, laboratories “should abandon the total error concept and 
estimate the uncertainty of the measurement procedure” [28, 29]. Also had 
been pointed out limitations like “the possibility of an acceptable TE masking 
unacceptable performance in one of its constituents”, as “an assay with very 
good precision, may carry a significant bias and remain within the TE goal”, 
which “may systematically misclassify patients in some settings” [30]. 
But, more significant than the arguments against TE are the ones favouring MU, 
advocating that “being a property of the result, also benefits from being able to 
be combined with different sources of variability (e.g. biological + pre-analytical) 
to produce uncertainties relevant for clinical decision making” [29, 30]. 
 
 
1.3 MU - Implementation goals:  
 
The intents of ISO 15189 are to make medical laboratory measurements and 
results transferable, or comparable, on a global basis, stating the idea that a 
good estimate of measurement uncertainty is necessary for laboratories and 
their customers to ensure results are fit for purpose and are traceable to 
international or national standards, to compare results between laboratories 
and/or specifications, legal tolerances or regulatory limits, to make informed 
decisions and improve test methods and results.  
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EA, in EA-4/16 Guidelines [3], state that there “are several advantages linked 
with the evaluation of measurement uncertainty in testing, although the task can 
be time-consuming: 
- Measurement uncertainty assists in a quantitative manner in important 
issues such as risk control and the credibility of test results; 
- A statement of measurement uncertainty can represent a direct 
competitive advantage by adding value and meaning to the result; 
- The knowledge of quantitative effects of single quantities on the test 
result improves the reliability of the test procedure. Corrective measures 
may be implemented more efficiently and hence become more cost-
effective; 
- The evaluation of measurement uncertainty provides starting points for 
optimising the test procedures through a better understanding of the test 
process; 
- Clients such as product certification bodies need information on the 
uncertainty associated with results when stating compliance with 
specifications; 
- Calibration costs can be reduced if it can be shown from the evaluation 
that particular influence quantities do not substantially contribute to the 
uncertainty.” 
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2 MEASUREMENT UNCERTAINTY 
 
The term uncertainty can easily be misunderstood on its applicability, as it in 
theory represents doubt, in this case doubt about a measurement or a result. In 
Medical Laboratories the patient’s results are presented as the best estimate to 
the measurand quantity, on the conditions taken, being an undeniable fact that 
any measurement has a variation associated to it. Recalling the formal 
definitions on both the VIM and the GUM, by characterising the dispersion of 
results regarding that single measurement, MU actually indicates how reliable 
the result really is, providing information on the level of confidence of that same 
measurement.  
 
 
2.1 MU - Different Approaches 
 
The different approaches for measurement uncertainty estimate derive from 
what has been categorised into either “bottom-up” or “top-down” methodologies. 
Although the examples cited in GUM concentrate on the “bottom-up” approach, 
the “top-down” approaches are not excluded by the GUM principles.  
The fundamental metrological “bottom-up” approach described in the GUM, also 
called “modelling”, is based on estimates of uncertainty, expressed as standard 
deviations, representing the standard uncertainty associated to each of the 
individual operations of an analytical procedure. The “bottom-up” approach 
incorporates all conceivable or potential sources of uncertainty of a method and 
covering all steps or components of the test, examination or procedure that 
produce the result in focus. This analytical approach is based on mathematical 
models formulated to account for the interrelation and interactions of all the 
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influence quantities that significantly affect the measurand in the measurement 
process, being the major sources of variability often assessed by method 
validation studies, experiment or from available information. Applying the law of 
propagation of uncertainties, the several standard uncertainties considered as 
influencing the measuring process are then combined to provide, after 
multiplication by a coverage factor, an expanded uncertainty associated with the 
specific result. 
As the GUM bottom-up approach reveals to be dense and involved in complex 
mathematical formulae and calculations, it is for many authors unfit to the 
medical laboratories and not being the method of choice for routine medical 
testing. The “top-down” approaches, also called “empirical”, on the other hand, 
start from real data, from results obtained from multiple measurements. Medical 
laboratories employ quality control schemes and reference materials to 
estimate, monitor and validate their methods, having available all the data from 
these laboratory test performance assays (method validation; internal quality 
control; inter-laboratory evaluation schemes), allowing them to use this 
information to calculate estimates of the standard uncertainty associated to the 
results produced by the overall testing procedures/methods [31].  
This approach, considered as the most appropriate for routine medical 
laboratory tests, is generally recognised as a direct estimate of the combined 
standard uncertainty of the whole procedure, respecting the principles of the 
GUM approach, but where the calculation is not based on the identification and 
knowledge of the all the different sources of uncertainty or the use of different 
mathematical models for the determination of each standard uncertainty. 
The “bottom-up” approach indicates the relative magnitude of the various 
sources of uncertainty, providing a clear understanding of the analytical 
operations that contribute significantly to the final overall uncertainty, allowing 
the analyst to identify and focus on improving these operations to reduce the 
uncertainty associated with test results. However it carries the risk of missing or 
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undervaluing a contributing factor, or missing a systematic error, which can 
result in underestimating the measurement uncertainty.  
The “top-down” approaches do not identify exhaustively all the independent 
sources of uncertainty, but assesses the measurement procedure as a whole 
using data from method validation, from intra-laboratory QC and inter-laboratory 
studies, or data obtained directly from the manufacturers, considering the 
random and systematic components of uncertainty and assuming the premise 
that all sources of variation or uncertainty affecting the final result of a 
measurement are reflected and contemplated. It is reasoned that the use of 
such data, generated over several months, will maximise the probability of 
including all potential contributions to uncertainty in estimates of measurement 
uncertainty. To medical laboratories, the “top-down” approaches avoid the risks 
of the “bottom-up” approach and, being its bases known and fully integrated in 
the laboratories routine procedures, they end up to be intuitive and possibly 
much more simply to implement.  
Again, according to the GUM, “the standard uncertainty of the result of a 
measurement, when that result is obtained from the values of a number of other 
quantities, is termed combined standard uncertainty and denoted by ݑܿ. It is the 
estimated standard deviation associated with the result and is equal to the 
positive square root of the combined variance obtained from all variance and 
covariance components, however evaluated; using what is termed in this Guide 
the law of propagation of uncertainty” (3.3.6). 
For example, if a measurement is considered to have three identified and 
measurable sources of uncertainty, a, b and c, for which the three standard 
uncertainties, or relative standard uncertainties, ua, ub and uc have been 
determined, then the combined standard uncertainty uc for the measurement is 
given by equation (2-1): 
ݑܿ = ඥuܽଶ + uܾଶ + uܿଶ (2-1) 
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2.2 Sources and Types of Uncertainty: 
 
For any of the approaches, each source or component of uncertainty can be 
assessed and calculated by different methods, depending this determination on 
the nature of the information/data available on the component itself, which can 
be classified as type A and type B. According to the Guide to the Expression of 
Uncertainty in Measurement (GUM) [2]: “the purpose of the Type A and Type B 
classification is to indicate the two different ways of evaluating uncertainty 
components and is for convenience of discussion only; the classification is not 
meant to indicate that there is any difference in the nature of the components 
resulting from the two types of evaluation. Both types of evaluation are based 
on probability distributions and, the uncertainty components resulting from 
either type are quantified by variances or standard deviations” (3.3.4). It is 
important to highlight, “these categories apply to uncertainty and are not 
substitutes for the words random and systematic” (3.3.3).  
So, standard uncertainty can be evaluated by two different methods; “Type A: 
method of evaluation of uncertainty by the statistical analysis of series of 
observations” (2.3.2); “Type B: method of evaluation of uncertainty by means 
other than the statistical analysis of series of observations” (2.3.3). Type B “is 
evaluated by scientific judgement based on all the available information on the 
possible variation of the measurand.  
The pool of information may include: 
i. previous measurement data; 
ii. experience with or general knowledge of the behaviour and properties of 
relevant materials and instruments;  
iii. manufacturer’s specifications;  
iv. data provided in calibration and other certificates;  
v. uncertainties assigned to reference data taken from handbooks” (4.3.1). 
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 When different sources of uncertainties are assigned to a measurement 
standard uncertainty, they can be of both, type A and type B. These standard 
uncertainties, or relative standard uncertainties, are combined according to its 
propagation law, or individual properties. Being the uncertainty sources 
considered independent (not correlated), individual standard uncertainties are 
combined using summation in quadrature, also called root sum of the squares. 
As mentioned by Badrick, et al. [32], when clarifying the concept of uncertainty 
and its applications in the medical laboratory, this variation or variability of the 
final result have five major components: pre-analytical factors, intra-individual 
variation, assay imprecision, operator differences and pathological processes.  
Technically, the pathological processes are the ones that in fact concern the 
medical practice and the clinician requesting the tests. It is this source of 
influence over a test result that must be valued in a patient’s evaluation. In 
consequence, the remaining components, or sources of variability, are the ones 
that need to be assured that are minimized and assessed in the laboratory, so 
they can be properly weighted and considered in the process of analysing the 
results presented. 
White and Farrance consider two major sources of uncertainty contributing to 
the total uncertainty of measurement of a routine quantitative diagnostic 
method. They characterize them as the “uncertainty associated with the value of 
a test result due to the random errors that normally occur when conducting the 
testing procedure” and the “uncertainty associated with the numerical value 
assigned to the measurand present in the calibrator material used in the routine 
method”, which “should be estimated by the commercial supplier of the 
calibrator” [33]. 
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So, on the analytical component, different variation factors affect the 
measurement accuracy. Measurement accuracy is defined by the VIM as the 
“closeness of agreement between a measured quantity value and a true 
quantity value of a measurand”, which is related to the conceptions in the GUM, 
since the objective behind the concept of measurement uncertainty is to 
determine an interval of reasonable values around the result where that true 
value of the measurand lies, i.e., “to estimate the dispersion of the values that 
could reasonably be attributed to the measurand”.  
“A quantitative estimate of the accuracy of a result is essential to define the 
degree of confidence that can be placed in it and the reliability of the decisions 
based on such result. Such parameter is the measurement uncertainty “ [34]. 
Thus, the concept of measurement uncertainty encompasses the combination 
of the variation components that affect the accuracy of a result, the qualitative 
performance characteristic of a measurement mentioned above. 
Mendito, et al. noticeably explain the concepts and the relation between the 
different performance characteristics [34], as illustrated on  
Figure 1. Assuming that variation sources influence a measurement result in 
both random and systematic ways, these concepts are directly related to 
accuracy, which includes the respective qualitative performance characteristic 
regarding random and systematic variation, precision and trueness.  
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Type of Variation Performance 
Characteristics 
Quantitative expression of 
performance characteristics 
   
Systematic  Trueness Uncertainty assigned to 
calibrator; Bias 
   
Total Variation Accuracy Measurement 
Uncertainty 
   
Random  Precision Imprecision (SD; CV %) 
(Intermediate precision; 
within-lab reproducibility) 
 
Figure 1 - Relationships between type of variation, qualitative performance 
characteristics and their quantitative expression. (Adapted from Mendito, et al. [34]) 
 
The VIM defines precision as the “closeness of agreement between indications 
or measured quantity values obtained by replicate measurements on the same 
or similar objects under specified conditions”, stating that “measurement 
precision is usually expressed numerically by measures of imprecision, such as 
standard deviation, variance, or coefficient of variation under the specified 
conditions of measurement”. In medical laboratories the concept can be 
translated to the performed IQC, where those long term determinations within 
the same measurement procedure, which can include different conditions, 
involving changes as new calibrations, different reagent lots or different 
operators, correspond to the intermediate precision determination, sometimes 
also known or addressed as “within-lab reproducibility” [35].  
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IQC is employed to assess the day-to-day testing and to technically validate test 
results on an everyday basis routine, monitoring the whole procedure’s 
imprecision. This is then accepted as the estimate of the intermediate precision 
of the measurement and considered to be the ideal source of data to the 
analytical random variation component, when determining measurement 
uncertainty [24, 31, 35-37]. 
Trueness is defined as the “closeness of agreement between the average of an 
infinite number of replicate measured quantity values and a reference quantity 
value”. “Measurement trueness is inversely related to systematic measurement 
error”, whereas bias is presented as the “estimate of a systematic measurement 
error” [1]. 
The variation associated with the calibrators used in the medical laboratory 
methods relates directly to trueness. The GUM, as the principles of 
measurement uncertainty, aims to the characterization of unbiased results, 
advocating the minimization, elimination, or correction, of any known bias. This 
minimization, and particularly its assurance, can only be accomplished through 
measurement’s metrological traceability, as stated by Dybkaer when 
considering that “the necessary anchor for the trueness of a measurement 
procedure is obtained by strict metrological traceability of result, based on a 
calibration hierarchy” [27]. The VIM describes metrological traceability as the 
“property of a measurement result whereby the result can be related to a 
reference through a documented unbroken chain of calibrations, each 
contributing to the measurement uncertainty”, which “requires an established 
calibration hierarchy”. Calibration hierarchy is described as the “sequence of 
calibrations from a reference to the final measuring system”, where the 
“measurement uncertainty necessarily increases along the sequence of 
calibrations”. 
 
 33 
 
Metrological traceability and calibration hierarchy concepts are understood and 
accepted in the medical laboratory scientific community, taken not only as the 
basis of results reliability and comparability, but as essential requirements to 
verify and fulfil in order to achieve the necessary and expected 
accuracy/trueness in medical laboratory measurements [38-41]. The relation 
between metrological traceability and measurement uncertainty is addressed 
and sustained in the ISO 17511standard [42], as illustrated in Figure 2, which 
together with another standard, the ISO 18153 [43], gives support to the 
European Union Directive 98/79/EC, on In Vitro Diagnostic (IVD) Medical 
Devices [44]. The EU Directive obligates manufacturers operating within the EU 
to assure and demonstrate the metrological traceability of their products, when 
used in conjunction with other components of their analytical system (platform 
and reagents), stating that ‘‘the traceability of values assigned to calibrators 
and/or control materials must be assured through available reference 
measurement procedures and/or available reference materials of a higher 
order’’. 
 
Figure 2 Relation between Metrological Traceability and Measurement 
Uncertainty (from ISO 17511:2003 Standard  [42]). 
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In addition to the previously mentioned standards, ISO provided further 
guidelines and requirements regarding the content and presentation of 
reference measurement procedures; the description of certified reference 
materials and the contents of its documentation and the requirements for 
reference measurement laboratories in laboratory medicine, respectively in the 
standards ISO 15193, ISO 15194 and ISO 15195 [45-47], which in general are 
applied directly to manufacturers and reference measurement laboratories, in 
the matters of traceability and standardization. 
The mentioned standards, which provide international agreement upon the 
requirements constituting higher-order reference materials and methods, serve 
as bases for the tasks of the Joint Committee for Traceability in Laboratory 
Medicine (JCTLM). The JCTLM was created in 2002 under the auspices of the 
Bureau International des Poids et Mesures (BIPM), the International Federation 
of Clinical Chemistry and Laboratory Medicine (IFCC), and the International 
Laboratory Accreditation Cooperation (ILAC), in response to the necessity of 
clarification on which reference materials and methods should be used by 
manufacturers and reference laboratories to anchor their assays [48]. Following 
on its own Mission Statement, JCTLM aims to support world-wide comparability, 
reliability and equivalence of measurement results in Laboratory Medicine, for 
the purpose of improving health care. 
The goal of JCTLM is to identify appropriate reference materials (RM) reference 
measurement procedures (RMP) and reference Measurement Services RMS), 
which is achieved through the operation of two working groups (WG): WG1 
assesses submissions for RM and RMP and WG2 assesses submissions for 
RMS. 
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According to Armbruster [48], medical laboratories perform analysis for about 
400-1000 different measurand, with only 10 % having well-recognised reference 
materials and methods exist and being traceable to the SI unit and others 
having either a reference measurement procedure or a reference material but 
not both. Referring that, to date, JCTLM identified reference materials and/or 
methods for about 120–150 analytes, he denotes that in the promotion of assay 
standardisation and global harmonisation in the clinical laboratories “the pace, 
completeness, and success of this movement depends on cooperation among a 
variety of entities, including professional societies, regulatory bodies and other 
governmental agencies, industry, and individual clinical laboratories” [48].   
Recently, the Journal of the International Federation of Clinical Chemistry and 
Laboratory Medicine (eJIFCC) dedicated its February (2016) issue to the 
“Harmonization of Clinical Laboratory Test Results”, in which Tate defined 
harmonization as the “ability to achieve the same result (within clinically 
acceptable limits) and the same interpretation irrespective of the measurement 
procedure used, the unit or reference interval applied, and when and/or where a 
measurement is made” [49]. As previously was affirmed, it is here reinforced 
that this achievement will englobe coordinate action, involving national and 
international associations and scientific societies and integrating the total testing 
process, with focused attention on the pre-analytical, analytical and post-
analytical phases [49, 50]. 
To promote harmonization among the 40 European Federation of Clinical 
Chemistry and Laboratory Medicine (EFLM) member societies the Working 
Group on the Harmonization of the Total Testing Process (WG-H) was recently 
established. The aims of the WG are: “1) surveying and summarizing national 
European and pan European harmonization initiatives; 2) promoting and 
coordinating the dissemination of especially promising harmonization initiatives 
among the EFLM member societies; and 3) taking initiatives to harmonize 
nomenclature, units and reference intervals at a European level” [51]. 
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Based on the results of its first questionnaire, surveying the status of various 
harmonization activities among the European laboratory medicine societies, 
some activities promoting the dissemination of best practice in blood sampling, 
sample storage and transportation, in collaboration with a Working Group on the 
Pre-analytical Phase, are already being promoted, as there are some initiatives 
to spread to all the European countries the use of SI units in reporting [51]. 
Similarly, the American Association for Clinical Chemistry (AACC) has created 
an International Consortium for Harmonization of Clinical Laboratory Results 
(ICHCLR), working with both its partners, domestic and international [52]. The 
consortium intends to address the key issues identified in an international 
conference promoted by the AACC, on traceability and harmonization in 
laboratory medicine. In order to organize the global harmonization efforts the 
infrastructure is to address: 1) prioritizing measurands by medical importance, 
2) coordinating the work of different organizations, 3) developing technical 
processes to achieve harmonization when there is no reference measurement 
procedure or no reference material and 4) promoting surveillance of the 
successes of harmonization [52]. 
There is also an important role reserved to the industry and to manufacturers on 
the road to harmonization, as addressed by Armbruster that states the 
imperative for a close coordination between industry and professional bodies, 
particularly in terms of coordinating and prioritizing projects leading to product 
development, which are largely conditioned by time and costs. While attributing 
major importance to traceability to reference measurements, some concerns 
are identified regarding “the cost of harmonization which includes physician 
education, patient safety and investment in product redevelopment”, according 
to which the process must be considered and “carefully weighed to understand 
the benefit of harmonization” [53]. 
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2.3 Measurement Uncertainty in the Medical Laboratory  
 
In the medical laboratory, it has now been given a critical role to this concept 
and to the estimate of measurement uncertainty. Mandatory, regarding the 
process of laboratory accreditation, the implementation of this new tool, once 
adapted and put to function, will allow define, quantify and evaluate the quality 
of its procedures and results, assuring the reliability of the whole laboratory 
process, as well as of the values that it produces, making evidence of the 
laboratory quality and competence. 
Therefore, the decisive step towards this reality implies not only consensus and 
specific information or regulation, on the determination of values of 
measurement uncertainty directly applied to the medical laboratory, but also its 
wide dissemination and discussion, for a correct understanding by all the 
involved and a gradual integration of the concept. This will promote and 
encourage an adequate appreciation on the interpretation of its outcomes and 
applications in the laboratory, regarding clinical diagnostic and patient 
monitoring. Only exhaustively studying the problematic in a comprehensive way 
will allow to assess methodological approaches and to set future guidelines 
[54]. Questions about the very acceptance of physicians, confronted with this 
information, as well as its effect in the final clinical decisions are still 
unanswered. Will this process serve to improve the efficiency and effectiveness 
in the evaluation, interpretation and diagnosis [55]? The problems associated 
with uncertainties measurement will continue until their application and 
understanding extends to most laboratories at national and worldwide levels, 
being an essential requirement the involvement of the medical community 
(clinical pathologists and physicians) and its associations, as well as the 
medical laboratory technical staff (Biomedical Laboratory Scientists).  
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Meanwhile, this application to medical laboratories has been under discussion 
since the inception of the GUM, and there are authors who consider it 
inadequate or unfit for laboratory testing in health, and do not recommend its 
implementation [56]. Having been in the genesis of Total Error, and being one 
of the critics of the GUM and ISO 15189 requirements regarding measurement 
uncertainty, James O. Westgard recently affirmed: “Given the difficulties in 
implementing the original recommendations in the Guide to the Expression in 
Measurement (GUM), more guidance is clearly needed if laboratories are to 
characterize the uncertainty of their many different measurement 
procedures.”[57].  
Nonetheless, as addressed, in the medical laboratory, the concept and the 
concern with the estimation of uncertainty is relatively recent and there is no 
standardized or globally implemented procedure to calculate the measurement 
uncertainty associated to its results.  
Being an international perception and understanding that the classical modelling 
approach of the GUM is not the fittest for medical laboratories application, many 
consider that its direct application is not feasible at all.  
Several models and different approaches have been studied over the last years 
[58-63], not having yet resulted a consensus on its implementation. Although 
encouraged, the determination of measurement uncertainty is not a common 
practice in the laboratory tests in health, raising yet too many questions, 
analytical and clinical [54, 55], having its application been subjected to several 
contradictory arguments since the publication of the GUM [63-65].  
Applied research studies will enable to substantiate the generalization of the 
estimative/measurement of uncertainties in medical laboratories, contributing to 
spread this practice, grounding the reasons to its application and for the 
association of its values to the laboratory results in Clinical Pathology, which are 
nowadays, in modern medicine, the foundations of clinical decision-making and 
medical practice, with estimated 70-80% influence in decisions affecting 
diagnosis or treatment [66-69]. 
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The sources of uncertainty of a medical laboratory result are many and varied 
but, focusing on “Top-Down” approaches, can all be embedded under the 
following broad categories: Biological Variation; Pre-Analytical Variation; 
Analytical Variation. 
In the literature are advocated several different combinations on this categories 
in order to reach a final estimate of measurement uncertainty. Some models 
value one category more than another; some emphasize different points on the 
process, not contemplating others; some even ignore or just discard one 
category, devaluing its contribute or considering that it is being accounted 
somewhere else along the way.  
Thereby, even when following a “Top-Down” approach, there can be found 
different models and procedures being applied to assess measurement 
uncertainty. There are reductive models, that directly transfer the concepts of 
Total Error to a process of combination of data from imprecision and bias, using 
this data as values of standard uncertainties to obtain the combined 
uncertainties, that are expanded to the final uncertainty of the results [70, 71], 
these arguments are also stated by Panteghini in an editorial of Clinical 
Chemistry and Laboratorial Medicine (CCLM), the official journal of the 
European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) 
[72]; There are some that take into account other factors, like the uncertainty 
associated to calibrators, internal QC or certified reference materials used in 
intra- and inter-laboratory test assessment schemes [73, 74]; Others argue 
about the inclusion, exclusion or correction of bias, or recall and include pre-
metrological factors and variability [31, 75, 76]. 
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3 Framework – Laboratory and Analytes 
 
3.1 GNÓSTICA - Medical Laboratory 
Gnóstica – Medical Laboratory (GN) was founded in 1986 and develops its 
activity of providing health services in the area of Clinical Analysis, which have 
always been done based on adequately controlled processes with the purpose 
of obtaining high quality results.  
In 2003, the awareness that the practice of quality services should be regulated 
and controlled by European and National Standards led to the implementation 
of a Quality Management System, using as reference the Portuguese Edition of 
the ISO 9001:2000 (NP EN ISO 9001:2000). Thus, GN was certified by the 
National Agency, the Portuguese Quality Institute (IPQ), within the scope of NP 
EN ISO 9001:2000, by the end of the same year. 
 
Figure 3 - Gnóstica Medical Laboratory (GN): A) Building facade; B) Waiting 
room; C) Sample collecting room. 
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The prospect of progress towards Total Quality, based on a continuous 
improvement philosophy, encouraged the ambitious process of accreditation by 
the NP EN ISO 15189:2007. The procedures were initiated in 2008, with the 
Portuguese Institute of Accreditation (IPAC), having the Laboratory obtained its 
Accreditation Certificate by the Standard NP EN ISO 15189:2007 in 2009 
(Appendix D), for 86 tests. The following year these were extended to a total of 
96 accredited tests.  
Fulfilling the requirements of ISO 15189, besides the methods validation 
protocols and the implemented IQC System  in the day-to-day results validation, 
GN meets the external validation requirements by participating in several 
EQAS, namely the Portuguese Program of External Quality Assessment 
(PNAEQ), from the reference laboratory of the National Health Institute – Dr. 
Ricardo Jorge (INSA); Randox - International Quality Assessment Scheme  
(RIQAS); Spanish Society of Clinical Biochemistry and Molecular Pathology 
(SEQC); National External Quality Assessment Scheme (UKNEQAS).  
 
Figure 4 - Gnóstica: external collection sites in the Algarve region. 
GN stands as the only Accredited Medical Laboratory in the south of Portugal 
(regions of Alentejo and Algarve). It currently have 41 external collection sites in 
the Algarve region, supporting the central laboratory, which registered a total 
volume of 962.822 tests performed last year (2015) for a total of 104.820 
patients.  
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Figure 5 - Roche’s auto-analyser cobas®6000: 1) Core unit; 2) C501 module; 3) 
c601 module. 
The clinical chemistry laboratory is equipped with Roche’s system. The auto-
analyser cobas® 6000 is constituted by two different modules, the cobas® c501 
and the cobas® e601, which can be assembled in 7 different module 
combinations, with up to 3 modules in one core unit, capable of running more 
than 160 assays on a single platform, as presented on Appendix E. The 
cobas® c501 is a photometric measuring unit (including ISE) and the 
cobas® e601 unit is based on ECL (Electrochemiluminiscence) Technology. All 
of the analytes in the study were determined on the cobas® c501 module, using 
the manufacturers' own and recommended methods and reagents, as well as 
calibration and control materials. 
 
Figure 6 - Roche’s auto-analyser cobas®6000 (side view) 
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3.2 Analytes: decision-making 
 
Before starting the first practical approach and implementation of the different 
methodologies for the determination of measurement uncertainty (MU) in the 
medical laboratory, it was necessary to take some decisions on the subject, in 
order to narrow the options and to define which analytes to include in the study. 
The list started with a list of 35 Clinical Chemistry possible analytes, which 
regarding the determination methods practically all were photometric based 
(only a few tests on the list were potentiometric). Considering the method 
performance for each analyte, were found 20 analytes with a result of excellent, 
4 with good, 4 within the acceptable, 6 that are non-conforming and 1 with no 
references. This evaluation based on comparing the Total Error for each analyte 
with the values from the “Desirable Biological Variation Database 
Specifications” [17]. (Should be noted that the non-conforming methods all 
proved to be inside the specifications of the “CLIA regulations table” [18], which 
also establishes guidelines for analytical quality requirements and acceptable 
performance criteria for medical laboratories, as stated before, being this way 
considered that all the methods fulfil the minimum desirable quality 
specifications.) 
Some studies on MU were found in the literature which, despite the different 
approaches being used, addressed some of these analytes and provided not 
only different perspectives on the theme, but also comparison data for future 
results to be obtained. Glucose was the most studied analyte, with several 
references [31, 59, 60, 70, 74, 76-79], followed by Creatinine with [70, 79-82]. 
Could also be found more than one reference to seven other analytes, being 
Albumin, Calcium, Alkaline Phosphatase, Potassium, Magnesium, AST/GOT 
and ALT/GPT. 
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Weighted the factors, and also after discussing the subject with the Technical 
Board at GN, the decision fell on Glucose, Creatinine and Total Cholesterol. 
Were chosen two different analytes already addressed in other studies, and so 
with data to compare if necessary and suitable, as well as an analyte with fewer 
studies on this matter (Total Cholesterol). This would contemplate two analytes 
with excellent quality performance, as well as one non-conforming, accordingly 
to the mentioned criteria (Creatinine), with three different test methods 
(Creatinine: kinetic method; Glucose: enzymatic UV method; Total Cholesterol: 
enzymatic colorimetric method).  
Although it was possible to starting with more analytes, that can also be done 
afterwards, as the intended is a future enlargement of the study, taking 
advantage of the framework of this work in order to implement this methodology 
to the whole laboratory.  
Nevertheless, the aim of the current study will always be to test and validate an 
approach and formula to estimate MU, able to be implemented in the laboratory 
and accepted by IPAC in the NP EN ISO 15189:2014 accreditation process. 
 
 
 45 
 
4 AIMS and OBJECTIVES 
 
4.1 Aims 
 
Based on the presented presuppositions and given the lack of studies on 
estimation of measurement uncertainty in Portugal, especially on its application 
in the medical laboratory, it is intended to study the subject, in an exercise 
exclusively dedicated to methods of quantitative analysis, particularly in the field 
of clinical biochemistry.  
In order to achieve this, different approaches and formulae for the estimate of 
measurement uncertainty will be tested and compared, considering its 
application in the context of the medical laboratory. The appraisal on the 
applicability and quality gains of the different models will enable focused 
discussion and considerations, allowing inferring or even concluding about their 
practical validity. 
In the course of the study, each formula and its outcomes will be appreciated 
and valorised bearing in mind the diverse sources/categories of uncertainty 
identified with direct and measurable influence on the final result. For instance, 
will be considered the inclusion/exclusion of Bias or of the uncertainty values 
assigned to the calibrators, as well as the assessment and quantification of the 
uncertainty of the pre-analytical phase and its variables; always prioritizing the 
suitability of each model and its applicability in the laboratory daily routine. 
Hopefully, this study will contribute to definition and optimization of a 
generalized model for the estimation of uncertainties associated to results in the 
clinical laboratory, subsequently providing easy access to it, allowing its wide 
application in Medical Laboratories and enabling the standardization of 
determination models and the comparison of estimated values. To achieve a 
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model that can gather consensus means to achieve a model that fits the 
characteristics of medical laboratories and meets their specific realities. This will 
allow a practical application of uncertainties measurement and its 
dissemination, liberalizing this procedure and, eventually in the future, the 
emission of results in clinical laboratories along with their associated uncertainty 
values. But, this is yet another subject held in great discussion, regarding the 
medical laboratory scientific community, but also and more importantly, the 
“costumers” of the laboratory, not only the users, but particularly the clinicians, 
situation that will require joint actions on the education of the involved. .   
The ultimate objective will be to ensure a formula that fulfils the mandatory 
requirements for laboratories accredited within the NP EN ISO 15189:2014 
standard, regarding the estimate on measurement uncertainty requisite, 
complying with the regulations of the Portuguese Accreditation Institute (IPAC).  
Consequently it aims to enable the Accreditation of Medical Laboratories in 
Portugal, in regards to this particular requirement, while meeting the principles 
concerning the measurement uncertainty estimate when applied to medical 
laboratory and clinical purpose. 
 
 
4.2 Objectives 
 
In a general overview, the various landmarks of the progress until the final goal 
can be easily identified and summarized. This set of milestones, described 
ahead in more detail, will be composed by: 
1. Characterization of the laboratory’s path and evolution towards its total 
quality goals. Retrospective analysis of data from the Quality 
Management System (QMS),  considering the progress in the quality 
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indicators (QIs) outcomes alongside the implementation of the 
Certification and, later, Accreditation processes; 
2. First approach to the measurement uncertainty estimation, comparing 
the application of two different formulae; (2011) 
3. Study focused on the pre-analytical phase, aiming to quantify the 
laboratory’s uncertainty associated to the pre-analytical variation. The  
pre-analytical variables represent a category, or source, of measurement 
uncertainty considered in one of the formulae implemented on the 
current study, in which was previously used data from the literature. 
4. New application of the previous formula, with the input of the obtained 
data regarding the pre-analytical uncertainty, directly associated to the 
specific conditions, materials and procedures of the laboratory in 
question. (2013) 
5. MU Estimate – Gnóstica’s Accreditation process and audit: presentation 
of a preliminary MU report, by the time of the first IPAC’s audit, regarding 
the accreditation process at Gnóstica, under the scope of the new a 
preliminary report is intended to be presented, NP EN ISO 15189:2014.    
6. Corrections and adjustments to the MU formula, considering the previous 
results and state of the art publications on the subject. Application of the 
final formula. (2015) 
7. Working spreadsheet to implement in the laboratory’s own quality 
procedures and routines providing an instrument that is credible and fit 
for purpose as well as user friendly and perfectly able to be integrated as 
one of the QMS assessment tools, giving response to Accreditation 
guidelines and standards and to its requirements on evidences of quality 
for the laboratory's analytical process and technical competence. 
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Figure 7 - Estimating Measurement Uncertainty in the Medical Laboratory - PhD Timeline 
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5 METHODOLOGY 
 
 
5.1 Quality Indicators 
 
An implemented quality management system intends not only to assure the 
quality of the processes and of the results, but it aims to support a full quality 
service, having the purpose of driving the whole structure towards this principle.  
When an organization develops its work based on a quality philosophy, with 
well-defined quality policies, quality improvement must be implicit in every 
aspect of the day-to-day practice and has to make part of the routine 
procedures and working habits off all the staff.  
Accreditation under ISO 15189 standard [5], in its Management Requirements, 
defines the need of a continual improvement concern and the demonstration of 
effective measures to identify opportunities for improvement, with the 
establishment of goals in all areas of the laboratory activity. This encompasses 
the pre-analytical, analytical and post-analytical phases, which should be 
assessed and subject of management reviews in order to compare the 
laboratory’s performance and to promote the development and execution of 
corrective and preventive actions. 
In order to accomplish this, the laboratory “shall establish quality indicators to 
monitor and evaluate performance throughout critical aspects of pre-
examination, examination and post-examination processes”.  These quality 
indicators, which shall be periodically reviewed to ensure their continued 
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appropriateness, enable monitoring non-examination procedures, providing 
valuable management information, allowing to systematically evaluating the 
laboratory’s contribution to patient care [5]. 
With the objective of characterising Gnóstica Laboratory, particularly in regards 
of its general quality outcomes, the most reliable source of information are its 
performance indicators, which allow following the development and 
improvement of some quality references. This monitoring process gives direct 
information on the laboratory’s performance and evolution in all areas, not 
restricted to the analytical results, demonstrating the growth of the laboratory in 
consequence of its investment in matters of quality policies. 
This study started with a retrospective analysis of the laboratory’s Quality 
Management System data, considering the evolution of several QIs during the 
implementation processes of NP EN ISO 9001:2000 Certification first, and 
afterwards Accreditation by the NP EN ISO 15189:2007. This aimed to evince 
the advantages of each of these processes, with a demonstration of the benefits 
and gains of choosing and implementing quality policies in a laboratory and of 
looking towards the offer of better services, client satisfaction and high quality 
results delivery. 
 
Figure 8 - Timeline from the process of Certification (NP EN ISO 9001:2000) to 
Accreditation (NP EN ISO 15189:2007) of Gnóstica Medical Laboratory 
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To evaluate the results of the QMS along the upgrade from Certification to 
Accreditation, the main Quality Indicators from Pre-Analytical, Analytical, and 
Post-Analytical phases were analysed for the period from 2003 to 2010.  
The data was accessed and collected from the laboratory’s QMS annual 
reports. The QMS review is an essential step of the quality chain and 
procedures, being the annual reports and the respective review meetings, for 
results analysis, requirements of the implemented quality standards.  
Aiming to a total quality management and continual improvement, these 
documents gather information relating to all the laboratory's services and 
practices. Procedures from all the phases of the laboratorial process are here 
considered, using the internal daily routine quality records and an anonymous 
questionnaire distributed annually to laboratory users. The QMS keeps records 
of key quality and performance indicators, identified and assessed for each one 
of these phases, right from the user’s first contact and registration, until the 
delivery of the results. 
Thus, being a part of the laboratory’s quality policy and procedures, the 
performance of Gnóstica Laboratory, the conditions and services offered to its 
clients, as well as their satisfaction and quality perception, are assessed by the 
results of the anonymous questionnaire, which is randomly applied every year 
to the users. A grand total of 3477 completed surveys were analysed, during 
this period. 
Referring to the pre-analytical phase the waiting time and the registry errors 
regarding user’s data/identification or requested tests (such as wrong names or 
the change/absence of analyses from the request) were analysed.  
On the analytical phase, to follow the evolution of the QIs, were controlled the 
numbers of repeat testing and evaluated the results from the External Quality 
Assessment Schemes.  
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Finally, were considered the errors detected on the post-analytical phase and 
also studied the records of the execution of the tests, with the turnaround time 
being assessed in terms of fulfilment of expected delivery date and the rate of 
results delivered in the same day of the request/sample collection.  
The information on the Management System was also considered, to analyse 
the evolution of the Laboratory regarding the number of users/clients and 
numbers of tests/analysis through the years.  
The results of this study were presented in the IFCC‐WorldLab‐EuroMedLab 
Congress; 21th International Congress of Clinical Chemistry and Laboratory 
Medicine; 19th IFCC ‐ EFCC European Congress of Clinical Chemistry and 
Laboratory Medicine; 8th Annual Meeting of the German Society of Laboratory 
Medicine and Clinical Chemistry; in Berlin (2011). The work was presented as a 
poster communication titled “Quality Indicators in a Clinical Laboratory: from 
Certification to Accreditation”. (Appendix B) 
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5.2 Measurement Uncertainty in the Medical Laboratory (I) 
 
 
5.2.1 Application of two different MU estimate formulae 
 
The experimental design for the first practical incursion in the study starts by 
adopting/defining two different measurement uncertainty estimating models, 
both according to Top-Down reasoning, followed by the application of the two 
formulae in the ISO-15189 Accredited Clinical Laboratory – Gnóstica Medical 
Laboratory. In each of the approaches, to achieve a final value of MU, the 
different dimensions of measurement uncertainty were then considered. 
Subsequently, the different sources or, better saying, categories of uncertainty 
contributed with a partial value to the final estimate.  
After assessing the several components of uncertainty in the procedure, which 
were considered as having a relevant contribution to the result, these 
intermediate values were converted to relative standard uncertainties to be 
combined and finally multiplied by a coverage factor, to give the final expanded 
uncertainty (U).  
Being both models based on the laboratory’s QMS data (year: 2011), one 
restrictedly used the laboratory’s IQC data and EQAS results, for imprecision 
and bias, adapting the concept of TE and combining the considered variation 
components in a squared model [83]. The second approach added a different 
perspective; with different variables being taken into account. Focusing on the 
uncertainty sources and on its influences along the different phases of the 
measurement process, was considered the data associated to the calibrating 
materials, provided directly by the manufacturers, being also introduced the 
well-known concept, often neglected in its quantification, of pre-analytical 
variation. 
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Therefore, were considered and applied Models A (MU-A) and B (MU-B). Each 
estimate followed a sequence of different basic steps that guide the 
implementation of the model, allowing a structured determination and a well-
defined evaluation of MU, as described below: 
 
MU-A) A six step uncertainty calculation model was used to evaluate MU [31, 
35, 70]: 
- Step 1: Defining the Measurand;  
- Step 2: Imprecision of Measurement;  
- Step 3: Bias of Measurement;  
- Step 4: Converting the components to a standard uncertainty;  
- Step 5: Calculate combined standard uncertainty;  
- Step 6: Calculate Expanded uncertainty / Expression of MU. 
 
The complete estimate is supported by the application of equation (5-1) to 
calculate the Expanded MU (with k=2, for a coverage probability of 95%). 
 
	ܷ = ݇	.ඥuܫ݉݌ݎ݁ܿ݅ݏ݅݋݊ଶ + uܤ݅ܽݏଶ (5-1) 
Considering the day-to-day imprecision and the bias value, 
respectively as the random and systematic variation components. 
 
MU-B) MU estimate by calculating the combined uncertainty (uc) using equation 
(5-2):  
	ݑܿ = ඥuܫ݉݌ݎ݁ܿ݅ݏ݅݋݊ଶ + uܥ݈ܽଶ + uܲݎ݁ଶ (5-2) 
In which was considered:  
- ݅) day-to-day imprecision;  
- ݅݅) uncertainty of the calibrator assigned value;  
- ݅݅݅) Pre-analytical variability.  
 55 
 
Subsequently, the same coverage factor was then applied to obtain the 
Expanded Uncertainty (U), as demonstrated by equation (5-3). 
 
ܷ = ݇	. ݑܿ (5-3) 
With the previously obtained combined uncertainty being multiplied 
by the factor k=2, for a coverage probability of 95%. 
 
Only with the purpose of comparison, was also presented and considered the 
values for Total Error, obtained from equation (5-4), where the estimate of bias 
is combined with the estimate of the methods imprecision (CVA) multiplied by a 
factor (z=2), also for a confidence interval of 95%.  
ܶܧ = bias + ݖ	. CVA (5-4) 
Again considering the day-to-day imprecision and the bias value, 
respectively as the random and systematic variation components. 
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5.2.2 Material and data  
 
As mentioned before, in the different approaches and MU estimates the data 
from the laboratory’s QMS will be used, namely the data from the IQC and the 
EQAS. Whenever possible and/or relevant, will also be used specifications and 
data from the manufacturers, as well as data from the literature, when needed 
and justified.  
In each estimate, the IQC material will contemplate the average results of each 
month's quality control results, regarding the year to which it refers, using two 
levels of control, normal/physiologic and pathologic levels, for each of the 
equipment in assessment. The data from the EQAS evaluation, performed 
monthly at the laboratory, provides for the bias results for each month, with the 
average corresponding to laboratory bias used in the subsequent calculations. 
The pre-analytical component was based only on reports in the literature. Were 
considered different publications [79, 84-87] and was used the data for pre-
analytical uncertainties from the studies of Fuentes-Arderiu, et al. [85], 
estimated regarding the global procedure variation, without differentiation of the 
individual steps.  
The values assigned to the calibrators, as stated, were obtained from the 
manufacturer’s specifications, in the case from the data on Traceability and 
Uncertainty - Cobas® c501 / c502 / c311 / c701 / c702 (C.a.s.f.), from Roche® 
(Appendix F), which presents values for Expanded Uncertainty (k = 2); that 
were assumed by the manufacturer to have been calculated in accordance with 
the “Guide to the expression of uncertainty in measurement” (GUM). 
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5.2.3 Expectations 
 
By  comparing the outcomes from the application of the two different uncertainty 
budgets, it was expected to proceed with the desired evaluation on the 
suitability of the different models to the clinical laboratory. Possibly this would 
enable the identification of eventual flaws in the estimates. It would also allow 
considering about the sources/components of uncertainty assessed, and its 
significant value, in way to conclude on the applicability and even validity of 
each of the models in study. 
The results of this study were presented in the 20th IFCC - EFLM European 
Congress of Clinical Chemistry and Laboratory Medicine; 21th International 
Congress of Clinical Chemistry and Laboratory Medicine; 45th Congress of the 
Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC); 
in Milan (2013). The work was presented as a poster communication titled 
“Measurement Uncertainty in the Medical Laboratory - Implementation and 
Evaluation of two Different Formulas in Clinical Chemistry Parameters: Total 
Cholesterol, Creatinine and Glucose Measurements”. (Appendix A) 
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5.3 Pre-analytical Uncertainty 
 
The pre-analytical phase, although widely recognized as the stage comprising 
the largest percentage of error rates in the total testing process, estimated to 
account for 60% to 70% of all the errors and occurrences in the medical 
laboratory [88-91], it is also often taken for negligible as a source of variation, or 
uncertainty, to the final result, as long as its procedures are standardized. 
However, these assumptions have already been disproved, or at least 
challenged, by several different authors [79, 84-87]. Despite not being 
considered by some measurement uncertainty approaches, that although 
recognizing the effects of the pre-analytical variation focus their attention only 
on the analytical phase, there are many who support its inclusion, defending 
that the variation associated to the pre-analytical phase should not be 
considered negligible and its value should be included when estimating 
measurement uncertainty in the medical laboratory [32, 59-61, 75]. The 
European Diagnostic Manufacturers Association (EDMA) supported these 
considerations in a position paper regarding the estimation of measurement 
uncertainties medical laboratories, when referring to the uncertainty sources to 
consider [92]. Also the Eurachem/Citac Guide for Uncertainty Quantification in 
Analytical Measurement [4] as well as the European guidelines on the 
expression of uncertainty in quantitative testing [3], although not explicitly 
covering the pre-analytical procedures, mention sampling and sample pre-
treatment as a source of uncertainty. 
When being considered as a source of uncertainty, the values of pre-analytical 
variation should be estimated by each laboratory, for its own conditions [92]. 
Ultimately, as addressed above, despite the standardization of the process, 
influences regarding phlebotomy and blood withdrawal; sample handling, 
including the pre-treatment process and processing time; the laboratory’s 
conditions (such as the waiting room, the collecting area or the Individual 
booths) and materials (collection tubes, centrifuge and centrifugation 
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specifications), or samples transportation and storage; may alter the 
measurable amount of an analyte in a sample and end up adding variation to 
the final result. This pre-analytical variation should then be acknowledged and 
taken into account in an uncertainty budget. It should also be considered 
specific to each laboratory in a reasoning eventually similar to the one applied 
to the variations in the analytical phase, which are properly valued and 
quantified, in spite of all the efforts, guidelines and procedures towards 
standardization of methods, equipment and materials. 
On this matter, being the literature extensive regarding the pre-analytical phase 
and errors, the bibliographical sources that provide quantitative information are 
rare, are not available for all tests/measurand and can hardly be considered 
wide-ranging or standardized so it can be directly and unconditionally  applied in 
any other laboratory and on its results. This literature can and should be used in 
an initial stage of the measurement uncertainty estimation process, being 
afterwards replaced by the laboratory’s own estimates. A laboratory’s estimate 
means a direct and representative value of the laboratory’s procedures and 
conditions, and so of its own pre-analytical uncertainty.   
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5.3.1 Gnóstica’s Pre-analytical Uncertainty Study 
 
Bearing in mind the presented facts, regarding the potential influence and 
significance of the pre-analytical phase in the total testing process, it was 
mandatory to include in this work a study of this uncertainty 
component/category and the quantification of the pre-analytical variation 
associated to the specific analytes in question.  
Considering that each laboratory should then estimate its own pre-analytical 
uncertainty values, for any quantities tested, it was implemented a protocol to 
this purpose, aiming to quantify this variable to subsequently substitute the data 
previously considered from the literature by values that correspond directly to 
the laboratory’s procedures and that are representative of its practices and 
associated variation. 
With the approval of the Management and Technical Boards of “Gnóstica - 
Medical Laboratory”, was developed and implemented an internal study to 
estimate and characterize the influence and variability from pre-analytical 
sources, associated to the laboratory’s patient results in the analytes of 
Creatinine, Glucose and Total-Cholesterol (The results of this study are not yet 
published, but a paper is in preparation to submit for publication in the Journal 
Clinical Chemistry and Laboratory Medicine (CCLM)). 
Thus, with the objective of estimate the uncertainty related to pre-analytical 
phase, were considered as sources of pre-analytical variation the following: 
sample collection (phlebotomy and handling); sample pre-treatment phase 
(processing and clotting time, before centrifugation); sample storage 
(refrigeration and freezing, after serum separation in different aliquots); sample 
transportation (considering the possible transportation of the samples by car to 
a central laboratory, after collection). 
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Gnóstica Laboratory, being NP EN ISO 15189 Accredited, has its procedures 
for the collection and for the handling of diagnostic blood specimen/samples by 
venipuncture standardized and validated. These standardized procedures were 
followed and the blood collection was performed by certified and trained 
phlebotomists, from the laboratory’s technical staff.  After signing an informed 
consent, 37 random users, attending the laboratory with programed routine 
tests previously ordered by their physicians, were voluntarily recruited to the 
study. The blood collection was made by the same phlebotomist, in both arms, 
on two different venous punctures, using the laboratory's standard collection 
tubes, with clot activator and gel for serum separation. For each person the 
samples were taken consecutively, reducing at the most the time interval 
between withdrawals, so that the effect of intra-individual variation could be as 
minimum possible, allowing it to be neglected. 
Following the laboratory’s standardized procedure all the tubes were 
centrifuged in a refrigerated centrifuge (4˚C), at 4500rpm for 15 minutes 
(Heraeus Megafuge 1.0R Refrigerated Benchtop Centrifuge). 
The tests were performed on two identical Cobas® 6000 – c501 module 
(Roche®), operating in the same room, under the same conditions, handled by 
the same technicians and using the same lot numbers of reagents, control and 
calibration material (Cobas® c501 / c502 / c311 / c701 / c702 - C.a.s.f.), from 
Roche® (Appendix EF). 
In all the tests the measurand for each analyte was the amount-of-substance 
concentration in the human serum samples analysed. For the Creatinine 
measurement the Cobas® 6000 – c501 module uses the Kinetic Jaffé Method 
(Rate blanked & compensated, Gen.2), a kinetic colorimetric assay. In alkaline 
solution, creatinine forms a yellow orange complex with picrate. The rate of dye 
formation is proportional to the creatinine concentration in the sample. The 
assay uses “rate-blanking” to minimize interferences, namely by bilirubin. 
Glucose was performed by the Hexokinase/G-6-PDH Method, in which 
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hexokinase (HK) catalyses the phosphorylation of glucose by ATP to form 
glucose-6-phosphate and ADP. Following this reaction, a second enzyme, 
glucose-6-phosphate dehydrogenase (G6PDH) is used to catalyse oxidation of 
glucose-6-phosphate by NADP to form NADPH. The concentration of the 
NADPH formed is directly proportional to glucose’s concentration in the sample. 
Total Cholesterol was determined by CHOD/PAP Gen. 2 Method where 
cholesterol esters are hydrolyzed by cholesterol esterase (CE) to cholesterol 
and free fatty acids. Free cholesterol, including that originally present, is then 
oxidized by cholesterol oxidase (CHOD) to cholest-4-en-3-one and H2O2. In 
presence of peroxidase (POD), the formed hydrogen peroxide affects the 
oxidative coupling of phenol and 4-aminoantipyrine (4-AAP) to form a red-
colored quinoneimine dye. The  intensity  of  the  color  produced  is  directly  
proportional  to  cholesterol concentration. Roche’s equipment methods and 
calibrators assure the traceability of the measurement to isotope dilution mass 
spectrometry (IDMS) reference measurement procedure. 
For each individual, Sample A (obtained from tube 1), corresponded to the 
sample collected within the referred programed tests, being its results included 
as the reference result for Sample B. From the second puncture, always 
performed on the other arm, three tubes were withdrawn (tubes 2, 3 and 4), 
which provided Samples B, B1, B2, C and D, respectively, being B, B1 and B2 
different aliquots from tube 2. The results from sample B were then used as the 
reference for the following samples. The study’s design is schematically 
represented in Figure 9, below: 
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1st Puncture 
(Arm 1) 
 2nd Puncture 
(Arm 2) 
           
Tube 1  Tube 2  Tube 3  Tube 4 
           
 
 
Recommended Clotting Time 
 
(30 min; room temperature – 20˚C) 
 
Pre-
treatment 
Delay 
 
 (90 min) 
  
Pre-
treatment 
Delay 
 
 (90 min) 
 
Transport 
(4˚C) 
 
(120 min) 
           
Centrifugation:4500 rpm x 15min (4ºC) 
           
Sample A  Sample B  Sample B1  Sample B2  Sample C  Sample D 
           
     
Refrigeration 
 
(4˚C) 
  
Freezing 
 
(-22˚C) 
    
           
     
Preservation / Storage 
 
(72h) 
    
           
           
           
Testing / Analysis 
 
C1 - Cobas®6000 - c501 Module: Equipment 1; C2 - Cobas®6000 - c501 Module: Equipment 2 
Figure 9 - Experimental design to estimate the uncertainty of the Pre-Analytical 
Phase.  
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Thus, after the 30 minutes of recommended clotting time, the Tubes 1 and 2 
were centrifuged.  From tube 2 three aliquots were separated, corresponding to 
samples B, B1 and B2. Samples A and B were analysed without delay and 
samples B1 and B2 were respectively refrigerated at 4˚C and frozen at -22˚C for 
72h, before analysis. Tubes 3 and 4 were kept in the sample sorting area, at 
room temperature (20˚C) for 90 minutes, following then the procedure 
designated for each experiment. Tube 3 was centrifuged in the same conditions 
as the previous and then analysed. Tube 4 was transported by car, in a thermal 
transport case for diagnostic samples, with controlled temperature, for 
approximately 120 minutes and only then was centrifuged and analysed as the 
remaining tubes. 
 
 
5.3.2 Determination of Gnóstica’s Pre-analytical Uncertainty 
 
So, the uncertainty related to sample collection and handling was characterised 
by the variations between the results from samples A and B. Then, comparing 
the results form sample B with samples B1, B2, C and D, allowed evaluating 
respectively the effects of sample storage (refrigeration and freezing), delay in 
the pre-treatment phase and regional transportation, and to estimate the 
standard uncertainty associated to each of these variability sources. 
As stated before, according the definitions [2, 4, 35], the different sources of 
uncertainty that are combined into to a measurement uncertainty estimate, 
represent the several uncertainty components in consideration and are 
designated as standard uncertainties or relative standard uncertainties (u). 
Being, in general, the result of a measurement, they are usually given in the 
form of a standard deviation, a relative standard deviation (SD), or a coefficient 
of variance (CV %), as most commonly expressed in the medical laboratory, 
particularly in clinical biochemistry. 
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To obtain the pre-analytical uncertainties associated to each variable in study, 
the paired results between the reference samples and the different 
alternative/experimental procedures were evaluated. For such, each uncertainty 
source was separately studied, by applying a methodology previously used in 
studies of similar design [85, 87, 93-95]. 
Thus, the general coefficients of variation (CV %; for B, B1, B2, C and D), 
derived from the variances of each uncertainty source, were calculated with the 
mean of the 74 measurements done for each quantity in the correspondent 
evaluation (which includes analytical variation plus pre-analytical variation). For 
each quantity and variable in study, general analytical variance was derived 
from the difference between the results obtained for the different runs/analysis, 
by applying equation (5-5):  
ݏ2 = 	 ∑(ݔ − ݕ)ଶ2݊  (5-5) 
Where, s
2
 is the general analytical variance (analytical variance plus 
pre-analytical variance), x and y are the measurement results 
obtained for the different samples from the same individual 
(reference and in-study) and n is the total number of individuals. 
 
Afterwards, the coefficients of variation regarding the pre-analytical variation 
(CVPre %) were calculated for each quantity by subtracting the CVA, obtained 
from the day-to-day imprecision data from the laboratory’s QMS, from the 
general CV calculated for each variable (B, B1, B2, C and D), which resulted in 
each variability source’s standard uncertainty (u). 
Finally, using equation (2-1), the standard uncertainties were combined (uc pre) 
and, to conclude, the Expanded Pre-analytical Uncertainty (Upre) was obtained 
applying equation (5-3), on page 55, with k=2, for a coverage probability of 
95%.  
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5.4 Measurement Uncertainty in the Medical Laboratory (II) 
 
5.4.1 Application of the different MU estimate formulae - Gnóstica´s 
Pre-analytical Uncertainty (2013 Update) 
 
This step consisted in combining the protocols above, in sections 5.2 and 5.3, 
updating the values of the several components, or uncertainty sources, with 
new data (year: 2013). The results regarding the pre-analytical uncertainty 
component obtained in the previous point were introduced on equation (5-2), on 
page 54, replacing the data that was being used from the literature, enabling the 
determination of MU with the laboratory’s own pre-analytical variability estimate. 
 
5.5 IPAC’s Accreditation Auditing 
 
In Portugal, the laboratories accredited by the ISO 15189 Standard had the first 
preliminary auditing under the new requirements of the ISO 15189:2012 
guidelines in 2015, which then reflected the implementation of the Portuguese 
version, NP EN ISO 15189:2014.  
To this purpose, the first results of this study and collaboration, regarding the 
tests already addressed, Creatinine, Glucose and Total Cholesterol, were 
presented to the auditing team, for IPAC's consideration, as an initial approach 
for compliance with these new requirements. These were validated, contributing 
for the renewal of the accreditation certificate (Appendix G). 
Later on, early this year (2016), on a follow up auditing, having the previous 
report been accepted and positively considered, the laboratory was required to 
present evidence for the remaining 93 tests under the scope of the 
accreditation, as well as for the methodology applied in the final MU estimates. 
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5.6 Measurement Uncertainty in the Medical Laboratory (III) 
 
Following the previous studies, and after the first practical test on the 
applicability of the formulae, it was decided the final approach to implement as 
Gnóstica’s model to the MU estimates. The analysis and reflection regarding 
the results obtained until now, were the in the basis of the decisions made 
before getting to the final equation. This third application of the equation, still 
considering a last adjustment, or update, .will concentrate only on the chosen 
formula, being applied to the year’s 2015 data, once again collecting information 
form the QMS, from the pre-analytical study and from the manufacturer. 
 
 
5.6.1 Gnóstica’s MU Estimate - Final Formula (MU-B) 
 
This study, being an applied research project focused in a single laboratory, 
was developed with the purpose of reaching a formula able to fulfil and respond 
to the laboratory’s necessities regarding the accreditation requirements and 
procedures. Also, it was intended to meet Gnóstica’s own will and determination 
of offering a service, measurement methods and results with proven and 
recognized quality, complying with the international quality standards, by using, 
or including in the process, the data available from its Quality Management 
System.  
Thus, the provisional results obtained in sections 6.2 and 6.4, as well as the 
outcomes and experience from section 6.5 results external assessment, were 
considered and discussed along with the Laboratory’s Technical Board. The 
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initial approaches and its outcomes were reviewed and it was finally achieved a 
formula that fulfilled that primary objective. 
The way forward regarding the final approach and equation which to be 
implemented, was also decided weighting over previous published work on the 
subject, being that guidance based on publications of National Accreditation 
Bodies [96, 97], on reference documents like the NordTest Report [35], or paper 
articles and studies from different authors [31, 37, 58, 59, 61, 76, 82] on the 
estimate of measurement uncertainties in the medical laboratory, as done 
before. However, having considered this different information, the final formula 
was defined mostly aiming to reach a tailored approach, found to be suitable to 
the laboratory’s intents, conditions and available data, that was simultaneously 
fit for purpose and that complied with the identified requirements. 
Thus, was decided that the final formula should include the uncertainty values 
assigned to the calibrators, bearing in mind that these data, when available, 
should be used in the MU estimate, adding the traceability component to the 
estimate and data regarding the method’s trueness, over the bias values. These 
last, when identified should be eliminated or minimised, not being accounted for 
in the MU [33, 73], as long as proper traceability has been assured.  
Recently, Farrance, et al. affirmed that, whenever a stable performance is 
assured, with minimal deviation, confirmed over internal traceability studies or 
proficiency testing surveys, assuring that it remains internally consistent and 
consistent with the comparator, “bias becomes largely irrelevant”. This 
considered bearing in mind that “result interpretation is largely by comparison”, 
being the test results always compared to patient’s previous results or 
population reference intervals [98].  
Nevertheless, bias might be considered significant. Whenever calibrator and 
method’s trueness and traceability cannot be assured or when, on its 
assessment, it violates the minimum desirable specifications, being considered 
international performance tables or a group’s mean in proficiency testing, it 
clearly indicates the presence of undesirable bias values. In these situations, if 
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not corrected and if considered significant after proper evaluation [25, 35, 99], it 
could be combined in the estimate.  
Other defended point of view stands that treating bias as a variance and adding 
it to the MU estimate can lead to misjudgements of its influence on the test’s 
performance, considering that it should never be included in the MU, but 
assessed and reported separately [100]. Once again, Farrance, et al., states 
that “having separate procedures for the assessment of imprecision and bias 
however, is simple and inherently logical” and that for a laboratory “what is 
required by ISO 15189 is to document (and understand) your chosen process” 
[98]. 
The influence of the pre-analytical phase on laboratory’s measurements and 
results was already addressed in section 5.3 and is demonstrated by the results 
on section 6.3. Although always referred to in guidelines and in different studies 
or opinion articles, this uncertainty source is frequently disregarded in the final 
uncertainty estimates. So, assuming the existing variations, even in 
standardized systems, was decided to also include this component in the final 
estimate. 
Finally, taking into to account the necessity of obtaining a flexible and broad 
model, covering the range of physiological and pathological values of test 
results, it was decided to calculate an overall long term value for the random 
variation, or laboratory’s intermediate precision component, by the use of a 
global and inclusive CV (CVpooled), being it a weighted mean of a large time 
interval (one year) at different concentration levels. This methodology recently 
proposed [99, 101] in other “top-down” approach studies, based on the 
NordTest Report TR537 [35], had already been defended to be the best to 
combined different imprecision estimates, for example for different levels of an 
IQC for the same measurement method [102]. The proposed methodology 
presents a random component of uncertainty calculated using the weighted 
mean of the monthly CV, of at least 6 months. Thus, in this study, using data 
from IQC performed at normal and pathological concentration levels, the long 
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term imprecisions (one year period) were combined with base on equation 
(5-6): 
ݑܫ݉݌ݎ݁ܿ݅ݏ݅݋݊ = ඨ൫(݊ܣ − 1) × ܥܸܣଶ൯ + ൫(݊ܤ − 1) × ܥܸܤଶ൯൫(݊ܣ + ݊ܤ) − 2൯  (5-6) 
In which: 
- A) is the Level 1, or Normal Level Control: 
- B) is the Level 2, or Pathological Level Control; 
- n) represents the number of entries/months considered for the 
pooled CV calculation;  
- CV) is the mean coefficient of variation for that period. 
Thus, with the above update in its application, the final MU-B model formula, 
initially represented in equation (5-2), on page 54, was then considered to be 
the one best fitting to the laboratory's objectives and to the study's purposes. 
This final equation and its outcomes were considered to be representative of 
the measurement process and the best estimate for the uncertainty of 
measurement and of the results. Thereby, it was lastly applied to the 
laboratory's data, for a final assessment. 
 
5.6.2 Standard Uncertainties’ Index 
 
Aiming to provide a visualization of the relative contributions from the different 
relative standard uncertainties was calculated the index for each of the variation 
sources, within the combined uncertainty for the analytes and measurements in 
study.This exercise brings the benefit of easy and direct identification of the 
weight of every component in the global estimate. This allows for the laboratory 
staff, usually the quality department and management, to analyse the outcomes 
and, whenever necessary or justified, prepare any eventually improvement 
actions.  
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5.7 MU Estimate Final Tool – Gnóstica's working spreadsheet 
 
The final step, and objective of this work, was to develop a practical tool that 
could be easily implemented in the laboratory's quality routine procedures, for 
the estimation of measurement uncertainty of its results. 
The best way to accomplish that was to create an Excel® (Microsoft) 
spreadsheet, that contemplate the uncertainty sources considered and that, by 
simply updating the monthly or annual values form the laboratory’s QMS and 
other documentation considered, would able to deliver the Laboratory’s 
Measurement Uncertainty for the selected tests or measurements.  
It was also given room for some improvement opportunities to the formula, with 
the possibility of introducing other variable as uncertainty sources, considering 
for example specific studies or measurement conditions, or for specific 
processes of monitoring patient’s health and diseases. 
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6 RESULTS 
 
 
The following chapter contains the main results obtained in this project. These 
results were collected over the period from 2011 to 2016, from Gnóstica – 
Medical Laboratory. 
 
Data collection consisted in three different dimensions. First, for the 
retrospective study aiming to present the quality theme and to characterize the 
laboratory was gathered data from years 2003 to 2010 (section 6.1). Then for 
the uncertainty measurement project itself, the data was collected in 2012, 2014 
and 2016, respectively for sections 6.2, 6.4 and 6.5. As for the third, regarding 
the practical laboratorial work and data collection, for section 6.3, was 
developed between 2012 and 2013, with the data being obtained directly from 
laboratorial results reports. All the remaining data was obtained from the annual 
quality reports, compiled by the Quality Management Department of Gnóstica, 
within the procedures of the implemented Quality Management System. 
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6.1 Quality Indicators 
 
This Section presents in Table 6-1 a summarized description of the laboratory’s 
overall performance characteristics, general quality data and the quality 
perception, as perceived by its users. The information assembled by the 
laboratory’s Quality Management System, allows characterizing the laboratory 
and its quality practices, by presenting the improvements and evolution 
resulting from the implementation of planned quality policies, through the 
outcomes of the registered quality indicators. 
The data was accessed and gathered from the laboratory’s quality reports that 
assemble information from the anonymous questionnaires, which are applied 
every year to its users, assessing user’s satisfaction and their perception 
regarding the service’s quality; and from the quality system records, which 
registers and follows the occurrences and non-conformities of the daily routine, 
with indicators that cover the different phases of the total testing process, from 
the pre-analytical, starting with the user and analysis registry, to the post-
analytical, until the delivery of the results. 
In respect of to the presented indicators, the “User’s Overall Satisfaction” is 
measured directly from the users’ replies to the annual survey, with the results 
being graphically represented in the laboratory’s quality reports. These are 
shown, as examples, in the Appendix H, regarding the years 2005-2007, 2009 
and 2010. The graphical representation of the “Waiting Time %”, which reveals 
the user’s satisfaction and evaluation concerning the time expended when 
attending the laboratory for the necessary procedures to the scheduled medical 
analysis (blood withdrawal or other biological sample collection), is also 
presented in Appendix I, showing examples for the years 2003-2007. 
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To both of these categories the response options in the questionnaires are: very 
good, good, sufficient, mediocre and bad, being here presented the most 
demonstrative categories, which represent always around 95% or more of the 
grand total. 
As regards to the remaining indicators, this data is monitored by computer 
record throughout the year, covering the different phases of the laboratorial 
procedures, as mentioned. Here, in the table below, are presented: 
 
- Registry Errors (%): representing the percentage of detected errors that 
lead to posterior changes in the registry, being that the most common 
are regarding the user’s name/identification or are analytes/tests related, 
involving exchanged tests (with added or missing tests) ; 
 
- Sample Collecting Repetition (%): indicating the percentage of sample 
collection repetitions derived from errors detected in pre-analytical 
sample screening;   
 
- Waiting Time (minutes): which shows the data from the computerized 
records concerning the time spent by users when attending the 
laboratory,  between registry and sample collection;  
 
- Repeat Testing (#) and Repeat Testing (%): being the number (#) and 
respective percentage of tests/analysis repeated, in view of the total 
number of tests/analysis executed in that same year; 
 
- EQAS: this category presents the total number of Schemes (#) in which 
the laboratory participates, with the indication of the average percentage 
of Correct Results (%), in those same schemes, per year. 
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- Fulfilment of Delivery Date (%) and Same Day results (%): reveals the 
percentage of results delivered on the predicted deadline and of results 
delivered on the day of the sample collection; 
 
- Non-Conformities (NC; #) and Non-Conformities (NC; %): a non-
conformity (NC) indicates an error detected after the emission/delivery of 
a patient’s result that implies the repetition of any procedure and involves 
re-calling that user to the laboratory. Here it is presented the number of 
NCs (#) and its respective percentage, in view of the total of number 
users/patients of the respective year. 
 
- NC - Reception/Registry (#) and NC - Reception/Registry (%):represent 
the number (#) and percentage (%) of NCs with particular respect to the 
Reception/Registry procedures. Where, again, the most common error 
causes occur in the user’s name and personal identification data 
registration process or are analytes/tests related (exchanged, added or 
missing tests) during that same registry. 
 
The last data presented are the annual totals for the number of Completed 
Questionnaires, Users/Patients registered and attended at the laboratory, as 
well as Tests/Analysis performed by the Laboratory. 
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Table 6-1 – Gnóstica - Medical Laboratory: Evolution of the quality indicators (2003 - 2010) 
 
Quality Indicators 2003 2004 2005 2006 2007 2008 2009 2010 
User’s Overall 
Satisfaction (%) 
Very Good 
  
44,0 59,9 63,7 45,2 44,1 57,9 49,6 45,9 
Good 45,7 36,1 33,0 48,2 50,9 35,3 41,7 50,0 
Sufficient 3,1 1,3 1,1 4,4 4,5 2,1 3,1 1,5 
Pre-Analytical 
Phase 
Registry Errors (%) 2,8 2,8 3,1 4,1 3,0 3,5 2,8 4,8 
Sample Collecting Repetition (%) 1,2 1,1 1,1 1,1 1,2 1,1 0,9 0,7 
Waiting 
Time (%) 
Very Good 27,0 35,5 30,3 27,0 28,0 33,9 34,9 31,9 
Good 42,0 44,1 54,3 43,6 54,5 55,8 47,5 48,6 
Sufficient 26,0 19,5 15,4 23,9 15,9 19,6 16,9 16,6 
Waiting Time (minutes) --- --- 21,2 25,4 15,5 12,1 11,9 9,7 
Analytical Phase 
Repeat Testing (#) 20157 6473 7294 9758 7758 12524 11814 8180 
Repeat Testing (%) 6,10 1,70 1,90 2,50 1,60 2,17 1,98 1,01 
EQAS Tests (#) 20 22 21 22 24 28 28 29 
Correct Results (%) 90 90 94 94 96 92 95 96 
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Table 6 – 1: Gnóstica - Medical Laboratory: Evolution of the quality indicators (2003 - 2010) – Cont. 
 
Quality Indicators 2003 2004 2005 2006 2007 2008 2009 2010 
Post-Analytical 
Phase 
Fulfilment of Delivery Date (%) 93 94 94 93 94 91 88 95 
Same day results (%) 52 54 57 52 39 36 30 52 
Non-Conformities (NC; #) – Total 45 68 44 71 53 97 38 25 
Non-Conformities (NC;%) – Total 0,12 0,17 0,11 0,17 0,11 0,18 0,06 0,03 
NC - Reception/Registry (#) 22 48 36 64 39 77 30 20 
NC - Reception/Registry (%) 48,9 70,6 81,8 90,1 73,6 79,4 78,9 80,0 
         
Completed Surveys (#) 293 227 179 166 427 235 710 1240 
Users / Patients (#) 36640 40790 40984 42129 49553 55269 59005 84327 
Tests /Analysis (#) 330441 380789 383911 390301 484867 577151 596655 810432 
NC; # - Total number of detected/registered Non-Conformities; NC; % - Percentage, considering the total number of users/patients. 
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6.2 Measurement Uncertainty in the Medical Laboratory 
 
Having defined the approaches and formulae to apply in the first practical 
incursion in estimating the measurement uncertainty at Gnóstica Laboratory, 
the data regarding the different sources of results variation being considered for 
the MU estimates was then assembled. 
This section's tables show the data gathered from the Laboratory’s QMS, which 
provided the laboratory’s results for imprecision and bias, taken from the IQC 
data and from the EQAS results. 
Additionally, are presented the data from the manufacturers’ specifications, with 
regards to the calibrators’ uncertainty information, and from the literature in the 
case of the pre-analytical uncertainty data.  
These information and data for the several uncertainty components was 
distributed into different tables, by grouping on the first subsection the random 
variability source, on the next the systematic variability, both from Gnóstica's 
internal quality system data. To these presented data is added, on sub-section 
6.2.3, the calibrator's and the pre-analytical uncertainty values, as a complete 
resume of all the variability sources entering the estimate. 
Lastly, also on sub-section 6.2.3, are presented the primary results from the 
application of the two different formulae for the MU estimate to the data 
collected, as well the results of the determination of the Total Error, for that 
same period, for comparison. 
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On note regarding the units displayed for the analytes and different parameters 
presented, despite metrological traceability being preferably reported to SI units, 
with the use of the amount of substance (mole) unit for expressing laboratory 
results, the data is presented using traditional units (mg/dL), as these are the 
units adopted and used by the laboratory on its reports. Being embedded on the 
Portuguese healthcare system, Gnóstica uses the units most commonly applied 
in this reality, which were kept in the study. 
To complement this information, this practice can perhaps be better understood 
when considering the results of a recent study by Ceriotti, et al., on behalf of the 
EFLM WG-H (Working Group on Harmonisation of total testing process), on 
“Harmonization initiatives in Europe”. In the study, when addressing the current 
use of SI units in Europe, in a universe of 40 countries surveyed, Portugal 
stands in the low bottom, with 10-20% of utilization. Being the unit of 
measurement an important issue, the most problematic situation identified was 
for some few countries who declared that they are not in favor of changing or 
promoting the adoption of SI units, as it was the case of Portugal. 
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6.2.1 Random Variability: determination of the laboratory's 
intermediate precision 
 
Regarding the year of 2011, are here presented the data from the IQC for the 
determination of the imprecision, giving the quantitative expression to the 
laboratory’s intermediate precision, sometimes designated as within laboratory 
reproducibility or within-lab long term reproducibility. This represents an 
important source of variation in the medical laboratory and as such a 
fundamental component of the MU estimate and demonstrative of the random 
analytical variation of measurement’s results. 
For each of the analytes considered in the study, creatinine, glucose and total 
cholesterol, designations that represent the measurement of each substance's 
concentration in human serum samples, is presented a table, respectively Table 
6-2, Table 6-3 and Table 6-4, introducing the IQC monthly mean values, and 
the final mean value for the year in question (IQC ()). Likewise, are also 
presented the coefficients of variation for each determination method, as well as  
the monthly mean values and the final annual mean, being this the value of the 
laboratory’s total Imprecision (CV%), and the referred numerical expression of 
the laboratory’s intermediate precision. These values are shown for both levels 
of the quality control material in use, normal and pathological, being considered 
the two identical equipment operating in the laboratory, the Cobas® 6000–c501 
(Roche®) auto-analyser, identified as C1 and C2. 
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Table 6-2 – Total Imprecision for the determination of Creatinine’s concentration in human serum samples, by the Kinetic Jaffé 
Method, on Cobas 6000 auto-analyser, module c501, from Roche®. (Data regarding the year 2011) 
Test 
Medical 
Decision 
Value  
Month 
IQC 
(mg/dL) 
-Normal- 
IQC 
(mg/dL) 
-Pathological- 
IQC () 
(mg/dL)  
-Normal- 
IQC () 
(mg/dL) 
-Pathological- 
IQC (CV%) 
-Normal- 
IQC (CV%) 
-Pathological- 
Imprecision 
(CV%) 
-Normal- 
Imprecision 
(CV%) 
-Pathological- 
Creatinine 1,2 mg/dL 
C1 
Jan 1,07 3,74 
1,10 3,78 
5,4 4,0 
4,31 3,31 
Feb 1,11 3,80 4,8 4,0 
Mar 1,13 3,79 5,4 4,5 
Apr 1,08 3,74 4,8 3,2 
May 1,11 3,74 4,4 3,8 
Jun 1,11 3,77 4,2 2,8 
Jul 1,10 3,83 3,6 2,6 
Aug 1,11 3,79 4,0 2,9 
Sep 1,12 3,83 3,6 2,5 
Oct 1,09 3,78 4,4 3,4 
Nov 1,13 3,85 3,8 3,0 
Dec 1,08 3,74 3,3 3,0 
C2 
Jan 1,11 3,86 
1,12 3,82 
4,9 3,9 
3,51 3,03 
Feb 1,12 3,86 3,8 2,6 
Mar 1,11 3,76 2,9 3,3 
Apr 1,12 3,88 2,7 2,9 
May 1,12 3,84 2,9 2,7 
Jun 1,12 3,80 3,5 2,8 
Jul 1,11 3,82 2,9 2,7 
Aug 1,10 3,73 4,0 2,8 
Sep 1,13 3,85 3,8 3,2 
Oct 1,10 3,75 3,5 3,3 
Nov 1,13 3,86 3,2 3,1 
Dec 1,13 3,87 4,0 3,1 
C1 - Cobas®6000 - c501 Module: Equipment 1; C2 - Cobas®6000 - c501 Module: Equipment 2 
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Table 6-3 – Total Imprecision for the determination of Glucose’s concentration in human serum samples, by the Hexokinase 
Method, on Cobas 6000 auto-analyser, module c501, from Roche®. (Data regarding the year 2011) 
Test 
Medical 
Decision 
Value  
Month 
IQC 
(mg/dL) 
-Normal- 
IQC 
(mg/dL) 
-Pathological- 
IQC () 
(mg/dL)  
-Normal- 
IQC () 
(mg/dL) 
-Pathological- 
IQC (CV%) 
-Normal- 
IQC (CV%) 
-Pathological- 
Imprecision 
(CV%) 
-Normal- 
Imprecision 
(CV%) 
-Pathological- 
Glucose 110 mg/dL 
C1 
Jan 97,52 235,15 
97,44 233,60 
1,1 1,9 
1,36 1,36 
Feb 97,86 234,83 1,7 1,4 
Mar 97,52 232,52 1,5 1,7 
Apr 96,68 233,44 1,0 1,4 
May 97,58 233,40 1,4 0,9 
Jun 98,73 236,23 1,1 1,0 
Jul 97,95 234,20 1,5 1,5 
Aug 96,69 231,28 1,4 1,3 
Sep 96,96 232,37 1,8 1,5 
Oct 96,48 232,07 1,4 1,7 
Nov 97,64 234,34 1,2 1,1 
Dec 97,66 233,41 1,2 0,9 
C2 
Jan 97,62 234,90 
97,98 234,71 
1,1 1,9 
1,63 1,75 
Feb 98,12 235,97 1,2 1,1 
Mar 97,80 232,67 1,6 1,7 
Apr 97,23 234,20 1,3 1,3 
May 97,88 233,68 1,5 1,6 
Jun 99,70 238,57 1,1 1,0 
Jul 98,10 234,88 2,1 1,9 
Aug 97,88 233,13 2,0 2,1 
Sep 97,96 233,65 1,9 1,9 
Oct 97,00 234,19 2,0 2,5 
Nov 99,40 237,79 1,6 1,5 
Dec 97,07 232,95 2,1 2,5 
C1 - Cobas®6000 - c501 Module: Equipment 1; C2 - Cobas®6000 - c501 Module: Equipment 2 
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Table 6-4 – Imprecision for the determination of Total Cholesterol’s concentration in human serum samples, by the CHOD-PAP 
Method, on Cobas 6000 auto-analyser, module c501, from Roche®. (Data regarding the year 2011) 
Test 
Medical 
Decision 
Value  
Month 
IQC 
(mg/dL) 
-Normal- 
IQC 
(mg/dL) 
-Pathological- 
IQC () 
(mg/dL)  
-Normal- 
IQC () 
(mg/dL) 
-Pathological- 
IQC (CV%) 
-Normal- 
IQC (CV%) 
-Pathological- 
Imprecision 
(CV%) 
-Normal- 
Imprecision 
(CV%) 
-Pathological- 
Total 
Cholesterol 190 mg/dl 
C1 
Jan 94,23 179,16 
95,76 180,06 
2,2 2,0 
1,88 1,62 
Feb 95,21 180,30 2,4 2,0 
Mar 95,24 177,87 1,5 1,4 
Apr 97,28 181,66 2,4 1,8 
May 95,52 178,87 2,8 2,1 
Jun 96,24 180,68 1,2 1,1 
Jul 96,48 181,06 2,3 2,0 
Aug 96,08 178,98 1,8 1,4 
Sep 96,35 180,76 1,4 1,2 
Oct 94,40 179,42 1,8 1,8 
Nov 96,49 181,48 1,5 1,6 
Dec 95,55 180,45 1,3 1,0 
C2 
Jan 94,56 180,02 
95,94 180,45 
2,8 3,2 
2,20 1,80 
Feb 96,54 182,41 3,2 2,1 
Mar 94,91 177,39 2,1 2,3 
Apr 95,14 178,95 1,6 1,6 
May 97,43 180,78 2,0 1,1 
Jun 97,84 182,07 2,3 1,0 
Jul 96,54 181,49 2,5 2,0 
Aug 95,28 180,57 3,3 2,4 
Sep 95,42 180,08 1,2 1,1 
Oct 94,46 179,15 1,6 1,6 
Nov 96,89 182,00 1,4 1,5 
Dec 96,22 180,55 2,4 1,7 
C1 - Cobas®6000 - c501 Module: Equipment 1; C2 - Cobas®6000 - c501 Module: Equipment 2 
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6.2.2 Systematic Variability: Trueness - Laboratory’s Bias 
determination 
 
Also for the year 2011 and still quantifying the performance characteristics of 
the laboratory’s selected methods, the following tables present the laboratory’s 
trueness quantitative expression, in the form of each method’s bias, determined 
from the EQAS results. Once more with each table referring to a different 
measurand, Bias, defined as the difference between the result of the laboratory 
measurement and the accepted reference value for the EQA programme, is 
here expressed as a percentage, determined monthly by the equation (6-1), 
where ݔ is the laboratory’s result and ݕ0 the target or accepted reference value 
for the EQAS: 
ܤ݅ܽݏ	(%) = 	 (ݔ − ݕ0)
ݕ0 	 . 100 (6-1) 
Where ݔ represents the laboratory’s result for the EQAS, ݕ0 is the 
EQAS Target Value for the assessment in question. 
So, on Table 6-5, Table 6-6 and Table 6-7 can be observed the monthly values 
determined from the participation on EQAS, as well as the final numerical 
expression for the systematic variability of the measurement, in the last column, 
quantifying trueness as the laboratory’s bias, with the year’s mean value. 
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Table 6-5 - Trueness/Bias assessment for the determination of Creatinine’s 
concentration in human serum samples, by the Kinetic Jaffé Method, on Cobas 
6000 auto-analyser, module c501, from Roche®. (Data regarding the year 2011) 
Test 
Medical 
Decision 
Value 
Month 
EQAS 
-Result- 
(mg/dL) 
EQAS 
-Target- 
(mg/dL) 
EQAS 
-Error- 
(%) 
Trueness  
(|BIAS| %) 
Creatinine 1,2 mg/dL 
Jan 0,60 0,67 -10,6 
3,85 
Feb 1,41 1,52 -7,1 
Mar 6,42 6,65 -3,4 
Apr 1,32 1,37 -3,7 
May 3,64 3,88 -6,2 
Jun 4,02 4,10 -1,9 
Jul 6,48 6,67 -2,8 
Aug 1,39 1,52 -8,6 
Sep 4,08 3,96 3,2 
Oct 4,23 4,11 3,0 
Nov 3,81 3,87 -1,6 
Dec 1,29 1,38 -6,5 
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Table 6-6 - Trueness/Bias assessment for the determination of Glucose’s 
concentration in human serum samples, by the Hexokinase Method, on Cobas 
6000 auto-analyser, module c501, from Roche®. (Data regarding the year 2011) 
Test 
Medical 
Decision 
Value 
Month 
EQAS 
-Result- 
(mg/dL) 
EQAS 
-Target- 
(mg/dL) 
EQAS 
-Error- 
(%) 
Trueness  
(|BIAS| %) 
Glucose 110 mg/dL 
Jan 35,0 35,5 -1,4 
1,15 
Feb 106,0 107,8 -1,7 
Mar 345,0 348,5 -1,0 
Apr 109,0 109,6 -0,6 
May 257,0 259,9 -1,1 
Jun 278,0 275,5 0,9 
Jul 345,0 348,2 -0,9 
Aug 106,0 107,5 -1,4 
Sep 194,0 199,5 -2,7 
Oct 270,0 275,3 -1,9 
Nov 259,0 259,3 -0,1 
Dec 107,0 109,0 -1,9 
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Table 6-7 - Trueness/Bias estimate for the determination of Total Cholesterol’s 
concentration in human serum samples, by the CHOD-PAP Method, on Cobas 
6000 auto-analyser, module c501, from Roche®. (Data regarding the year 2011) 
Test 
Medical 
Decision 
Value 
Month 
EQAS 
-Result- 
(mg/dL) 
EQAS 
-Target- 
(mg/dL) 
EQAS 
-Error- 
(%) 
Trueness  
(|BIAS| %) 
Total 
Cholesterol 
190 
mg/dl 
Jan 114,0 118,2 -3,6 
0,95 
Feb 154,0 159,6 -3,5 
Mar 303,0 303,1 0,0 
Apr 152,0 156,2 -2,7 
May 278,0 280,8 -1,0 
Jun 287,0 292,2 -1,8 
Jul 310,0 302,7 2,4 
Aug 157,0 159,8 -1,7 
Sep 208,0 211,9 -1,9 
Oct 298,0 293,2 1,6 
Nov 289,0 281,2 2,8 
Dec 153,0 156,3 -2,1 
 
 
 
 
 
 
 
 
 88 
 
6.2.3 Implementation of the MU estimate formulae: MU-Model A 
Formula and MU-Model B Formula. 
 
Finally, Table 6-8 gathers the previous presented data, on precision and 
trueness, for both equipment (C1 and C2) and all three analytes, adding the 
calibrator's and the pre-analytical uncertainty values, thus completing the 
necessary data from of all the variability sources being considered and 
contributing with a partial value to the final MU estimate. 
The uncertainty declared by the manufacturer for the calibrator assigned value 
corresponds to the expanded uncertainty (with a coverage factor k = 2, giving a 
level of confidence of approximately 95%). This value must be divided by its 
coverage factor, giving the standard uncertainty associated to the calibrator, 
and then by the assigned value to obtain the relative standard uncertainty 
(CV%). As for the pre-analytical uncertainty values, are given in the literature as 
relative standard uncertainties, allowing its direct application. 
The estimates are then presented on Table 6-9, where can be observed the 
values determined from the application of the designated formulae to Gnóstica’s 
quality assessment data and to the remaining collected data, all included in the 
estimating, under the defined criteria, as relative uncertainties. Those 
calculations’ results are presented for Total Error, as previously mentioned, but 
more importantly for the MU-A formula, that restrictedly used the laboratory’s 
IQC data and EQAS results, for imprecision and bias, and for the MU-B formula, 
which considered the data associated to the calibrating materials and the pre-
analytical variation as uncertainty sources. Thus, after the relative uncertainties 
being combined, the results were multiplied by a coverage factor (k=2, for a 
coverage probability of 95%), to give the final Expanded Uncertainty (U). The 
last two columns, on the right, give information about the quality performance 
specifications and goals, for matters of enabling comparing the different 
equations’ outcomes. 
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Table 6-8 – Data collection (Imprecision, Bias, Calibrator Uncertainty and Pre-analytical Uncertainty) for the implementation of 
the different MU estimating Formulae in study (Data regarding the year 2011) 
 
Test 
Imprecision 
(CV%) 
-Normal- 
Imprecision 
(CV%) 
-Pathological- 
Trueness 
(|BIAS| %) 
Calibrator 
 Expanded 
Uncertainty 
(mg/dL) a 
Calibrator 
Value 
(mg/dL) 
Calibrator 
Standard 
Uncertainty  
(CV %) 
Pre-
analytical 
Uncertainty  
(CV %) b 
Creatinine C1 
4,31 3,31 
3,85 0,06 4,1 0,71 2,3 
C2 3,51 3,03 
Glucose C1 
1,36 1,36 
1,15 1,63 193 0,42 3,2 
C2 1,63 1,75 
Total 
Cholesterol 
C1 1,88 1,62 0,95 1,46 165 0,44 1,2 
C2 2,20 1,80 
C1 - Cobas®6000 - c501 Module: Equipment 1; C2 - Cobas®6000 - c501 Module: Equipment 2 
a – Traceability and Uncertainty - Cobas® c501 / c502 / c311 / c701 / c702 (C.a.s.f.), from Roche® 
b – Pre-metrological (Pre-analytical) Variation of Some Biochemical Quantities. Fuentes-Arderiu, et al. [85] 
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Table 6-9 – Estimated values for Total Error, MU Model-A and MU Model-B Formulae (Data regarding the year 2011) 
 
Test 
Total Error 
-Normal- 
(%) 
Total Error 
-Pathological- 
(%) 
MU (A) 
-Normal- 
(%) 
MU (A) 
-Pathological- 
(%)- 
MU (B) 
-Normal- 
(%) 
MU (B) 
-Pathological- 
(%) 
 
TEa (%) 
European 
Table [17] 
TEa (%) 
CLIA 
Table [18] 
Creatinine 
C1 12,5 10,5 11,6 10,2 9,9 8,2  
8,9 15 
C2 10,9 9,9 10,4 9,8 8,5 7,7  
Glucose 
C1 3,9 3,9 3,6 3,6 7,0 7,0  
6,9 10 
C2 4,4 4,6 4,0 4,2 7,2 7,3  
Total 
Cholesterol 
C1 4,7 4,2 4,2 3,7 4,6 4,1  
8,5 10 
C2 5,3 4,5 4,8 4,1 5,1 4,4  
C1 - Cobas®6000 - c501 Module: Equipment 1; C2 - Cobas®6000 - c501 Module: Equipment 2. 
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6.3 Pre-analytical Uncertainty 
 
The pre-analytical phase, comprising the largest percentage of error rates in the 
total testing procedures, has already been proved to be an effective source of 
variation potentially affecting the medical laboratory test results. Consequently, 
several authors have stated that the variation associated to the pre-analytical 
phase should not be considered negligible and its value should be included 
when estimating measurement uncertainty in the medical laboratory 
On this particular subject, and source of uncertainty, the references and data 
from the literature can and should be used in an initial stage of the 
implementation of measurement uncertainty estimation process in a laboratory. 
After that period, it should be replaced by the laboratory’s own estimates. A 
laboratory’s estimate means a direct measurement applied to the laboratory’s 
procedures and conditions, being a specific and representative value of its own 
pre-analytical uncertainty.  
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6.3.1 Gnóstica’s Pre-analytical Uncertainty Study 
 
Recognising the added value of estimating and knowing Gnóstica’s own pre-
analytical uncertainty values, was implemented a protocol to this purpose, 
aiming to quantify this variable associated to the analytes in study. The 
objectives were to confirm the findings in other studies and to, subsequently, be 
able to substitute the data previously considered from the literature, when 
estimating the laboratory’s MU, by values that corresponded directly to the 
laboratory’s procedures and that were representative of its practices and its 
specific variability. 
With the approval of the Management and Technical Boards of “Gnóstica - 
Medical Laboratory”, was developed and implemented an internal study, based 
on the laboratorial determinations of the concentration of the analytes 
Creatinine, Glucose and Total-Cholesterol, in its patient serum samples. 
Thereby, being NP EN ISO 15189 Accredited Laboratory, Gnóstica has its 
procedures for the collection and handling of diagnostic blood standardized and 
validated. These procedures were followed and the study was realized using 
the laboratory’s own materials and according to its day-to-day conditions, was 
performed by its phlebotomists/laboratory technicians and the tests executed 
during the daily routine work, with the laboratory’s routine equipment, the 
Cobas® 6000 – c501 module (Roche®). 
In the study here considered as sources of pre-analytical variation the following: 
sample collection (phlebotomy and handling); sample pre-treatment phase 
(processing and clotting time, before centrifugation); sample storage 
(refrigeration and freezing, after serum separation in different aliquots); sample 
transportation (considering the possible transportation of the samples by car to 
a central laboratory, after collection). The protocol was previously described in 
Section 5.3.1 and is represented schematically in Figure 9. 
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Table 6-10, Table 6-11 and Table 6-12 shows the obtained results for the 37 
individuals, respectively for the three different analytes studied, Creatinine, 
Glucose and Total-Cholesterol, for the different samples considered from these 
volunteer participants, randomly selected from the laboratory’s users, according 
to the study planning 
On the referred results tables, the different samples from every individual are 
identified, considering the variation source that each would allow to assess, as 
follows: 
A) Reference measurement sample 
B) Study of the uncertainty associated to the sample collection and handling; 
B1) Evaluation of the effects of sample storage (refrigerated samples); 
B2) Evaluation of the effects of sample storage (frozen samples); 
C) Evaluation of the effects of sample processing (delay in the pre-treatment); 
D) Evaluation of the effects of regional transportation. 
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Table 6-10 – Creatinine measurement: Kinetic Jaffé Method  
  (Sample analyte data / mg/dL) 
Samples A B B1 B2 C D 
1 1,58 1,58 1,63 1,62 1,65 1,57 
2 0,56 0,64 0,58 0,58 0,57 0,58 
3 0,73 0,75 0,72 0,76 0,72 0,72 
4 0,75 0,72 0,72 0,73 0,69 0,65 
5 0,68 0,67 0,67 0,70 0,69 0,68 
6 0,94 0,82 0,85 0,88 0,84 0,88 
7 0,64 0,62 0,66 0,66 0,63 0,63 
8 0,73 0,73 0,72 0,73 0,72 0,71 
9 0,94 0,92 0,93 0,90 0,90 0,89 
10 0,63 0,60 0,60 0,62 0,62 0,58 
11 0,53 0,53 0,61 0,58 0,54 0,54 
12 0,95 0,92 1,01 1,00 0,97 0,95 
13 0,87 0,93 0,98 0,99 0,91 0,90 
14 0,79 0,78 0,84 0,84 0,81 0,79 
15 0,68 0,62 0,71 0,72 0,65 0,65 
16 0,86 0,78 0,87 0,84 0,79 0,82 
17 0,98 1,00 1,05 1,09 0,97 0,92 
18 0,94 0,98 0,92 0,96 1,00 1,00 
19 0,78 0,77 0,75 0,71 0,76 0,74 
20 0,91 0,91 0,85 0,82 0,85 0,87 
21 1,03 1,00 0,96 0,94 0,94 0,96 
22 1,07 1,04 0,98 0,95 1,02 0,97 
23 1,02 0,99 1,00 0,92 0,98 0,95 
24 1,02 0,95 0,91 0,89 0,93 0,92 
25 0,96 0,94 0,91 0,88 0,97 0,92 
26 0,79 0,77 0,73 0,74 0,76 0,74 
27 0,74 0,69 0,64 0,63 0,69 0,65 
28 0,59 0,57 0,59 0,59 0,54 0,55 
29 0,80 0,73 0,80 0,77 0,78 0,74 
30 0,93 0,83 0,94 0,86 0,85 0,82 
31 0,87 0,78 0,80 0,77 0,77 0,74 
32 0,61 0,54 0,55 0,55 0,54 0,55 
33 1,17 1,11 1,12 1,06 1,08 1,07 
34 0,84 0,76 0,75 0,73 0,72 0,73 
35 0,58 0,56 0,60 0,61 0,58 0,56 
36 0,73 0,70 0,77 0,75 0,70 0,71 
37 0,54 0,57 0,58 0,62 0,54 0,55 
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Figure 10 - Graphical illustration of the variation due to sample collection and handling, for Creatinine measurement. 
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Figure 11 - Graphical illustration of the variation due to sample storage, for Creatinine measurement. 
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Figure 12 - Graphical illustration of the variation due to processing delay, for Creatinine measurement. 
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Table 6-11 – Glucose: Hexokinase/G-6-PDH  Method 
  (Sample analyte data / mg/dL) 
Samples A B B1 B2 C D 
1 179 178 179 179 180 170 
2 81 79 80 79 76 70 
3 100 95 95 95 92 87 
4 93 98 97 100 94 87 
5 91 97 96 97 90 79 
6 112 112 111 110 104 99 
7 92 91 92 91 84 83 
8 99 99 98 97 92 90 
9 100 100 101 97 94 91 
10 93 88 86 85 84 80 
11 84 82 81 80 77 71 
12 91 91 91 90 86 83 
13 88 92 91 91 83 80 
14 92 90 90 90 85 84 
15 87 90 89 90 82 74 
16 93 95 94 95 89 82 
17 179 184 185 185 180 174 
18 93 97 98 98 89 88 
19 92 96 95 95 89 89 
20 87 89 90 91 83 86 
21 85 84 87 86 77 76 
22 91 94 95 95 85 86 
23 81 84 85 84 75 74 
24 85 100 100 99 91 87 
25 91 85 86 86 82 79 
26 88 79 79 80 73 68 
27 97 91 91 90 84 82 
28 130 126 127 126 123 117 
29 90 90 90 90 87 84 
30 84 84 83 84 77 72 
31 94 86 85 84 80 80 
32 87 90 92 89 85 85 
33 88 88 88 87 82 81 
34 90 95 94 94 85 84 
35 94 94 95 94 86 83 
36 94 92 92 93 82 84 
37 85 88 85 86 80 79 
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Figure 13 - Graphical illustration of the variation due to sample collection and handling, for Glucose measurement. 
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Figure 14 - Graphical illustration of the variation due to sample storage, for Glucose measurement. 
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Figure 15 - Graphical illustration of the variation due to processing delay, for Glucose measurement. 
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Table 6-12 - Total Cholesterol measurement: CHOD/PAP Gen. 2 Method  
  (Sample analyte data / mg/dL) 
Samples A B B1 B2 C D 
1 180 174 180 181 176 178 
2 239 234 238 237 233 239 
3 190 193 196 199 194 194 
4 270 258 268 265 268 266 
5 204 198 204 199 200 200 
6 218 216 216 215 216 219 
7 186 185 185 182 187 186 
8 206 204 202 200 205 204 
9 237 244 238 210 243 243 
10 177 175 171 160 171 173 
11 185 190 186 177 186 187 
12 278 276 274 278 280 279 
13 176 177 176 174 177 180 
14 229 227 223 226 228 230 
15 168 159 160 158 160 159 
16 153 151 152 151 153 153 
17 184 189 183 183 187 187 
18 200 195 198 196 196 197 
19 156 154 157 159 155 156 
20 231 228 231 229 228 229 
21 254 251 253 248 249 249 
22 270 275 275 272 271 276 
23 131 126 127 127 127 129 
24 194 185 189 186 185 187 
25 212 210 210 214 210 213 
26 162 160 161 158 160 163 
27 194 174 172 174 172 172 
28 125 122 120 120 122 122 
29 199 195 196 188 196 198 
30 268 262 260 261 260 265 
31 178 175 176 173 171 173 
32 199 198 199 196 196 200 
33 182 178 182 179 178 177 
34 216 206 207 203 205 206 
35 185 185 186 185 187 186 
36 204 208 210 209 204 207 
37 186 186 188 189 186 187 
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Figure 16 - Graphical illustration of the variation due to sample collection and handling, for T. Cholesterol measurement. 
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Figure 17 - Graphical illustration of the variation due to sample storage, for T. Cholesterol measurement. 
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Figure 18 - Graphical illustration of the variation due to processing delay, for T. Cholesterol measurement. 
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6.3.2 Determination of Gnóstica’s Pre-analytical Uncertainty 
 
Applied the practical protocol to the 37 individuals that entered the study, the 
different uncertainty sources, within the pre-analytical variation, were assessed 
being were considered the paired results, between the reference samples and 
the different alternative/experimental procedures, to evaluate each variable in 
study. 
The general coefficients of variation for each uncertainty source, were 
calculated (CV %; for B, B1, B2, C and D), corresponding to the total variation 
for each one, which included the analytical variation plus pre-analytical 
variation.  
In Table 6-13 are presented the mean concentration values, for the 37 samples, 
for each category (B, B1, B2, C and D), of each analyte. In the same table the 
results for the general coefficients of variation are also shown, once again for 
each category, or pre-analytical uncertainty source. 
Later, the coefficients of variation for the pre-analytical variation (CVPre %) 
were calculated for each quantity by subtracting the analytical coefficient of 
variation (CVA), obtained from the day-to-day imprecision data from the 
laboratory’s QMS, from the general CV calculated for each variable (B, B1, B2, 
C and D). resulting in each variability source’s standard uncertainty (u). 
These results are presented in Table 6-14, along with the values for the 
uncertainty estimate. The combined uncertainties (uc pre) were obtained by the 
use of the general equation (2-1), and the final Expanded Pre-analytical 
Uncertainty (Upre) was calculated by applying equation (5-3), on page 55, with 
k=2, for a coverage probability of 95%. 
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Table 6-13 - Sample Analyte Data (Mean Concentrations and CV's %) 
Test /  
Analyte 
Mean Concentration (mg/dL) CV % 
A)  
Reference 
Measurement 
B) 
Blood 
Collection 
B1) 
Refrigerated 
Samples 
B2) 
Frozen 
Samples 
C) 
Sample 
Processing 
D) 
Regional 
Transport 
B)  
Blood 
Collection 
B1) 
Refrigerated 
Samples 
B2) 
Frozen 
Samples 
C)  
Sample 
Processing 
D) 
Regional 
Transport 
Creatinine 0,83 0,81 0,82 0,81 0,80 0,79 4,31 4,37 4,65 2,76 3,13 
Glucose 96,76 97,11 97,11 96,81 91,00 87,78 3,26 0,85 0,97 4,94 7,48 
Total 
Cholesterol 200,70 197,92 198,62 196,24 197,89 199,16 2,06 1,20 2,58 0,92 0,92 
 
Table 6-14 – Pre-analytical Uncertainty Components (Combined and Expanded Pre-analytical Uncertainty) 
Standard Uncertainty of Combined 
Preanalytical 
Uncertainty 
 
 uc pre (%) 
Expanded 
Preanalytical 
Uncertainty 
 
 Upre (%) 
Test /  
Analyte CVA (%) 
B)  
Blood 
Collection  
(uB %) 
B1) 
Refrigerated 
Samples  
(uB1 %) 
B2)  
Frozen 
Samples  
(uB2 %) 
C)  
Sample 
Processing  
(uC %) 
D)  
Regional 
Transportation  
(uD %) 
Creatinine 3,16 1,15 1,21 (*) 1,49 (*) < CVA < CVA 1,15 2,30 
Glucose 1,50 1,76 < CVA < CVA 3,44 5,98 (*) 3,87 7,74 
Total 
Cholesterol 1,77 0,29 < CVA 0,81 (*) < CVA < CVA 0,29 0,58 
(*) - Not included in the calculations of Combined Uncertainties; < CVA – Variation was smaller than the analytical coefficient of variation (CVA) 
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6.4 Measurement Uncertainty in the Medical Laboratory (II) 
Having determined Gnóstica’s pre-analytical uncertainty, the Measurement 
Uncertainty for this specific analytes could be updated. Moreover, having new 
data from the laboratory’s QMS, this internal quality outcomes could also be 
used to obtain an update the whole estimate. 
 
6.4.1 Application of the different MU estimate formulae - Gnóstica´s 
Pre-analytical Uncertainty (2013 Update) 
 
The results in this section consist in the outcomes of combining the previous 
sections 5.2 and 5.3 methodology and results, respectively, updating the 
remaining uncertainty components with data from the current year QMS reports 
(referring to year 2013), for obtaining the new MU estimate, considering now the 
laboratory’s own pre-analytical variability  
Table 6-15 gathers the necessary data from of all the variability sources for the 
application of the different formulae to the analytes in study, namely the data on 
precision and trueness, once again including the two auto-analysers (C1 and 
C2), and the calibrator's standard uncertainty values, considered as described 
in section 6.2.3, plus the pre-analytical from the internal study on section 6.3. 
The updated MU estimate is presented on Table 6-16, where are also shown 
results for Total Error, as it was before, and displayed the outcomes from the 
application of both the MU formulae do the current data. As previously 
determined, MU-A formula uses the laboratory’s IQC data and EQAS results, 
for imprecision and bias, and for the MU-B formula, are additionally considered 
the uncertainties associated to the calibrator and the pre-analytical. Again, it is 
also presented information on the quality performance specifications and goals, 
for matters of enabling comparing the different equations’ outcomes 
 109 
 
 
 
Table 6-15 – Data collection (Imprecision, Bias, Calibrator Uncertainty and Pre-
analytical Uncertainty) for the implementation of the different MU estimating 
Formulae in study (Data regarding the year 2013) 
Test 
Imprecision 
(CV%) 
-Normal- 
Imprecision 
(CV%) 
-Pathological- 
Trueness 
(|BIAS| %) 
 Calibrator 
Standard 
Uncertainty  
(CV %) 
Pre-analytical 
Standard 
Uncertainty  
(CV %)  
Creatinine 
C1 4,83 3,87 3,22  
0,71 1,15 
C2 3,15 2,45 0,33  
Glucose 
C1 1,47 1,39 0,44  
0,42 3,87 
C2 1,60 1,61 1,25  
Total 
Cholesterol 
C1 2,48 1,75 0,90  
0,44 0,29 
C2 2,23 1,78 0,93  
C1 - Cobas®6000 - c501 Module: Equipment 1; C2 - Cobas®6000 - c501 Module: Equipment 2 
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Table 6-16 - Estimated values for Total Error, MU Model-A and MU Model-B Formulae (Data regarding the year 2013) 
Test 
Total Error 
-Normal- 
(%) 
Total Error 
-Pathological- 
(%) 
MU (A) 
-Normal- 
(%) 
MU (A) 
-Pathological- 
(%)- 
MU (B) 
-Normal- 
(%) 
MU (B) 
-Pathological- 
(%) 
 
TEa (%) 
European 
Table 
TEa (%) 
CLIA 
Table 
 Creatinine 
C1 12,9 10,9 11,6 10,1 10,0 8,2   
8,9 15 
C2 6,6 5,2 6,3 4,9 6,9 5,6   
Glucose 
C1 3,4 3,2 3,1 2,9 8,3 8,3   
6,9 10 
C2 4,5 4,5 4,1 4,1 8,4 8,4   
Total 
Cholesterol 
C1 5,9 4,4 5,3 3,9 5,1 3,7   
8,5 10 
C2 5,4 4,5 4,8 4,0 4,6 3,7   
C1 - Cobas®6000 - c501 Module: Equipment 1; C2 - Cobas®6000 - c501 Module: Equipment 2    
  
 
 
 111 
 
 
6.5 IPAC’s Accreditation Auditing 
 
Following the update on the ISO 15189 Standard, in Portugal, the first auditing 
procedures under the new version (NP EN ISO 15189:2014) started in 2015. 
As exposed, this new version of the ISO15189 does not suggest, it requires the 
measurement uncertainty estimate to be presented for the quantitative testing 
under the scope of the accreditation. At this time, just calculating the Total Error 
does not fulfil the standard’s, or the auditing team's, requirements anymore.  
Having already realized the first tests with the formulas in study, with 
satisfactory results for the years of 2011 and 2013, to the concern of Gnóstica’s 
Quality Department, data from 2014 was collected and considered to be 
presented to the auditing team. 
In this section, on Figure 19, are shown the first outcomes on MU, from the 
current study, presented for IPAC’s consideration regarding fulfilment of the 
accreditation requirements, which were then included on the report for the 
accreditation auditing.  
For a matter of comparison, are included the results for Total Error, as well as 
for both of the MU formulae that are being applied in the study. With this, being 
the first auditing under the new requirements, which are still in the beginning of 
being implemented, it is also a moment of learning and discussion. 
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Figure 19 Measurement Uncertainty report for IPAC's Accreditation Auditing 
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6.6 Measurement Uncertainty in the Medical Laboratory (III) 
 
In this section are presented the results of the application of the final MU 
formula. After the studies with the laboratory’s data regarding the years 2011 
and 2013, in this final phase of the project, with updated data from 2015, the 
last and improved version of the MU formula was applied. 
Being the primary objective, since the beginning of the project, to reach to a 
formula responding to Gnóstica’s necessities regarding the accreditation 
requirements and procedures, imposed by the ISO 15189 standard and applied 
according to IPAC's auditing rules and criteria, the whole work was developed 
with that focus.  
The final review and decisions were than operated in order to fulfil those 
intentions, considering not only the outcomes from sections 6.25.2 and 6.4, but 
most importantly the experience and feedback obtained from overcoming that 
first external assessment, after the procedures on section 6.5. This step 
extremely significant, since it revealed the positive outcomes of the work 
developed in this project, confirming the applicability and potential of successful 
implementation of the present proposed approach, and so fulfilling its goals. 
 This third application of the equation, still considering a last adjustment, or 
update, .was focused only on the chosen formula, being applied to the year’s 
2015 data, once again collecting information form the QMS, from the pre-
analytical study previously developed and from the manufacturer’s 
specifications. 
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6.6.1 Gnóstica’s MU Estimate - Final Formula (MU-B) 
 
In view of the above, decisions were made, considering MU-B model formula, 
represented in equation (5-2), on page 54, to be the one best fitting to the 
laboratory's objectives and to the study's purposes. 
After demonstrating and quantifying the potential influence of the pre-analytical 
phase in the laboratory’s measurements and results, on the studied analytes, 
was decided that this variation source should be considered and valued, being 
included in the Laboratory’s MU estimate. 
Assuming that the trueness control provided by the manufacturers, in the 
Traceability and Uncertainty Certificate (Roche) (Appendix J), represents the 
most appropriate approach for the quantitative expression of that performance 
characteristic, it was the best understanding that, being the required and 
necessary information regarding the traceability to higher order of the 
calibrators and the data on the uncertainty of that calibrating material available 
from the manufacturers, the MU estimate should also include those uncertainty 
values associated to the calibrators’ assigned values. 
Considering the above and since the mentioned manufacturer’s specifications 
certificate for the calibrators used in the study’s measurements, adequately 
state the traceability of the materials to the Reference Measurement Procedure 
(Isotope Dilution Mass Spectrometry - IDMS), indicating each calibrator’s value 
and the correspondent associated uncertainty, was possible to meet the 
necessary conditions to implement applicate MU-B model equation (5-2). 
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Finally, bearing in mind recent publications’ proposals in regards to the 
treatment of the random component [99, 101], enabling a simpler and 
straightforward application of the MU formula and its implementing in the 
laboratory’s routine, was decided to calculate an overall value for the 
laboratory’s intermediate precision component by the use of an global and 
inclusive CV (CVpooled). This was achieved by combining the long term 
imprecisions from IQC (one year period), which were performed at normal and 
pathological concentration levels, by the use of equation (5-6). 
Decided the final formula it was applied to the laboratory's with updated data, 
for a final assessment. This data, collected from the year 2015 exercise, is 
presented in Table 6-17. The relative standard uncertainties to include in the 
estimate, the results obtained for the measurement Combined Uncertainty and 
the final Expanded MU, for each studied analyte, are presented in Table 6-18. 
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Table 6-17 - Imprecision; Calibrator Uncertainty; Pre-analytical Uncertainty (2015) 
Test  
Imprecision  
(CV %) 
 
-Normal- 
Imprecision  
(CV %) 
 
-Pathological- 
 Calibrator 
Expanded 
Uncertainty  
(mg/dL) 
Calibrator 
Value  
(mg/dL) 
 Pre-analytical 
Expanded 
Uncertainty  
(CV %)  
Creatinine 
C1 5,13 4,02  
0,0576 4,06 
 
2,30 
C2 2,89 2,20   
Glucose 
C1 1,42 1,54  
1,63 193,0 
 
7,74 
C2 1,55 1,43   
Total 
Cholesterol 
C1 1,93 1,88  
1,70 168,0 
 
0,58 
C2 1,78 1,56   
C1 - Cobas®6000 - c501 Module: Equipment 1; C2 - Cobas®6000 - c501 Module: Equipment 2 
 
 
Table 6-18 – Data; Combined and Expanded Uncertainty (2015) 
Test 
Imprecision 
Pooled 
(CV %) 
Calibrator 
Standard 
Uncertainty  
(CV %) 
Pre-
analytical 
Standard 
Uncertainty  
(CV %) 
 
MU (B) 
- Combined 
Uncertainty - 
MU (B) 
- Expanded 
Uncertainty - 
Creatinine 
C1 4,60 
0,71 1,15 
 4,80 9,60 
C2 2,57  2,90 5,80 
Glucose 
C1 1,48 
0,42 3,87 
 4,16 8,32 
C2 1,49  4,17 8,34 
Total 
Cholesterol 
C1 1,91 
0,51 0,29 
 2,00 4,00 
C2 1,67  1,77 3,54 
C1 - Cobas®6000 - c501 Module: Equipment 1; C2 - Cobas®6000 - c501 Module: Equipment 2 
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6.6.2 Standard Uncertainties’ Index 
 
In this last phase, to evince and perceive the effective influence of each 
uncertainty source, which are being considered in the MU estimate, their 
relative weights were calculated, regarding the final result. So, the “index” 
indicates the relative contributions to the combined final result. The values 
obtained are presented in Table 6-19, showing each considered variation 
source’s relative standard uncertainty and the respective index, regarding the 
combined uncertainties, for each of the components. These outcomes are also 
graphically displayed in Figure 20 below, to promote a more visual perception of 
the findings. 
Determining this Uncertainty Index allows identifying the components that most 
contribute to the MU value, which consequently have the most potential of 
causing any variation on the final measurements results. This evaluation 
provides important information, revealing the measurements' probable weak 
points, in terms of variability of its results, accomplishing so one of the possible 
benefits of implementing a protocol for estimating measurement uncertainties. 
The added value of these outcomes lies on enabling the laboratory with a tool 
that potentiates its power and ability to increase the reliability of their results. 
The laboratory, by analysing these findings, valuing its evidences and acting in 
consequence, may implement the necessary measures to enhance its 
procedures and methods, being able to improve the quality of the 
measurements performed and of the services offered to its users. 
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Table 6-19 Standard Uncertainties’ Index 
Test 
Imprecision 
Standard 
Uncertainty 
(CV %) 
Calibrator 
Standard 
Uncertainty 
(CV %) 
Pre-analytical 
Standard 
Uncertainty 
(CV %) 
 
Imprecision 
Standard 
Uncertainty 
(Index) 
Calibrator 
Standard 
Uncertainty 
(Index) 
Pre-analytical 
Standard 
Uncertainty 
(Index) 
Creatinine 
C1 4,60 
0,71 1,15 
 0,71 0,11 0,18 
C2 2,57  0,58 0,16 0,26 
Glucose 
C1 1,48 
0,42 3,87 
 0,26 0,07 0,67 
C2 1,49  0,26 0,07 0,67 
T. Cholesterol 
C1 1,91 
0,51 0,29 
 0,70 0,19 0,11 
C2 1,67  0,68 0,21 0,12 
C1 - Cobas®6000 - c501 Module: Equipment 1; C2 - Cobas®6000 - c501 Module: Equipment 2 
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C1 - Cobas®6000 - c501 Module: Equipment 1; C2 - Cobas®6000 - c501 Module: Equipment 2 
Figure 20 Graphical illustration of Standard Uncertainties Index 
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6.7 MU Estimate Final Tool: 
Gnóstica’s Working Spreadsheets (Templates) 
Towards the objective of an effective, but simple, way of proceeding with the 
implementation of MU estimate in the laboratory’s routine, was created a 
practical tool to be introduced amongst the other quality management 
procedures.  
That was accomplished by developing an Excel® (Microsoft) spreadsheet, 
contemplating the uncertainty sources considered, which allowed to use and 
update the monthly or annual values already being collected within laboratory’s 
QMS, along with other data necessary, concerning the formula application, 
enabling to easily obtain the estimates of the Laboratory’s Measurement 
Uncertainty for the results of the selected tests or measurements.  
Concerning the data introduction, the tables are easy to replicate, allowing 
adding different tests to it. It was also predicted the possibility of considering the 
introduction of other uncertainty sources, being automatically included on the 
formula and combined in the final estimate.  
The following section displays simple snapshots of the working spreadsheet, on 
Figure 21, Figure 22 and Figure 23, regarding respectively the introduction of 
data from the laboratory’s intermediate precision (IQC); from the systematic 
variation source (EQAS), obtaining the measurements’ bias (if the 
circumstances so require, as addressed on the previous sections); and the final 
sheet, which will deliver the MU Estimates, and contemplates an inserted data 
summary compilation, with a reserved area for the input of the last necessary 
data.  
In every worksheet, the white columns represent data input areas and the 
darker columns (grey) indicate an outcome for each specific identified 
parameter. These dark areas are blocked to the user, such as the formulae 
area, which do not show, not being accessible in the working area environment. 
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Figure 21 Random Variability Component (IQC data, corresponding to the laboratory's intermediate precision determination) 
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Figure 22 Systematic Variability Component: Laboratory’s Bias determination 
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Figure 23 MU Estimate Worksheet  
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7 DISCUSSION 
 
 
7.1 Quality Indicators  
 
Quality indicators are important management tools that can be used to evaluate 
the organization’s overall performance and the effectiveness of implemented 
policies. The observation in detail of specific aspects of performance allows to 
analyse and follow not only the evolution of the quality of the services offered by 
the laboratory but also the users perception of it, as well as its consequences in 
terms of working volume growth (clients and tests). 
Usually, the assembled information, sometimes including suggestions directly 
from the users, reveals improvement opportunities, becoming starting points to 
progress and upgrade in the pursuit for a better service with higher quality 
standards. 
Based on the Quality Management System data, was performed a retrospective 
study with the objective of evaluate the available quality indicators. During the 
period covered by this study could be observed the evolution of the Quality 
Management System while the laboratory was passing through two different 
processes: Certification by the standard: ISO 9001:2000 (in 2004), and later, 
Accreditation by the standard NP EN ISO15189:2007 (in 2009). 
First of all it is important to emphasize that throughout these years, following the 
certification/accreditation processes, it is verified a considerable growth in the 
number of inscriptions in the laboratory, resulting in an increase from 36640 
(2003) to 84327 users/patients (2010) and in a consequent increase in the 
number of tests/analysis from 330441 to 810432, during the same period.  
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During this same time the waiting time in the Laboratory was reduced to 9,7 
minutes (2010), after having reached a maximum record in 2006, with over 25 
minutes. Also the number of repetitions of sample collecting decrease from 
1,2% (2003) to 0,7% (2010) and there was a great improvement in repeat 
testing, dropping from 6,1% (2003), to 1,0% (2010);  
On the External Quality Assessment Programs, comparing the percentage of 
correct results in 2003 (20 different schemes) and in 2009 (29 programs 
completed), there was an important improvement from 90% to 96%; 
In an overall analysis, it’s important to highlight the record of 0,03% non-
conformities (2010), in comparison with the values of the previous years of 
0,12%; 0,17% or 0,18% (2003; 2004/2006; 2008). The majority of non-
conformities (80% in 2010) have had origin in the reception, revealing a 
possible weak point and an opportunity to improve. These numbers resemble 
the findings of a recent study on pre-analytical errors, which reported booking-in 
errors as the most common errors reported by the participating laboratories, 
with a 70,1% rate [103]. 
But, in fact, if considered the increase in the working volume, it can be verified 
the quality system’s benefices at this level. When looking to the absolute 
number of NC it can noticed the decrease of its values, shown not only in the 
total of non-conformities but also in the reception registries, where the progress 
exist, although there is also still room for improvement. It is also possible to infer 
about the improvement in the remaining procedures of the pre-analytical phase 
(excluding the patients registry at the reception), as well as in the analytical and 
post-analytical phases, where the 5 NC detected result in 0,006% of NC, 
considering the total of 84327 users/patients. 
Similarly, relating with the increase in the working volume, are considered as 
positive the results of the user’s overall satisfaction, as well as the fulfilment of 
the delivery dates and of the percentage of results delivered in the same day. 
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These indicators, which maintained the same level of results, apparently not 
showing neither improvement nor worsening, end up revealing the stability of 
the implemented procedures and of the quality system established, taking into 
account the growth in users/patients and tests/analysis requested and 
executed. 
The QIs observed reveal real improvements brought by the Certification, later 
reinforced by the Accreditation process. There is still much work ahead and 
improvements to achieve, but this seems to be the way in the search for Total 
Quality, by monitoring and valuing the quality indicators assessed, also by 
listening to the users and taking upgrade initiatives and implementing 
improvement projects and actions, aiming to achieve the highest standards and 
recommendations for quality and quality systems management. 
An example is the implementation of user-focused policies, responding to their 
criticisms and suggestions, which allowed the application of corrective actions, 
namely in the reduction of waiting time, transforming a weakness in a strong 
point. It also could be observed the increase in the number of users and 
analysis per year, to which can be added a reduction of costs due to the 
decrease in the number of test and sample collection repeating (non-quality 
costs). 
Thus, the present study shows indications that the implementation of ISO 
Standards for Quality Systems in Clinical Laboratories (ISO9001 and 
ISO15189) is very important to monitor the laboratory’s overall performance and 
contribution to patient care, providing tools to improve the quality of services, 
processes and results.  
The objective was not to exhaustively analyse and evaluate the performance of 
each indicator, as it merely aimed to perceive and demonstrate the advantages 
and the evolution brought by the implementation of the quality system, as well 
as the improvements arising from the upgrade to Accreditation by the ISO 
15189 standard, which are evident in view of the presented data. 
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Being also an essential requirement in accreditation processes, it is important 
that laboratories not only adopt strategies and tools to enable monitoring QIs, 
but also to identify key quality indicators, to harmonize its evaluation procedures 
and to establish goals and performance levels for its management. 
This work as to be promoted and enhanced by international bodies and by the 
scientific associations, as it is already being done, “yet with no consensus on 
the use of QIs focussing on all steps of the laboratory total testing process 
(TTP), and further research in this area is required” [104]. 
The IFCC has created a working group on ‘‘Laboratory Errors and Patient 
Safety’’ (WG-LEPS) which, focused in reduce the errors in laboratory testing, 
developed a series of Quality Indicators, specifically designed for clinical 
laboratories, aiming to the development of a common reporting system for 
clinical laboratories based on standardized data collection, and to define state-
of-the-art and Quality Specifications (QSs) for each QI [104]. 
On behalf of the IFCC Working Group on ‘‘Laboratory Errors and Patient 
Safety’’ (WG-LEPS), Sciacovelli, L., et al., published a preliminary report 
entitled “Quality Indicators in Laboratory Medicine: from theory to practice”, 
suggesting that the implementation of QIs through EQAS programmes as tools 
to monitor and control the total testing process would lead to the development 
and improvement of specific QIs for clinical laboratories as well as quality 
specifications for each one of them. This would not only allow the identification 
of potential risks to patient safety, but also the sharing of practices that can help 
reduce/prevent errors, enabling the dissemination of improvement measures.  
With special focus on the extra-analytical phases Hawkins, R. [105], elected the 
management of these particular procedures in the total testing process as the 
“next challenge for laboratory medicine”, valorising the publication of QIs and 
proposed QSs by the IFCC WG-LEPS, as it provides “useful benchmarking data 
for laboratories embarking on extra-analytical quality improvement 
programmes”.  
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These statements find sequence in the publications by Plebani, M., et al., and 
Sciacovelli, L., et al., on performance criteria and quality indicators regarding 
the pre-analytical phase and the post-analytical phase respectively [106, 107].  
After stating the necessity of consensus in the implementation and evaluation of 
quality indicators in laboratory diagnostics, as well as the harmonization of its 
monitoring practices, as being essential to drive real improvements in laboratory 
medicine and health care [108], and while “there is no consensus for the 
production of joint recommendations focusing on the adoption of universal QIs 
and common terminology in the total testing process”, Plebani, M., et al., have 
published an opinion paper [109], following the work of the IFCC WG-LEPS, 
highlighting the preliminary consensus achieved in the road to the 
harmonization of quality indicators in laboratory medicine. It is presented a 
revised list of QIs developed by IFCC WG-LEPS, and proposed definitions to all 
the QIs with examples to allow the clarification and help to the comprehension 
of the meaning of each QI. 
In conclusion it is reinforced that “the measurement and monitoring of QIs in 
laboratory medicine serve many purposes: 1) document the quality of the 
service provided; 2) improve performance and patient safety; 3) make 
comparison (benchmarking) over time between laboratories; 4) make judgments 
and set priorities (corrective actions to be performed); and 5) support 
accountability, quality improvement and accreditation” [109]. 
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7.2  Measurement Uncertainty in the Medical Laboratory 
 
7.2.1 Application of the different MU estimate 
As exposed, in Portugal, for the demonstration of determination of 
measurement uncertainty during the accreditation process for clinical 
laboratories it was accepted that the laboratories presented the calculations of 
Total Error. Once again, as stated, this study was developed in a Portuguese 
ISO15189 Accredited Medical Laboratory, having all the procedures for the 
assessed analytes being included in the mentioned process and are all 
accredited as well. In the accreditation process it is a mandatory requisite the 
proof and demonstration of participation in External Quality Assessment 
Schemes (EQAS), as it is the record of good performance in those schemes. All 
of these premises are, in this case, fulfilled. 
The results from the Quality Management System were considered, particularly 
the data from the Internal Quality Control (IQC) and from the External Quality 
Assessment (EQAS). From here, it was also possible to calculate the Total 
Error (TE), which was used in Portuguese Laboratories, at this time 
(2011/2012), to assess and validate the laboratory methods, as well as to make 
proof of technical capability and competence in the process of Accreditation, as 
stated earlier. These results were compared against the reference values for 
allowable total error (TEa), from international tables and guidelines, such as the 
“Desirable Biological Variation Database Specifications” [17] or the “CLIA 
regulations table” [18]. For this purpose, were considered three different 
analytes, being Total Cholesterol, Creatinine and Glucose, all measured in 
human serum. There are two identical Cobas® 6000 – c501 module (Roche®), 
so where are presented the results obtained for both of them, as it was 
information of value to the laboratory and for its quality management 
department, allowing eventually further comparison material and possibilities. 
As mentioned, both work under the same conditions, handled by the same 
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technicians with the same reagents, controls and calibration material (Cobas® 
c501 / c502 / c311 / c701 / c702 - C.a.s.f.), from Roche®. 
Combining these data allowed applying directly the proposed Model-A formula 
(5-1). Plus, by gathering information on the values of uncertainty assigned to 
the calibrator, from the manufacturers certificate (Roche®), and of the pre-
metrological variability for these same analytes, from the literature [85], it was 
possible to apply Model-B (5-2), formula both presented earlier in Section 5.2. 
By comparing the outcomes with quality goals and performance specifications 
from both of the Tables, the European and CLIA’s, it is possible to affirm that for 
total cholesterol all the results are within both limits. In the Creatinine’s case, all 
the values are within the less tight values of CLIA’s Table, failing the limits of 
the European Table for TE and MU-A, while for MU-B the results for the 
pathological (high) level fall within these limits, while the ones for normal control 
level fail the desirable specification limits. As for Glucose, the values of TE and 
MU-A all meet the goals of the European and CLIA’s Tables, while the results 
for MU-B also fails to comply with the limits required by the European Table. 
However, this is a rather relative exercise, bearing in mind that the 
implementation of ISO 15189 standard, although requiring to the medical 
laboratories measurements uncertainty estimate, does not provide any 
guidance or specifications regarding acceptable limits under which the 
measurement uncertainty should be determined and afterwards evaluated. 
For this purpose, in an opinion paper regarding “Permissible limits for 
uncertainty of measurement in laboratory medicine”, Haeckel, et al., considering 
that “the most common concept for establishing permissible uncertainty limits is 
to relate them on biological variation defining the rate of false positive results or 
to base the limits on the state-of-the-art”, presented a proposal of an algorithm 
to deliver the necessary performance goals. Claiming that it “can be applied to 
all measurands and consider any quantity to be assured”, the approach tries to 
reconcile the biological variation concept, the GUM uncertainty model and the 
technical state-of-the-art [110]. 
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Recently, also Farrance, et al., raised the question on “what performance 
specifications (quality goals) can supporters of the GUM approach use as a 
guide to actual or comparative performance?” Then, providing a possible 
answer, the authors reference Ricos’ “Desirable Biological Variation Database 
Specifications Table” [17], stating that, being biological variation and the total 
error independent entities, biological variation can be applied to compare and 
evaluate measurement uncertainty outcomes, just as it is used in the 
assessment of the total error determinations and principles [98]. 
In addition to the desirable specifications for Total Error, Ricos’ Table presents 
data for intra-individual (or within-subject - CVw) and inter-individual (or 
between-subject - CVb) biological variation, which are the basis for the 
remaining specifications presented. Yet without specific performance limits 
defined for measurement uncertainty, besides the allowable total error values, 
considering bias and precision as components, have been proposed to use 
analytical goals for imprecision, based on intra-individual biological variation to 
assess uncertainty outcomes [33, 111]. 
Nevertheless, assuming that comparing measurement uncertainty with 
biological variation derived limits, considering that the possible variation interval 
delivered by the uncertainty estimate for a given a test result should be 
comprised within permissible limits set on the light of that concept, which is well 
implemented and studied in the medical laboratory community and able to 
providing a reliable scientific basis, can be legitimate and a logical starting point. 
Nevertheless, the truth is that until today no consensus on this particular 
question resulted in any clear recommendations, approved guidelines or widely 
disclosed tables with these specifications. 
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Hence, it will be necessary, for the medical laboratory’s scientific community, to 
work upon the different questions, challenges and opportunities that the MU 
estimate brings to the laboratories. To adopt a concept that aims to contemplate 
all the several variation sources, or at least their effects on the patients’ results, 
those different uncertainty sources have to be considered when setting quality 
goals and specifications.  
The proposal of Haeckel, et al., can be a step forward, as even if the presented 
approach does not include pre-analytical variability, it states that “uncertainties 
of the pre-examination phase and/or the post-examination phase can be easily 
added if the corresponding data are available and add relevant information to 
the requesting party” [110]. 
This stand as essential on the process for a wide implementation of the MU 
concept in medical laboratories, since “unless there is clear rationale for 
defining goals or targets for acceptable measurement uncertainty, laboratories 
may not recognize whether the observed uncertainty is good or bad and 
whether improvement is needed or not” [57]. 
When directly comparing TE, MU-A and MU-B, it is observed that the results for 
MU-A consistently showed lower percentages and consequently tighter error 
associated / intervals of values reasonably attributable to a patient result. As for 
MU-B, three different situations can be verified. For total cholesterol the values 
are superior to MU-B, but inferior to the ones from TE. For creatinine the MU-B 
values are the lowest between the three formulae. On the other hand, they are 
the highest, regarding the glucose determinations. The case for creatinine is 
interesting, because it can be seen bias in that situation. For the glucose 
measurement it can be attributed the main influence on the result to the high 
value of the pre-analytical uncertainty, confirming the pre-analytical phase as 
one of the sources of uncertainty with potential impact on the final values of 
uncertainty and on the, consequently, on the potential variation of patients 
results. 
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By analysing Table 6-9, it is easy to identify some similar outcome values 
between the results for TE and Model-A Uncertainty (MU-A), as it was expected 
attending to the data used on both calculations. Regarding the results for the 
Model-B formula for measurement uncertainty (MU-B), it was observed some 
variation that ended up making the difference when comparing the results with 
the goals of the mentioned international tables. Those differences can be 
attributed to the variables being considered in each equation, taking into 
account the added data of pre-analytical uncertainty and of the uncertainty of 
the calibrator assigned value, considered in MU-B, and the absence of the bias 
value for each measurement, obtained from the EQAS results for the other 
equations, which was simultaneously disregarded also in MU-B.  
So, they have a formula for MU (Model-A) which resembles the TE calculation, 
using the exact same data, only varying the mathematical basis for combining 
that data. Thus, this first formula does not introduce any new concepts to the 
usual evaluation performed for TE, it just applies the rules for uncertainty 
combination/propagation to the same data. Submitting these values to the 
appreciation under the TEa limits/guidelines, it can be observed the same 
performance for all the analytes, which could be expectable, according to the 
premises supporting both. Concerning the Model-B formula, it introduces 
something new, adding the variability/uncertainty associated with the pre-
metrological procedures, as well as the uncertainty assigned to the calibration 
material.  
The pre-analytical phase is the step of laboratory procedures that most 
contributes as a source of errors; this reality is well known and recognised 
[112]. Others studies state that extra-analytical phases can account up to 93% 
of the errors within the entire diagnostic process, pointing out more than 80% 
attributable to the pre-analytical phase [113], reinforcing this stage as an 
important source of concern and potentially variability/uncertainty. This 
variability can be considered as pre-metrological uncertainty, “beginning when 
the needle is first inserted into the vein and lasts until the sample enters the 
measurement system” [75]. This way, there are several sources of error in the 
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pre-analytical phase that can contribute to erroneous results [90, 113-116], 
which directly adds variability to the final result and can in some cases be the 
dominant font of uncertainty [75, 86] . Anyhow, errors such as missing 
identification, wrong sampling tubes or ordered tests are not accountable and 
should not be confused with the quantifiable pre-metrological uncertainty 
described [79]. In the last years, several studies have been providing records 
and useful data on this subject, proving these facts and demonstrating how 
these gross errors should not be accounted for. [79, 84-87]. 
 
These premises, as well as the observed weight and influence on the final 
uncertainty value due to the pre-analytical factors variation (Upre), support the 
necessity of further studies in this specific uncertainty component. This should 
be a reality for all laboratories, as these variations can manifest in response to 
the conditions, materials and procedures of each laboratory. The input values 
considered should therefore reflect the intrinsic variation of those same 
laboratories, which directly affects the results of the analysis of their patients’ 
samples. Bearing this in mind, the next step on this work was exactly to 
promote kind of study, thereby obtaining such data and information, in order to 
be able to substitute the used literature values, incorporating actual data 
regarding Gnóstica’s day-today work and its influences concerning the pre-
analytical phase and variables. 
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7.3 Pre-analytical Uncertainty 
 
Historically, the focus on improvement of the laboratory quality management 
has been directed to the analytical phase. Still, in the medical laboratory 
community, it is widely recognised that the pre-analytical phase is where most 
of the laboratory errors occur during the total testing process (TTP), accounting 
for approximately 60% to 70% of all the occurrences affecting the testing 
process or even the test final result [88-91]. Sources of pre-analytical variability 
can be identified through the different procedures during this phase, starting 
with patient’s preparation but expanding in the sample collection, transportation, 
processing and storage [90, 91, 113, 115, 116]. 
Even the time required for the pre-analytical phase is often underestimated, 
being appraised that “it takes up more than 58% of total laboratory time 
required”, with the “actual analytical phase only taking up around 25% of the 
time” [116]. 
Being the pre-analytical phase “recognised as the most vulnerable part of the 
total testing process” and given its “impact on the quality of results of laboratory 
testing, pre-analytical errors have been included within the greatest challenges 
to the laboratory professionals” [91, 117].  
Although it is extensive the literature on the subject, with different standards 
issued, per example, by the Clinical Laboratory Standards Institute (CLSI), with 
guidelines regarding the collection of blood specimens or the handling, 
processing and the transport of samples, the “management of unsuitable 
specimens and reporting policies are not fully standardised, nor harmonised 
worldwide” and “the compliance to those guidelines is low” [117], just as 
“venous blood sample collection guidelines are not always followed [118]. 
In a recent study developed in medical laboratories in the UK, on pre-analytical 
errors monitoring and reporting, it was observed 30% of the laboratories do not 
routinely monitor the pre-analytical phase. Another finding was that there are 
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only two quality indicators from this particular phase which are recorded by 
greater than 50% of laboratories, being “mislabelled samples and booking-in 
errors”. Also, stated as “most surprising” was the fact that “markers of sample 
quality such as haemolysis, which is well documented to interfere in test results, 
are monitored by less than 50% of laboratories” [103]. 
These facts take particular relevance considering UK’s position as a reference 
in good laboratorial practices, being inclusively one of the few countries in 
Europe with 50% or more of medical laboratories already accredited, rising to 
80% if it refers only to clinical biochemistry laboratories [13]. 
The IFCC WG-LEPS, in an attempt to reduce errors in laboratory testing, 
developed a project aiming to create a common system for the monitoring and 
reporting of quality indicators incorporating the main TTP phases. In a 
publication with some preliminary data of the project, in what regards the pre-
analytical phase and considering the volunteer participating laboratories 
responses, revealed an high percentage of errors, suggesting to the authors the 
lack of appropriate documentation for defining criteria and operative procedures 
or the lack of its proper implementation by the laboratory staff [104]. 
So, even though it is often assumed that pre-analytical variation, or the 
uncertainty associated to this phase, can be considered negligible if all the 
sources of variation are standardised, the facts above cannot be disregarded. 
Moreover, the results from previous studies, which demonstrate that the pre-
analytical variation is not negligible for many analytes, support pre-analytical 
variation as a factor that should be taken into account when estimating the 
measurement uncertainty in the medical laboratory [84-86]. 
The most frequent mistakes registered in the pre-analytical phase are related 
with the incorrect/insufficient tube filling, the usage of inappropriate containers 
and patient identification or request procedure errors. Concerning the influence 
or the effects of these errors in patients’ outcomes, it is estimated that 
approximately 25% of the occurrences are considered to have direct influence 
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in the test results or the patients’ healthcare procedures, with most of the cases 
ending up resulting in test repetitions [90]. 
Being, as stated, pre-analytical variation sources considered various and 
diverse, “ranging from biological and physiological events to technical details of 
specimen collection and transport” [84], the major variables involve patient 
preparation, sample collection and handling, as well as sample transportation, 
processing and storage [91]. Sylte, et al. also states that the uncertainty chain 
starts with the preparation and choice of blood-collection tube, in a continuum 
through “variations in variables that include filling volume, sample mixing, 
clotting time, extent of haemolysis, centrifugal force, room temperature and 
humidity, and amount of time before analysis”. The authors end up concluding 
that “even with optimal routine, some variation is inevitable” [86].   
It is know that, directly regarding the analytes in study, the factors that can 
influence the most in any potential result variation are icteric, haemolysed or 
lipemic samples, mostly in the case of creatinine; cellular glycolytic activity, this 
particularly in the case of glucose, which can decrease up to 5% only in the first 
hour; or factors like the patient’s posture and the prolonged use of the 
tourniquet during the venipuncture, especially in the case of total cholesterol 
[115, 119, 120] .  
These variation/uncertainty sources, for individual samples, are systematic in 
their nature. Nonetheless, on daily laboratory work these errors can be 
considered as random and its variations determined to estimate the pre-
analytical component, allowing later to account for them in the combined 
uncertainty estimate, associated to patients’ results [85, 87, 95]. 
In practice, when studying these variables looking for an estimate of the 
laboratories pre-analytical variability, it is necessary to adapt the methodologies 
to the procedures and resources of the laboratory in question, integrating the 
experiment as a part of the normal laboratory processes [84]. 
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As the objective was to determine Gnóstica’s specific pre-analytical uncertainty, 
its specific practice and procedures were applied, this without comparing or 
addressing the using of different types of collecting tubes, collecting and 
handling procedures or centrifugation conditions. This allowed, on every 
puncture and blood withdrawal taken, simulating just another sample collection 
and processing, considering and estimating the variability from the procedure 
and due to processing deviations that can occur during the normal daily work 
flow, within the laboratory’s own and normal routines. Afterwards, the sources of 
variation/uncertainty were individually studied as blood collection, sample 
storage, sample processing and regional transportation. 
So, the aim of this study was to quantify the uncertainty associated to a clinical 
laboratory result, arising from the pre-analytical variation, on the specified 
analytes: creatinine, glucose and total cholesterol.  
As for the pre-analytical factors and their influence on the analytical outcomes, it 
was demonstrated, for the analytes tested, that venipuncture represented a real 
source of variation, being the only variable common to all the three quantities. 
Glucose, as expected, showed to be sensitive to sample processing delays, as 
well as to regional transportation. Sample storage and different storage 
conditions seemed to affect more the other two analytes, particularly in the case 
of creatinine testing. In the mentioned situations, the obtained coefficients of 
variation were higher than the analytical imprecision, CVA (%), corresponding to 
the laboratory's intermediate precision. 
The results obtained were consistent with those from other similar studies, to 
the same analytes, where Fuentes-Arderiu, et al. [85] and Sylte, et al. [86] 
reported, respectively, coefficients of variation of 2,3% and 1,5% for Creatinine; 
3,2% and 4.0% for Glucose and 1,2% and 1,6% for Total Cholesterol. Also 
Kouri, et al. [84] estimated a pre-analytical variation for Total Cholesterol to be 
0.7%. These values that can be compared to the ones from the present study, 
excluding sample storage or regional transportation (Creatinine: 1,15%; 
Glucose: 3,87%; Total Cholesterol: 0,29%). 
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These last variables referred, and the associated data, although not included in 
the final calculations of combined uncertainties, are presented both to 
demonstrate its potential variation effects and so that they can be taken into 
account considering the presence or absence of those particular procedures in 
the laboratory’s routines. Different laboratories, or samples with different 
“origins” but tested within the same laboratory, will have different uncertainty 
chains associated, which should be considered regarding the laboratory’s reality 
in terms of its daily work routines, samples collection and processing.  
Recently Fuentes-Arderiu stated that “when measuring a sample in any moment 
of the stability storage conditions, a new stability-specific measurement 
uncertainty appears”. According to the author “this measurement uncertainty 
should be added to the uncertainty budget of the measurement under 
consideration”, which supports the need for the laboratories to undertake such 
studies, as he also advocates [121]. Supporting this statement, Kutasz, et al., 
considering temperature and storage time as major factors affecting the stability 
of clinical samples, stand by the need and possibility of laboratories assessing 
these variables, depending on its own day-to-day realities. Remembering 
situations of “determinations added to a stored sample” or “patients distributed 
over large geographical areas”, the authors agree with the mentioned proposal 
of Fuentes-Arderiu, affirming that such result’s MU should reflect the clinical 
sample’s stability, as all sources of variation should be considered and those 
can vary according to the samples treatment and the quantity studied [122]. 
In Gnóstica sample storage may be a possibility, over weekends or on tests not 
performed on a day-to-day basis. Also regional transportation might be an 
important factor, bearing in mind the existence of multiple and external 
collection sites in the Algarve region. So, if not negligible, this data should be 
included in the calculations of the combined uncertainty of samples subject to 
these particular conditions. 
In compliance with previous studies and publications [79, 84-87, 94, 95], it was 
demonstrated that the pre-analytical phase should always be considered as a 
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potential source of variability and uncertainty, as demonstrated in previous 
studies and publications. Thus, the relative uncertainty associated to the pre-
analytical phase should not be considered negligible and its value should be 
included when estimating the uncertainty of measurement results on patients 
samples, in medical laboratories, as other authors have previously done or 
defended [32, 59-61, 75]. These considerations are also supported in a position 
paper by the European Diagnostic Manufacturers Association (EDMA) 
regarding the estimation of uncertainty of measurement in medical laboratories 
and the uncertainty sources to consider [92].  
It is so recommended that laboratories develop studies if this nature, allowing 
not only to estimate their own pre-analytical uncertainty, which is associated to 
the results of their patients, but also to identify the sources of variation with the 
most influence in the and weight on the final result. This is one of the great 
potential outcomes of the uncertainty determination, which empowers the 
laboratories with the capacity to act and to improve, once identified the 
weaknesses on chain of procedures of their own routines.  
Thus, it is essential that each laboratory’s particular circumstances are 
considered, taking into account the processes of sample collection, its 
materials, procedures and conditions, as of sample storage and regional 
transportation, so that each potential variation source it can be assessed in 
detail, and its individual contribution to the combined pre-analytical uncertainty 
can be reflected.   
Along with the implementation of quality guidelines and recommendations, to 
improve quality and minimize pre-analytical uncertainty it is mandatory to raise 
awareness at the laboratory’s management and staff levels, to locally, on site, 
know, study and identify the various variation factors, their influence and how to 
deal with each one. Several authors have defended that “to reduce random pre-
analytical variation it is vital to identify the contributions of the various 
uncertainty sources, from venipuncture to analysis” [86]. Also that “more 
quantitative information is required in this field, especially to learn if the pre-
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metrological variance varies with the value of the measured quantity 
(heteroscedasticity)” [85]. Being particularly important the necessity to agree 
upon the factors to be included and excluded in the estimates, considering the 
extent of laboratory services, such as regional responsibility. “The estimates 
could be tabulated, for example, for fasting morning samples, afternoon 
samples and regional transportation” [84].  
A positive point is that laboratories are alert to the present situation, being 
aware and willing to “invest” in the pre-analytical phase quality improvement.  
Cornes, et al., in its recent study, entitled “Monitoring and reporting of pre-
analytical errors in laboratory medicine: the UK situation”, reported that “of the 
laboratories surveyed, 95.9% expressed an interest in guidance on recording 
pre-analytical error and 91.8% expressed interest in an external quality 
assurance scheme” [103], which is definitely a significant resource and an 
important tool to implement, allowing benchmarking between laboratories and 
enhancing any potential improvement opportunities. So we have to agree that 
“managing the extra-laboratory phase of the total testing cycle is the next 
challenge for laboratory medicine” [105], laying up as a critical milestone in 
order to improve patient safety and on the road to total quality management. 
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7.4 Measurement Uncertainty in the Medical Laboratory (II) 
 
 
7.4.1 New application of the different MU estimate formulae - 
Gnóstica´s Pre-analytical Uncertainty (2013 Update) 
 
After estimating the pre-analytical uncertainty specifically associated to 
Gnóstica Medical Laboratory, its patients’ samples and test results, it was then 
possible to substitute on the MU-B formula (5-2) the data from the literature, 
previously used to account for this uncertainty component in the total 
measurement uncertainty estimate. 
The aim of that particular study was set to deliver a more realistic value of the 
final global uncertainty. In the end, applying those results to the MU-B formula 
allows to present the best uncertainty estimate, with that being the one that best 
describes or characterizes each measurement and the dispersion of values that 
can probably be attributed to a particular measurand, at Gnóstica Medical 
Laboratory. 
It also demonstrated the necessity to consider the pre-analytical phase variation 
as an assumed uncertainty component, not only confirming it as a source of 
variation, which was already widely recognized and documented, but validating 
its measurability and above it all its potential major influence in an uncertainty 
estimate, consequently holding a potential of influence on patient's results. 
This analysis could be operated at two levels, by directly comparing the 
outcomes from the 2011 data, on Table 6-9, with the 2013 results, on Table 
6-16, and also by considering the individual influence of this particular 
uncertainty source, on each analyte, analysing Table 6-16, considering the data 
on Table 6-15. 
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So, in the first case, observing and comparing the variation of the pre-analytical 
uncertainty from the literature (creatinine: 2,3%; glucose: 3,2%; total 
cholesterol: 1,2%), and the results of the study developed at Gnóstica 
(respectively: 1,15%; 3,87%; 0,29%), becomes evident that this pre-analytical 
influence is differentiated, depending on the analyte, but also that it varies 
accordingly to the laboratory conditions and procedures, justifying the 
realization of in-house specific studies by different laboratories, in order to 
assess and quantify the pre-analytical uncertainty associated to each 
laboratory’s results, in compliance with other authors findings and statements 
[121, 122]. 
In general, when comparing the uncertainties estimate (MU-B: year 2011 and 
year 2013) it can be verified the increase or decrease in the measurement 
uncertainty final value, reflecting the same way change in the pre-analytical 
standard uncertainty, for each analyte. This indicates, once again, that the 
uncertainty estimate not only can be affected by the pre-analytical component, 
but also and most importantly, as stated above, that this uncertainty source can 
be variable from laboratory to laboratory, considering the results from the 
developed study, in view of the previous data used. 
Regarding the within analyte variation, when comparing the different formulae 
and considering the latest results (year 2013), three situations can be observed. 
What is first noticed is the high value of pre-analytical uncertainty affecting the 
results of glucose’s measurements. This variation source assumes 
preponderant weight on the estimate, increasing the value of the MU-B 
outcomes, when comparing to the other MU formula, or with the TE calculation. 
Total cholesterol, having the lowest pre-analytical uncertainty, when this value 
is combined with the calibrator uncertainty and with imprecision, for the MU-B 
estimate, the final results become very close for the different estimates, as there 
are not considerable differences regarding the measurement bias value used 
and the previous mentioned uncertainty components, capable of affecting or 
differentiating the final estimates. 
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On the creatinine’s results, concerning the MU-B model formula, where the data 
from the calibrator uncertainty and the pre-analytical uncertainty are lower than 
the bias value, it is observed the decrease in the final result of the measurement 
uncertainty. However, it is observed a considerable difference between bias 
values for the two auto-analysers, which is reflected later on the final 
uncertainty values, when comparing the different applied formulae.  
This fact reveals the importance of bias studies, supporting its usefulness in the 
medical laboratory. In order to reduce, minimize or eliminate bias, it is important 
to study it, acknowledging its existence and measure it. This should be done, if 
not in other way, by means of the EQAS results or other proficiency testing 
studies. These are part of the practical and technical requisites of the ISO15189 
standard, for the medical laboratories’ quality management systems and 
records, in the validation processes of the implemented measurement methods 
which are submitted to the accreditation process by the mentioned standard. 
Regarding the use of the bias or of the uncertainty assigned to the calibrators in 
the different MU estimates, the centre of the question is traceability, being a 
vital tool to ensure trueness having a calibration hierarchy traceable to a high 
reference measurement procedure. Values assigned to calibrators should be 
metrologically traceable as far up a calibration hierarchy as possible, so that 
end results are also traceable and thereby can reliably provide for trueness and 
comparability to the measurement [27, 65]. Assuming that the trueness control 
provided by the manufacturers represents the most appropriate approach for 
the quantitative expression of that performance characteristic, where a 
traceable calibrator is used, the analytical bias should not introduce uncertainty 
to the testing system [33, 73], being the calibrator’s uncertainty, if presenting 
high order traceability, the element of choice to the trueness input value. 
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Nevertheless, EQAS results are used in medical laboratories procedures aiming 
to detect, accordingly to the established performance goals, deviations to those 
desirable or minimum quality requirements. This is usually performed 
considering the Total Error, which has defined specifications for allowable total 
error, but can also be accomplished for other performance characteristics, as 
imprecision or bias.  
Consequently, in this study, the bias was assessed considering the mentioned 
measurement validating procedures under the scope of the accreditation by the 
ISO 15189 standard. So, the bias values were compared with the international 
quality specifications tables from Ricos, et al.[17], which contain the desirable 
specifications for bias, along with the specifications for imprecision and 
allowable total error, with these last ones being presented in Table 6-16. The 
results could, also be compared with other tables, if and whenever necessary 
for assessment, as already discussed in this work. 
In the previously mentioned situation, for the creatinine measurement, although 
it was identified a considerable difference between the determined bias values 
for the two used equipment, this specifications were not violated. Specifically in 
this case, for which was obtained a maximum bias of 3,22%, being at 4% the 
desirable specification for bias for serum creatinine, on the “Desirable 
Specifications for Total Error, Imprecision and Bias Table”, by Ricos, et al. [17]. 
Note that the same final considerations can be made for the other two analytes, 
since all fulfilled these quality goals. 
If it had been verified the occurrence of any failure to comply within these 
quality performance assessments, that would have been shown in the EQAS 
results, and had then to be subjected to reflection and evaluation by the 
laboratory’s Quality Management Department, being subsequently submitted to 
the appropriate procedures to eliminate or minimize the confirmed occurrence. 
Subsequently, the bias, and its uncertainty should be assessed for significance, 
being considered its eventual inclusion on the uncertainty estimate, even with 
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the traceable calibrators and their associated uncertainties being already 
accounted for in the estimate.  
The added-value, and one of the objectives, of introducing in a laboratory’s 
routine and measurement procedures high standard calibrators, traceable to 
reference materials and methods, with uncertainties associated to their 
assigned values, is exactly the reduction of bias to residual or negligible values, 
seeking to increase the results trueness and to ensure the comparability of 
those measurements. Nevertheless, even though one of the basic concepts 
behind the implementation of uncertainty measurement in the medical 
laboratory is that the measurement procedures should be, in principle, unbiased 
[27, 72], when a variation affecting that same measurement is detected at this 
level, revealing possible implications regarding the measurement’s trueness, it 
should be assessed and considered for significance. 
As discussed above, even in methods with traceable calibrators are possible to 
occur, being detected, problems or irregular variations regarding measurement 
bias, on the other hand, methods without traceable calibrators are expected and 
most likely to being affected by these situations, carrying verified significant 
bias. It is possible to know and account for that bias and its uncertainty by 
assessing it directly using certified reference materials (CRM). Alternatively it is 
also possible to do so by participating in proficiency tests or by the results of 
EQAS. Subsequently, different approaches for the estimate can be found [31, 
35, 99], all having in common the understanding that when calculating the 
uncertainty of bias it comprises the uncertainty of the bias itself, regarding the 
measurements for its estimate, but also the uncertainty regarding the reference 
value or reference material used in the assessment [123]. So, the bias value 
cannot be exactly known, as it always encompasses the uncertainty of the 
certified reference materials used and/or the unavoidable imprecision of the 
routine procedures used to obtain the replicate measurements or the mean 
value for the reference material  [25].  
 147 
 
Notwithstanding, to be in compliance with the GUM principles, any known bias 
should be reduced or minimized by re-calibration or by the use of a correction 
factor, being this way corrected or even  eliminated. But, if this principle 
generally acknowledged, it is also of unanimous comprehension that a 
correction of the bias carries itself an uncertainty that has to be considered 
whenever that same correction is performed [25, 123]. 
Anyway, the known bias and its uncertainty, or the uncertainty associated to the 
bias correction, should only be accounted as an uncertainty source in a 
measurement uncertainty estimate if considered significant. For that matters, 
different approaches have been proposed, being evaluated the significance of 
the bias, facing its uncertainty value, by a statistical t-test result [31, 73], or it 
may even be considered a more empirical and decision rule, with laboratories 
considering “to ignore uncertainty of bias values it they are less than an 
arbitrary cut-off of 20-30% of the intermediate imprecision” [25]. 
Considering this problematic, different analysis and reviews can be found on the 
literature on the bias subject, being each more or less extensive, such as 
Linsinger’s, T. P. [123], or more recently from Theodorsson, et al. [124].The 
authors usually address bias and its causes, the general ones and the 
measurement specific, considering the method itself, its interferences, the 
matrix effects and the commutability of the materials used. Are also approached 
the bias estimate and its own associated uncertainty, as well as the potential 
correction, or not, of the values detected, considering about possible restrictions 
and impediments to do so. The conclusions point the reference measurement 
methods and commutable reference materials as the basis of all efforts for 
minimizing or eliminating bias yet considering about the bias significance and its 
possible use and inclusion in measurement uncertainties estimates [123, 124]. 
As stated by Theodorsson, et al., hitherto there is no consensus or clear 
guidance on how to account for observed uncorrected bias as an uncertainty 
component in the uncertainty estimation. So, several different approaches and 
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models have been proposed as alternatives to include bias in measurement 
uncertainty estimation [125-127].  
Ultimately, as mentioned above, considering that where a traceable calibrator is 
used, analytical bias should not introduce uncertainty to the testing system [33, 
73], since the manufacturers specifications for the calibrating materials used in 
this study stated its traceability to the Reference Measurement Procedure 
(Isotope Dilution Mass Spectrometry - IDMS) and assuming that the presented 
uncertainties associated to each calibrator provided the trueness component for 
the measurement, were considered to be fulfilled the necessary conditions to 
adequately implement MU-B model (5-2).  
Thus, based on the specifications of the manufacturers method of calibration, 
joining the fact that the EQAS for these analytes did not indicate any bias 
problem [31, 82, 96], the bias could be assumed negligible. 
Finally, the uncertainties associated to the calibrators assigned values could be 
used, as mentioned, as the trueness components in the MU estimates, being 
considered along with each analyte pre-analytical uncertainty, as well as the 
specific imprecisions for each one, enabling the MU-B model formula not only to 
be properly implemented as to be considerable suitable for the designated 
purpose. 
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7.5 IPAC’s Accreditation Auditing 
 
The main reason for this collaboration and for Gnóstica’s investment in this 
project was finally put to test at this phase.  
Although having now a mandatory requirement regarding measurement 
uncertainties, neither the accreditation standard nor the IPAC specify an 
estimating model or formula to implement. As already addressed, not the GUM 
or other publications with particular focus on the medical laboratory, even when 
outlining the principles and possible approaches to this estimates, deliver a 
definitive and consensual approach to follow [98, 128]. 
Consequently, having no particular model suggested as preferential, the IPAC 
only requires that the applied approach proves to be technically valid and 
applicable to the methods in question, following the ISO 15189 Standard 
statement “as the laboratory shall define”. 
So, like was stated before, this first contact between the auditing teams and the 
accredited laboratories, following the new version on the implemented standard, 
represents also a moment of learning and discussion among peers. 
Besides the inexistence of a defined or restrict model implemented for the MU 
estimate, also there are no published performance goals specifically for the 
outcomes of this quality tool, as addressed on section 7.2. For this reason, are 
again presented the specifications on Ricos, et al. and on the CLIA’s tables, 
which were used as point of reference.  
To this particular, all the analytes, on the outcomes for each formulae applied, 
fulfil the quality requirements presented, being the ones on Ricos’s Table, or the 
broader ones on the CLIA’s Table, considering that either one is accepted for 
setting the minimum quality specifications. 
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Considered a normal procedure in these processes, the auditing report 
identified different situations, marked as Non-Conformities (NC), which required 
the analysis, correction and reporting back, by Gnóstica's Quality Department.  
Being this a maintenance auditing, as Gnóstica was seeking to keep the 
Accreditation Certificate that already had, as opposite to being a new candidate 
to the accreditation process, the laboratory got from one to three months to 
respond to the identified situations, depending on being considered “Major” or 
“Minor” NCs. 
Among the different NCs identified, were also the required MU estimates. The 
reason for that was that were only presented estimates for three of the 96 
analytes and measurements under the accreditation scope.  
Thus, the laboratory was asked give response to this particular requisite, 
showing “the Combined and Expanded MU estimate for all the quantitative 
methods under the accreditation scope, with evidence of considering the 
laboratory’s intermediate precision (imprecision) in those estimates”. This 
particular excerpt of the auditing report is presented in Appendix M. 
For replying to IPAC, the formulae were directly applied to the remaining 
analytes and measurements, discriminating the uncertainty sources being 
considered. The principles supporting the approaches were also included in the 
technical report, having the laboratory assumed the objective of including the 
values of uncertainty associated to the measurements calibrators in the future 
MU estimates, as well as data from other uncertainty sources, namely the pre-
analytical uncertainty. In compliance, the laboratory is already gathering the 
necessary data, asking the manufacturers of the measurements and methods 
involved to provide for information and uncertainty certificates for those 
analytes. Also, regarding the pre-analytical uncertainty, following the work 
developed in section 5.3 and applying the same methodology, the study was 
already implemented to sixteen other analytes, as shown in Appendix K and 
Appendix L, being the intention to proceed with the studies, by assessing the 
other remaining analytes. 
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While aiming to, in the future, being able to define proper performance goals to 
the MU estimates, in Gnóstica’s response to the auditing report was also stated 
that, considering the absence of specific MU desirable limits and publications on 
the matter, in this first phase, and in parallel, the laboratory will continue 
calculating the Total Error. 
Although having already received positive feedback from the IPAC regarding 
the response to the preliminary auditing report, including the information sent to 
give answer to the NC about the measurement uncertainties estimate, 
validating the data sent and confirming the renewal of the accreditation, a new 
certificate will only be emitted posteriorly. With the approval to the responses 
sent in the sequence of the auditing report, the accreditation certificate, issued 
in the end of 2015 (Appendix G) remains valid, until the emission of a new one, 
which will to replace and update the previous. 
 
 
  
 152 
 
7.6 Measurement Uncertainty in the Medical Laboratory (III) 
 
This section presents the final application of the MU formula, realized after the 
preliminary testing performed until now. After the studies with the laboratory’s 
data regarding the years 2011 and 2013, in this final phase of the project, with 
updated data from 2015, the last and improved version of the MU formula was 
applied. 
Considering the main objective of reaching a formula able to respond to 
Gnóstica’s necessities regarding the accreditation requirements and 
procedures, imposed by the ISO 15189 standard and applied according to 
IPAC's auditing rules and criteria, the provisional results obtained from the 
implemented methodologies from sections 5.2, 5.4 and particularly section 5.5, 
were considered and discussed with the laboratory’s Technical Board.  
Revising the initial approaches’ outcomes allowed to finally achieving a formula 
that fulfilled that primary objective, being essential the experience, criticisms 
and posterior acceptance, or validation, of this project's work and of its results', 
attained after, and from overcoming, the experience with the IPAC’s auditing. 
Being able to obtain, from an external review, commentaries on the work 
developed, with a feedback assuming, with recognized expertise, that model 
and approach presented as being valid and applicable in the laboratory’s 
routine was the best confirmation of the potential success of this project. 
With the previously mentioned update on its application, this final formula and 
its outcomes were considered to be representative of the measurement process 
and the best MU estimate for the results at Gnóstica Medical Laboratory. 
Thereby, the equation was lastly applied to the laboratory's data, for a final 
assessment, being the necessary data collected for the calculations presented 
in Table 6-17. The relative standard uncertainties to include in the estimate, as 
well as the obtained MU Combined Uncertainty and the final MU Expanded 
Uncertainties, for each studied analyte, are the presented in Table 6-18. 
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7.6.1 Gnóstica’s MU Estimate - Final Formula (MU-B) 
 
The studies previously developed, presented on the early sections, resulted in 
consecutive updates to the model being implemented. First, they enabled to 
integrate the values of Gnóstica’s own pre-analytical uncertainty on the 
laboratory’s MU estimates, regarding the measurements methods under the 
scope of the project. Later, after analysis, the final formula was optimised to 
incorporate, in only one estimate, the measurement uncertainty for a broad 
range of values, combining the high and low levels of the measurement’s 
intermediate precision.  
Furthermore, was decided to use the uncertainty associated to the calibrator, 
considering it to be the most reliable data representing the trueness of the 
respective measurement, assuring its traceability and comparability, also 
objectives of the implementation of measurement uncertainty estimates in the 
medical laboratory. This decision takes support in the actions of the EU 
Directive 98/79EC, seconded by the ISO Standards 17511 and 18153, 
obligating the IVD manufacturers to assure and demonstrate the metrological 
traceability of their products and to make available the uncertainties associated 
to the calibrators assigned values, as it was addressed on section 2.  
Also as mentioned before, bias, as a systematic source of variation, is to be 
properly handled, reduced and minimized or eliminated, being this to one of the 
basis of MU. Thus, as long as adequately assessed and controlled, considering 
its recommended desirable specifications, preferably through internal studies 
using certified reference materials or by the means of external evaluations, like 
EQAS, it should not be added to the estimate. So, considering the available 
certificates from the manufacturers, regarding the methods' calibrators in the 
study, trueness and traceability were found to be assured, and the values of the 
calibrators’ uncertainties were included in the estimates, accounting for that 
performance characteristic. 
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Looking to adapt the final MU formula to a broader application, combining the 
imprecision data from the different levels of the IQC allowed achieving a MU 
value that can be applied to the whole range of results in a measurement, 
characterizing the dispersion of values in different dimensions of results, with 
only one estimate.  
Although it possibly requires further studies, to validate the procedure internally 
at Gnóstica, this experimental combination of the different levels of imprecision, 
incorporating in the MU estimate a pooled imprecision, as proposed elsewhere  
[99, 101, 102, 129, 130], covering the low and high range of the measurement 
was considered positive, revealing adequate outcomes, comparable to the 
previous. Anyway, this should take consideration on the possibility of different 
variations along a wide range of measurement, as a described 
heteroscedasticity phenomenon [58], what could justify different MU estimates 
at the different control levels, for different concentrations of the measurand [37, 
130]. 
Something similar to the pooled imprecision could be attempted to do with the 
equipment. However, just observing the imprecision values for the creatinine 
measurement it is obvious the necessity of doing a dedicated study to evaluate 
the possibility, considering for any significant differences between the 
equipment. This was performed by Magnusson, B., et al., in a study where the 
authors assured similar variation within and between seven different equipment 
assuming the bias to be negligible, compared to the precision [37]. 
As already addressed, regarding the performance specifications and the MU 
goals, has been considered that an approach based on biological variation may 
be applied to compare and evaluate measurement uncertainty outcomes [98, 
99, 111], this approach should actually be preferred as a basis for establishing 
the desirable or minimum quality goals, specifically for MU, “because of its 
transparency and scientific base”, over other different approaches [110].  
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The new RiliBaek, the “Guidelines of the German Medical Association on quality 
assurance in medical laboratory testing”, integrating new quality permissible 
deviations, determined based on a root mean square deviation (%RMSD) 
calculation, and so, expressing these performance goals in an approach similar 
to the concepts of uncertainty estimates, present minimum specification 
performances that can be also be considered when intending to compare and 
evaluate the laboratory’s MU estimates outcomes [131]. 
As addressed before, on section 7.2, the proposed “Permissible limits for 
uncertainty of measurement in laboratory medicine”, by Haeckel et al., seems to 
have given a consistent step towards the creation of new and adapted 
performance specifications. This proposal also claims the possibility, hereafter 
and given its relevancy, of accounting for different sources or variation, like pre-
analytical uncertainty, which is not being considered presently [110]. 
Relating this subject to the discussed above, regarding the pooled imprecision, 
these Tables present specifications for a range of values, fact that helps to label 
this as a suitable procedure when estimating measurement uncertainties. For 
that matters, Haeckel’s Table and the RiliBaek’s Guidelines presents similar 
permissible limits, according to which, comparing the final results here obtained, 
in section 6.6, the MU estimate generally complies with the specifications, being 
observed punctual borderline violations in the creatinine and glucose estimates, 
but only in Haeckel’s Table (Permissible U%: Creatinine=9.55; Glucose=8.25; 
MU Estimate (%): Creatinine=9.6; Glucose=8.34) [110]. 
These violations are observed in the analytes with the higher associated pre-
analytical uncertainty, which has to be remembered as not being contemplated 
in these performance specifications, fact that can be considered as supporting 
and justifying the necessity for the establishment of new and consensual 
guidelines, adapted and updated to the concept and tool being introduced in the 
medical laboratory. This is reflected in Westgard, J.O. statement, affirming that: 
“unless there is a clear rationale for defining goals or targets for acceptable 
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measurement uncertainty, laboratories may not recognize whether the observed 
uncertainty is good or bad and whether improvement is needed or not” [57]. 
 
 
 
7.6.2 Standard Uncertainties’ Index 
 
Lastly, determining the different relative uncertainties index, regarding the final 
combined uncertainty, allows identifying the components differentiate 
contributions to the MU final value. This, consequently, reveals which have the 
most potential of causing any variation on the final measurements results, but 
also indicates on what component the laboratory should concentrate efforts to 
reduce its variation. Thus, this evaluation provides important information, 
revealing the measurements' probable weak points, regarding the causes or 
origins of the variability of its results. This is one of the possible benefits, if not 
an objective, of implementing a protocol for estimating measurement 
uncertainties.  
From the presented results can be observed that variations between 10-20% 
regarding the calibrator’s uncertainty, being this the component that consistently 
less contributes to the global uncertainty. As expected, the most evident source 
of variation relies on the methods intermediate precision, by the values of the 
different measurements imprecision, presenting values never lower than 25%, 
going up to 71%. The exception here, representing the bottom margin for the 
imprecision levels, is the glucose measurement, having its pre-analytical 
uncertainty assuming as dominant source of uncertainty, with 67% of the total of 
the combined uncertainty, in a component that reveals to be as low as 11%, in 
the case of total cholesterol testing.  
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This exercise serves as a graphical demonstration, which illustrates a situation 
that probably as reflection on many different analytes and on their 
measurements, where the predominant source of uncertainty is the method’s 
intermediate imprecision, justifying all the procedures and attention that these 
testing phase gathers in the laboratory. Other analytes will probably present 
high values of pre-analytical uncertainty to, being, as demonstrated in this 
study, a variation source to consider and that properly be valued, in order to 
improve its performance characteristics, not over-increase the MU estimates. 
 
 
7.7 MU Estimate Final Tool – Gnostica’s working spreadsheets 
 
As mentioned above, in section 6.7 is presented the MU estimating tool, 
developed for the implementation of these concept and procedures at Gnóstica 
Medical Laboratory. 
The principles and methodology applied have had the approval of the 
Laboratory’s Quality Management Department, having its implementation, 
practical applicability and MU outcomes also been validated, on the sequence 
of the procedures, and reports, regarding the renewal of Gnóstica’s 
Accreditation Certificate, as well as the feedback on the last Accreditation 
Auditing. 
The implementation of the presented tool is meant to be simple and intuitive, 
using data and terminologies applied in the everyday routine and already being 
collected within laboratory’s QMS. It can be applied either restrictedly by 
elements of the quality department or by distributing responsibilities to other 
members of the laboratory technical staff, as decided and assigned by the 
laboratory’s management. 
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Concerning the data introduction, the tables are also easy to replicate. The 
objective is to have one file for each different section of the laboratory, per 
assessment year. However, the application in the laboratory may be decided 
otherwise. Anyway, regardless of the decision, the important is to distinguish 
between the different working sheets of the file, which are interrelated. All the 
data introduced on the sheets represented in Figure 21and Figure 22, 
respectively the laboratory’s intermediate precision (IQC) and the systematic 
variation data (EQAS), (for such cases where there is a significant bias being 
considered, as addressed on the previous sections), is automatically integrated 
in the Figure 23 table, for the final estimate.  
Finally, the MU estimate will be obtained considering the inclusion on that final 
sheet of the remaining uncertainty components. Generically, as proposed on 
section 5.6, these last components are the Calibrator’s and the Pre-analytical 
Uncertainty. The final MU values are obtained through the integrated application 
of equation (5-2), resulting in the Combined Uncertainty (uc). The final 
Expanded Uncertainty (U) is obtained directly, with the spreadsheet using the 
uc, previously calculated, being applied on equation (5-3), on page 55. In the 
situation where other uncertainty components are considered, the first step of 
the process, to obtain the uc is accomplished by the use of the general equation 
(2-1), with the final step being the same as described before. 
In order to avoid unwanted and unexpected mistakes, in every worksheet, the 
white columns are meant for the data input; the darker columns (grey) indicate 
where an outcome for each specific identified parameter will be displayed. 
These dark areas are blocked to the users, likewise the formulae areas, which 
are not shown on the above figures of the spreadsheets, not being accessible in 
the working area environment. 
This is the corollary of this mid-term project, which is now being put to test, with 
Gnóstica’s MU Estimates already being determined, for the current year's data, 
through the implementation of the working tool here presented. 
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8 CONCLUSION 
 
 
8.1 Conclusion 
 
Medical Laboratory Accreditation, based on ISO 15189:2012 Medical 
Laboratories – Requirements for quality and competence, in its technical 
requirements, states that the applying laboratories “shall determine 
measurement uncertainty for each measurement procedure”, plus it yet 
declares that the laboratories “shall define the performance requirements for the 
measurement uncertainty of each measurement procedure”. 
Given this broad and flexible definition, laboratories may have the freedom to 
choose the methodology to implement, along with performance specifications to 
apply. However, National Accreditation Bodies (NABs), which usually hold these 
procedures, its assessment and approval, have recommended guidelines, 
narrowing individual creativity and promoting the technical validity, reliability and 
comparability of the implemented methodologies. 
Although this has been verified in some countries Governments or NABs, like 
the National Pathology Accreditation Advisory Council (NPAAC) [96], from 
Australia, the South African National Accreditation System (SANAS) [97]or the 
Ontario Laboratory Accreditation (OLA) [130], from Canada, amongst others, 
the proposals are not unanimous or even consensual. 
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Regarding the Scientific Organizations, Clinical and Laboratory Standards 
Institute (CLSI) have already issued the C51-A Expression of Measurement 
Uncertainty in Laboratory Medicine, while the International Organization for 
Standardization (ISO), had a preliminary project for a Standard, that was 
cancelled before any publication. Currently ISO has another ongoing project, 
which is still under development for a Standard, ISO/NP TS 20914 Medical 
Laboratories – Practical guide for the estimation of MU.  
In Portugal, particularly, this is a subject whit great lack of studies as of internal 
references and guidance. This fact may be reflected in the low search for 
objective implementation of accreditation systems, and consequently little 
knowledge and application of this valuable resource and quality tool. 
Thus, this project started with the main objective of developing an approach for 
the estimate of measurement uncertainties in the medical laboratory, aiming to 
ensure a formula capable of meeting the mandatory requirements for 
laboratories accreditation, within the NP EN ISO 15189:2014 standard, fulfilling 
the necessary procedures and requisites to comply with the regulations of the 
Portuguese Accreditation Institute (IPAC).  
In order to achieve this, different approaches and formulae for the estimate of 
MU were tested and compared, considering its application in the context of the 
medical laboratory, its outcomes and fit for purpose. In the process was given 
value to the inclusion of different categories and sources of variation or 
uncertainty, in the attempt to achieve a final model that best considered and 
characterised the result and the dispersion of values that can be attributed to a 
specific measurand  
Having tested two different formulae, the Model-B formula was considered to 
produce very sustainable outcomes, providing reliable and realistic values of 
measurement uncertainty, capable of defining the procedure and its variability, 
well representing the dispersion of values which can reasonably be attributed to 
the measurand final result. 
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Regarding the formula itself, it is always possible to think in amendments or 
sought out for improvements. In fact there are other factors, sources or 
components of uncertainty that can be considered not being part of the 
categories now assessed. Sources like biological variation can be considered 
important to assess, for instance, when comparing two test results from the 
same patient or for individuals requiring consecutive monitoring, including in the 
uncertainty budget data corresponding to the within-subject biological variation 
[29, 33, 59, 76, 84, 96]. Also, have been demonstrated that influence quantities, 
classified as endogenous or exogenous, can possibly represent an important 
component of the uncertainty of a patient’s result [75], being possible to adapt 
the formula.  
Although these can reveal to be important issues, especially in the situation 
where the pointed potential sources of variation have effective influence, the 
most relevant question appears to be the reliability and traceability of the 
estimate. Having this guaranteed, assuring one of the main objectives of 
implementing MU in medical laboratories at scale, measurement uncertainty 
estimate has the flexibility or the capacity of combining those multiple sources, 
arising from laboratorial or clinical justification. Such possibility can be 
represented in using the general equation (8-1): 
ݑܿ = ඥu݅ଶ + u݅݅ଶ + u݅݅݅ଶ + u݅ݒଶ (8-1) 
In which will be considered the different components of uncertainty: 
- ݅) day-to-day imprecision;  
- ݅݅) uncertainty of the calibrator assigned value;  
- ݅݅݅) Pre-metrological variability.  
Eventually, in specific situations other uncertainty sources can be 
considered; e.g.: 
- ݅ݒ) endogenous influence quantities [75], or  
- ݒ) biological variation values [17].   
Subsequently, the same coverage factor will be applied to obtain the 
Expanded Uncertainty, as demonstrated by equation (5-3), page 55. 
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The above reinforces one of the critical points, the disregard of measurement 
bias, under the addressed adequate conditions and as long as guaranteed the 
measurement traceability to reference methods and high order calibrating 
materials. This is assured through a specific and respected hierarchy calibration 
chain, with the use of certified calibrators traceable to the highest order 
possible. Thus, the discussion is brought to the manufacturers and to their role 
and responsibilities in the medical laboratory. 
For these matters, ISO standards ISO17511 [42] and ISO18153 [43] followed 
the direction, and supported of the European Union Directive 98/79/EC [44], on 
In Vitro Diagnostic Medical Devices, stating that for correct medical 
interpretation and comparability it is essential that results reported to both 
patients and physicians are adequately accurate (true and precise), supporting 
the obligation on manufacturers to ensure traceability of their analytical systems 
to recognised higher-order references and to indicate the expected uncertainty 
of the assay calibrators. In a position paper, in 2006, the European Diagnostic 
Manufacturers Association (EDMA), assumed IVD manufacturers as 
responsible for providing information on traceability and methods imprecision, 
comprising the selection of reference material and methods and documentation 
on the uncertainty of the calibrators assigned values [92]. In compliance, clinical 
laboratories should take part on these responsibilities, asking for the mentioned 
certificates to their manufacturers and also committing to always choose and 
prefer the suppliers able to demonstrate and provide these requirements. 
Again, the introduction and implementation of use of certified calibrating 
material, traceable to high order reference procedures and materials, with the 
uncertainties associated to the assigned values, is mandatory and vital to this 
process. This is the only way to aim for obtaining results traceable to those 
high-level calibrators and reference measurement procedures, reaching to a 
reliable calibration chain hierarchy that allows aiming for the desired and 
required trueness of the measurement procedure. The use of such materials, 
integrating its uncertainties in the MU estimates, allows disregarding, or to 
consider negligible the bias, supporting its withdrawal of the estimate.  
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This has been supported, being in some sense an imperative of the uncertainty 
concept, the bias, if known should be minimized or eliminated. Nevertheless, it 
is crucial to continue assessing and controlling laboratory bias, keeping the 
EQAS a particular and fundamental importance, since if detected do be 
significant, the bias value, or its correction bias, should be considered. As 
discussed, some options claim that, even then, bias should always be handled 
separately and never added to the uncertainty estimate. 
Nevertheless, attending to the values presented and considering its weight in 
the total measurement uncertainty, these values can, and should, always be 
verified and re-calculated by the laboratories [129, 132-134] The same way, 
laboratories can and should develop studies assessing their own pre-analytical 
uncertainty, evaluating their specific resources and human, technical and 
environmental conditions, as developed on section 5.3 of this study. This 
particular laboratorial phase can affect the subsequent phases (analytical and 
post-analytical), with errors regarding sample handling or transportation be in 
higher level than the analytical errors [128]. 
In the mentioned protocol, it were demonstrated both, the potential of variation 
and influence of this uncertainty source, as well as the need for it to be 
assessed by each particular laboratory, regarding its own day-to-day working 
conditions and procedures. The environmental and technical conditions of each 
laboratory, in conjunction with the actual procedure itself, can be of great 
influence to these values, contributing to the final uncertainty of the results. As a 
recommendation, this should also be included as a requisite and part of the 
mandatory demonstration of quality and technical competence of a laboratory 
when involved in any process of certification or accreditation, along with the 
other quality indicators already foreseen. 
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Documenting, verifying and reporting data; creating quality manuals and 
procedures for the entire laboratory competences, accounting for all of the 
phases of the analytical process – specially related to sampling and samples 
processing, transport and storage; investing in continuous learning and training 
is the only way to actually achieve a reliable quality, reducing errors and the 
effective cost of the non-quality and improving the whole patient care system.  
One important step forward is the improvement of pre-analytical EQAS. Existent 
pre-analytical external quality assessment programs should be having 
considerable investment from the medical laboratory scientific community, 
growing in both, scope and specificity. Once again, shared responsibilities must 
be taken between International Scientific Organizations, Manufacturers and the 
National Bodies.  
According to the authors, the few programs implemented seem to substantially 
different, being defended a combination of the different models now in action, 
as “probably necessary to be able to detect and monitor the wide range of 
errors occurring in the pre-analytical phase”. The authors conclude that further 
to implement this specific programs, it should be promoted the results 
publication since “information of such schemes and their ability to improve pre-
analytical routines in the laboratories are scarce in the literature” [135]. 
Simultaneously, it is necessary a strong effort towards total standardization of 
working methodologies, an effort that must be vertical, applied and implemented 
to all phases of the laboratory procedures, being submitted to constant and 
programed reviews and evaluation. As seen, this should, have special focus in 
the pre-analytical phase, by far the most neglected, despite the evidences of 
being in the total testing process, the one that most contributes to the laboratory 
error, also affecting results variation. Again, this should also comprise written 
procedures and protocols for the whole pre-analytical phase process; 
registration of all occurrences and a well-defined and strictly followed policy of 
acceptance/rejection of samples; supported by an intense training programs. 
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Recently, Kallner, A., strengthened the concept of MU, electing it to preferably 
“characterizing the performance of a measuring system”. It was again 
mentioned the reduction of bias and sustained the possibility of taking pre-
analytical and biological variations into account in these estimates, but, more 
importantly, was suggested the possibility of using computer applications to 
help and simplify implementing the estimates [29]. 
Making the connection to the principal objective of this project, these last 
recommendations are pointing right at the final product of this work: a tool ready 
to use and put to practice, meant to simplify the introduction of this concept in 
the daily routine of the laboratory and enabling the proper application of this 
quality resource. 
This to say that the main goal was accomplished, as at the end of the process 
was obtained, as aimed to, a working spreadsheet to implement in the 
laboratory’s own quality procedures and routines providing an instrument that is 
credible and fit for purpose as well as user friendly and perfectly able to be 
integrated as one of the QMS assessment tools, giving response to 
Accreditation guidelines and standards and to its requirements on evidences of 
quality for the laboratory's analytical process and technical competence. 
This success was anticipated in sections 5.5, 6.5 and 7.5, when the model in 
study and development was put to test, in the first Accreditation auditing. After 
some clarification about the concept and the formula applied, supporting the 
options made regarding the sources considered, the model was praised to be fit 
for purpose, and so accomplish its objectives and fulfilling the requirements of 
ISO 15189, and the procedures of IPAC, contributing to the desired and 
anticipated Accreditation approval and certificate renewal. 
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8.2 New applications; Future Work and Recommendations 
 
 
A challenge and precious goal for the near future relies on the applicability and 
fit for purpose, not only of the formulae and calculations of MU, but essentially 
of the uncertainty concept itself, and, of course, of its implementation amongst 
the medical community, both pathologists and clinicians/physicians, the medical 
laboratory staff, including technicians and finally to the patients and users of the 
medical laboratory services.  
On this matter, questions regarding the reporting and introduction of MU 
estimates to the laboratory users are not consensual, with arguments forward 
and against, considering the opposing facts related to both clinicians/physicians 
and patients. If ones are already given too much information, the others are not 
aware of the possible variation associated to laboratory results. On the other 
hand taking knowledge of uncertainties associated to the results as the potential 
of reducing misinterpretation and probably consequently to reduce mis-
diagnosis, wrong treatments or unnecessary new tests.  
Other important issues regards test results deriving from calculations, like the 
creatinine clearance or the anion gap, or qualitative testing in the medical 
laboratory. The whole area of microbiology is another differentiate problem to 
approach in future studies. Thus, there is much to explore, and also already 
much being made, like in direct application and considerations regarding 
different the clinical situations, with several examples published elsewhere [96, 
136, 137]. 
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Also not addressed, the question of post-analytical uncertainty, concerning 
which other authors have considered, mainly referring the important problem 
regarding an appropriate number of significant figures, as reporting results, or 
addressing the influences in result interpretation [33, 96, 128].  
As for issues that were addressed but require further studying, can be referred 
the combined imprecision, which was properly approached but of course 
requires continuity. Other similar study, as mentioned, is to verify the possibility 
of combining the equipment in the estimate, originating an uncertainty estimate 
for the laboratory. The objective and commitment in this project with Gnóstica is 
to continue the studies in the pre-analytical phase as well, aiming to include the 
remaining analytes.  
Other studies are being developed, exploring the possibilities of MU 
applications in the medical laboratory. In a couple of examples, Ceriotti, et, al., 
proposed “the use of the uncertainty approach to develop an effective alarm 
system”, regarding the evaluation of IQC [99]. Jones et, al., used the 
uncertainty in an approach to correct laboratory results for the effects of 
interferences [138]. In one last example, Badrick, T. and R. C. Hawkins, 
“described a novel approach to the determination of the reporting interval for an 
assay, one that is determined by the uncertainty of the measurement process 
and therefore provides useful information to the clinician about the interpretation 
of the result” [139] .  
From the application of the Model-B formula for MU, became clear the 
necessary investment from manufacturers and reference laboratories in 
producing and providing certified reference material, standard calibrators with 
high metrological traceability together with the uncertainties to their assigned 
values, this is one important source of uncertainty and consequently one 
important indicator of the result’s quality. 
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The objective, as addressed, should comprise the investment of all involved in 
the medical laboratory community, being of particular importance the effort of 
the manufacturers, being ambitious goals an attempt of global standardization, 
including the pair reference method/reference material, following the steps of 
the International consensus on the Worldwide Standardization of the 
Hemoglobin A1C Measurement. This is maybe an utopia for now, but the way to 
global standardization, traceability and comparability.  
Another essential, it is crucial that International Scientific Organizations and 
Governments invest as well, in both studying and developing new guidelines 
and tables with new goals and limits, well defined according to the new 
evaluation methodologies and tools being introduced in the medical laboratory. 
It is obvious the necessity of actualization of the ones in use, with the 
incorporation of the concept and determination of uncertainty, introducing new 
requisites for performance and maximum allowable values. The suggested 
definition by each laboratory of its measurement goals or “performance 
requirements” does not seem to be the most indicated.   
The major challenge and objective should be to follow the path towards 
traceability and comparability, allowing getting to a proven and accepted model 
of uncertainty determination, applicable to the Medical Laboratory, providing 
Measurement Uncertainties fit for purpose, enforcing and enhancing the way to 
Total Quality Management. 
The combination of all the above would produce an undoubted improvement to 
the general and total quality and reliability of the medical laboratories 
procedures, performances and consequently of its results, enhancing 
traceability and comparability of laboratories methods’ and results’, in the end 
leading to more efficient and reliable laboratory services, securing patient safety 
and a better and stronger health care. 
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Appendix D - Accreditation Certificate (Year2009) 
D.1 Gnóstica Medical Laboratory - Accreditation Certificate: ISO 
15189:2007 (IPAC - 2009/07/01) 
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Appendix E - Roche’s Cobas® 6000 Tests 
E.1 Cobas® 6000: module c501 list of tests  
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E.2 Cobas® 6000: module c501 list of tests 
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Appendix F - Roche’s Traceability and Uncertainty 
Certificate (Calibrator Uncertainty) 
 
F.1 Traceability and Uncertainty - Cobas® c501 / c502 / c311 / 
c701 / c702 (C.a.s.f.), from Roche® (2011) 
 
 
 
 
 
 198 
 
 
 
F.2 Traceability and Uncertainty - Cobas® c501 / c502 / c311 / 
c701 / c702 (C.a.s.f.), from Roche® (2011) 
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Appendix G - Accreditation Certificate (Year2015) 
G.1 Gnóstica Medical Laboratory - Accreditation Certificate: 
ISO 15189:2014 (IPAC - 2015/12/22) 
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Appendix H - Quality Indicators (6.1 Results) 
H.1 User’s Overall Satisfaction (2005 – 2006 – 2007) 
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Appendix I - Quality Indicators (6.1 Results) 
I.1 Pre-analytical Phase - Waiting Time (%) – 2003 - 2005 
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I.2 Pre-analytical Phase - Waiting Time (%) – 2005 - 2007 
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Appendix J - Roche’s Traceability and Uncertainty 
Certificate (Calibrator Uncertainty) 
J.1 Traceability and Uncertainty - Cobas® c501 / c502 / c311 / 
c701 / c702 (C.a.s.f.), from Roche® (2014) 
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J.2 Traceability and Uncertainty - Cobas® c501 / c502 / c311 / 
c701 / c702 (C.a.s.f.), from Roche® (2014) 
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Appendix K - Pre-analytical Uncertainty: Sample Analyte Data (Mean Concentrations and CV's %) 
Mean Concentration CV (%) 
Test /  
Units 
A)  
Reference  
Measurement 
B) 
Blood 
Collection 
B1)  
Refrigerated  
Samples 
B2)  
Frozen  
Samples 
C)  
Sample  
Processing 
D)  
Regional  
Transportation 
B)  
Blood 
Collection 
B1)  
Refrigerated  
Samples 
B2)  
Frozen  
Samples 
C)  
Sample 
Processing 
D)  
Regional 
Transportation 
ALB / g/dL 4,66 4,57 4,62 4,56 4,58 4,61 3,20 1,54 1,83 1,09 1,19 
ALP / U/L 61,21 59,93 60,07 59,59 59,93 59,72 2,44 0,98 1,73 0,98 1,46 
ALT / U/L 18,50 18,58 18,08 16,42 19,12 18,35 6,94 3,12 9,90 9,87 2,60 
AST / U/L 20,70 20,97 20,97 20,70 20,80 21,07 3,16 2,30 4,96 3,44 2,68 
Ca / mg/dL 9,58 9,42 9,36 9,25 9,35 9,32 1,90 2,23 3,13 1,26 1,01 
CK / U/L 132,80 136,73 133,83 129,43 132,23 131,93 4,13 2,60 5,51 4,11 4,32 
Cl / mmol/L 101,14 100,77 100,78 100,42 100,41 100,25 0,76 0,73 0,74 0,58 0,62 
GGT / U/L 26,67 26,63 26,30 25,70 26,43 26,20 2,42 1,83 6,80 2,66 3,13 
HDL-C 50,90 50,80 49,50 49,60 50,77 50,73 1,63 2,40 4,10 0,98 1,02 
K / mmol/L 4,27 4,27 4,34 4,24 4,25 4,38 3,74 3,25 3,10 1,51 2,84 
LDH / U/L 323,57 331,70 305,27 318,13 338,27 343,83 4,44 8,18 5,68 3,45 5,15 
Mg / mg/dL 2,05 2,03 2,06 2,04 2,05 2,03 1,20 2,29 2,59 1,21 4,51 
Na / mmol/L 141,00 139,80 140,13 139,33 140,03 139,70 0,91 0,45 0,69 0,58 0,62 
TBIL / mg/dL 0,60 0,58 0,53 0,54 0,56 0,54 4,60 8,89 7,48 7,46 8,07 
TP / g/dL 7,17 7,06 7,11 7,04 7,07 7,08 1,95 1,33 2,12 0,84 0,80 
TG / mg/dL 137,43 134,70 138,70 136,50 135,20 133,87 2,44 2,28 1,95 1,11 5,20 
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Appendix L - Pre-analytical Uncertainty Components (Combined and Expanded Pre-analytical Uncertainty)  
Standard Uncertainty of  
Combined 
Preanalytical 
Uncertainty 
 uc pre (%) 
 
 
Expanded 
Preanalytical 
Uncertainty 
 Upre (%) 
 
Test /  
Analyte CVA (%) 
B) 
Blood 
Collection  
(uB %) 
B1) 
Refrigerated 
Samples  
(uB1 %) 
B2) 
Frozen 
Samples  
(uB2 %) 
C) 
Sample 
Processing  
(uC %) 
D) 
Regional 
Transportation  
(uD %) 
ALB 1,93 1,27 < CVA < CVA < CVA < CVA 1,27 2,54 
ALP 2,17 0,27 < CVA < CVA < CVA < CVA 0,27 0,55 
ALT 1,84 5,10 1,28 8,06 8,03 0,76 12,56 25,11 
AST 2,18 0,98 0,12 2,78 1,26 0,50 3,24 6,49 
Ca 1,49 0,41 0,74 1,64 < CVA < CVA 1,85 3,70 
CK 1,30 2,83 1,30 4,21 2,81 3,02 6,66 13,33 
Cl 1,30 < CVA < CVA < CVA < CVA < CVA < CVA < CVA 
GGT 2,37 0,05 < CVA 4,43 0,29 0,76 4,51 9,01 
HDL-C 1,95 < CVA 0,45 2,15 < CVA < CVA 2,20 4,39 
K 1,21 2,53 2,04 1,89 0,30 1,63 4,11 8,23 
LDH 1,50 2,94 6,68 4,18 1,95 3,65 9,38 18,75 
Mg 1,59 < CVA 0,70 1,00 < CVA 2,92 3,17 6,33 
Na 1,12 < CVA < CVA < CVA < CVA < CVA < CVA < CVA 
TBIL 3,96 0,64 4,93 3,52 3,50 4,11 8,14 16,28 
TP 1,27 0,68 0,06 0,85 < CVA < CVA 1,09 2,17 
TG 1,60 0,84 0,68 0,35 < CVA 3,60 3,78 7,56 
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Appendix M - Accreditation Auditing Report 
M.1 Gnóstica’s Accreditation Report (IPAC 2016) 
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M.2 Gnóstica’s Accreditation Report (IPAC2016) 
 
 
